Economic impact of COPD: Empirical and model-based studies on the cost-effectiveness of treatment options by Hoogendoorn, M. (Martine)
Economic impact of COPD
Empirical and model-based studies on the
cost-effectiveness of treatment options
Martine Hoogendoorn
Econom
ic im
pact of CO
PD
  Em
pirical and m
odel-based studies on the cost-effectiveness of treatm
ent options 
M
artine H
oogendoorn
Economic impact of COPD
Empirical and model-based studies on the cost-effectiveness 
of treatment options
Martine Hoogendoorn
Funding
The research projects described in this thesis with respect to the development of the 
COPD model were supported by two grants from the Netherlands Asthma Foundation 
(NAF: 3.4.01.75 and NAF: 3.4.06.0.59). The INTERCOM study was financially supported by 
the Netherlands Asthma Foundation (NAF: 3.4.01.63), the “Stichting Astma Bestrijding 
(SAB)”, Nutricia Netherlands, Pfizer, and Partners in Care Solutions (PICASSO) for COPD. 
The study described in chapter four was funded by the Dutch Ministry of Health. 
Hoogendoorn, M.
Economic impact of COPD. Empirical and model-based studies on the cost-effectiveness 
of treatment options.
Dissertation Erasmus University Rotterdam, the Netherlands
© M. Hoogendoorn, 2011
All rights reserved. No part of this publication may be reproduced, stored in a retrieval 
system, or transmitted, in any form or by any means, electronically, mechanically, by 
photocopying, recording, or otherwise, without the prior written permission of the 
author. 
Chapters reprinted with kind permission of Elsevier (chapter 2 and 7), European Respira-
tory Society Journals Ltd (chapter 3, 6 and 8), BMJ group (chapter 4), Dove Medical Press 
Ltd (chapter 5) and Cambridge University Press (chapter 9).
Cover image "Lung Tissue Section" (iStockphoto)
Printing: Optima Grafische Communicatie, Rotterdam, the Netherlands
ISBN: 978-94-6169-148-4
Economic impact of COPD
Empirical and model-based studies on the cost-effectiveness
of treatment options
Economische impact van COPD
Empirisch en modelmatig onderzoek naar de kosteneffectiviteit
van behandelmogelijkheden
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam 
op gezag van de
rector magnificus
Prof.dr. H.G. Schmidt
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op 
dinsdag 29 november 2011 om 11.30 uur 
door
Elizabeth Jantina Ike Hoogendoorn-Lips
geboren te Gouda
Promotiecommissie
Promotor  
Prof.dr. M.P.M.H. Rutten-van Mölken
Overige leden 
Prof.dr. H.C. Hoogsteden 
Prof.dr. J.A.M. van der Palen 
Prof.dr. J.L. Severens
Copromotor 
Dr. T.L. Feenstra 
Contents
Chapter 1: General introduction 7
PART ONE: Studies related to the development of a COPD progression model 
Chapter 2: Severity distribution of chronic obstructive pulmonary disease 
(COPD) in Dutch general practice
29
Chapter 3: A dynamic population model of disease progression in COPD 37
Chapter 4: Long-term effectiveness and cost-effectiveness of smoking 
cessation interventions in patients with COPD
61
Chapter 5: Association between lung function and exacerbation 
frequency in patients with chronic obstructive pulmonary 
disease, results from a systematic review 
81
Chapter 6: Case-fatality of COPD exacerbations: a meta-analysis and 
modeling approach
99
Chapter 7: Developing an applying a stochastic dynamic population 
model for chronic obstructive pulmonary disease 
115
PART TWO: Studies related to the economic evaluation of an interdisciplinary 
community-based COPD management program
Chapter 8: Is INTERdisciplinary COMmunity-based COPD management 
(INTERCOM) cost-effective? 
143
Chapter 9: Self-report versus care provider registration of healthcare 
utilization: impact on cost and cost-utility
163
Chapter 10: General discussion 179
Summary 199
Samenvatting 207
List of publications 213
Dankwoord 215
Curriculum Vitae 219

Chapter 1
General introduction
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
8 Chapter 1
General introduction
Chronic obstructive pulmonary disease (COPD) is a disease characterized by progressive 
airflow limitation that is not fully reversible and is accompanied by extra-pulmonary 
effects that can lead to important co-morbidities. The treatment of COPD is associated 
with substantial healthcare costs, which are expected to increase in the future. Therefore 
the need for information on efficient treatment options in terms of both effects and 
costs is high. This thesis aims to investigate the costs and cost-effectiveness of treatment 
options for COPD to contribute to evidence-based policy making. This introduction 
provides background information on COPD and describes the disease characteristics, 
epidemiology, the social and economic burden and the available treatment options and 
their potential cost-effectiveness.
Disease characteristics
This overview starts with a description of the most important disease characteristics of 
COPD. The main respiratory symptoms are cough, sputum production and dyspnoea or 
abnormal shortness of breath [1]. In more severe stages of the disease respiratory failure 
can lead to right heart failure, which is an often occurring complication in COPD [2]. The 
most important systemic effects and co-morbidities of COPD are weight loss, loss of fat-
free mass (cachexia), skeletal muscle dysfunction, cardiovascular disease, osteoporosis, 
diabetes, lung cancer and depression [3]. 
The progression of COPD is often accompanied by periods of increasing symptoms 
named exacerbations. A COPD exacerbation is defined as a sustained worsening of the 
patient’s condition, from the stable state and beyond normal day-to-day variations, 
that is acute in onset and necessitates a change in regular medication in a patient with 
underlying COPD [4]. In clinical studies several definitions of an exacerbation have been 
used, which can be roughly divided into definitions based on an increase in symptoms 
(symptom-based definitions) and definitions based on an increase in healthcare use due 
to an increase in symptoms, such as use of antibiotics and/or oral steroids or hospital-
ization (event-based definitions). Although the exact cause of exacerbations remains 
unknown in about one third of cases, most exacerbations appear to be caused by viral 
and bacterial infections [5]. A large observational study showed that the best predictor 
of getting an exacerbation was a history of exacerbations in the year prior to the study 
indicating that some patients seemed to be more susceptible to exacerbations than oth-
ers [6]. Exacerbations are important events in COPD because they are associated with 
an increase in mortality [7,8], a significant impairment of health-related quality of life 
[9-11] and an increase in healthcare use and associated costs [12,13], especially in case 
of a hospitalization [14]. 
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General introduction 9
Long-term smoking is the most important risk factor for the development of COPD 
[1,15,16]. Besides smoking, genetics and occupational exposures can play a role in the 
development of COPD. Factors, such as outdoor air pollution and second-hand smoke, 
seem to be associated with COPD, although causality is less clear [17]. In developing 
countries biomass fuel smoke may be an important risk factor too [18]. 
Diagnosis of COPD requires lung function measurement obtained by spirometry test-
ing. Most relevant outcomes of this test to set the diagnosis of COPD are the forced 
expiratory volume in one second (FEV1), the volume of air that can be expelled from 
maximum inspiration in the first second, and the forced vital capacity (FVC), the volume 
of air that can be forcibly expelled from the lung from the maximum inspiration to the 
maximum expiration. Airflow limitation is most often defined as a FEV1/FVC ratio of less 
than 0.7, although a FEV1/FVC ratio below the lower limit of normal (<5%) is increasingly 
recommended [1,19,20]. However, in daily practice the diagnosis of COPD is still often 
based on symptoms and a history of exposure to risk factors for the disease, especially 
when spirometry results are unavailable [21]. If patients are diagnosed with the disease, 
the severity of the COPD can be classified based on the degree of airflow obstruction. 
One of the most often used severity classifications for COPD based on the FEV1 as per-
centage of the predicted value is the classification proposed by the Global initiative for 
chronic Obstructive Lung Disease (GOLD). The GOLD classification distinguishes four 
severity stages: mild (FEV1% predicted ≥ 80%), moderate (50% ≤ FEV1% predicted<80%), 
severe (30 ≤ FEV1% predicted <50%) and very severe COPD (FEV1% predicted<30%) [1]. 
Because COPD is more and more regarded as a multi-component disease, it is increas-
ingly recognized that the severity of the disease should be based on more indicators 
than lung function alone. One of the most important factors determining disease 
severity of COPD is the presence of co-morbidities. Other factors influencing disease 
severity are the level of dyspnoea and the degree of exercise impairment. The recently 
performed ECLIPSE study showed that within each GOLD severity stage there was a 
wide variation in symptoms, number of reported exacerbations, exercise tolerance and 
prevalence of co-morbidities, indicating that the complexity of COPD is not captured by 
lung function alone [22]. In the recent past different composite measures are proposed 
to assess the severity of COPD. These measures combined several parameters such as 
body mass index (BMI), airflow obstruction, dyspnoea, exercise capacity, smoking status, 
age or exacerbation frequencies into one outcome [23-25]. Although these composite 
measures of severity are good predictors of mortality and quality of life, their usefulness 
in guiding treatment in routine clinical practice remains to be proven.
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10 Chapter 1
Prevalence
The World Health Organization (WHO) estimated that worldwide 64 million people 
suffer from COPD [26]. Prevalence estimates show wide variation between regions, but 
differences in estimates also occur as a result of differences in methods and criteria used. 
Two large population-based surveys performed in 17 different cities around the world 
reported prevalence estimates based on spirometry ranging from 7.8 to 26.1% for the 
population above 40 years of age, 11 to 28.7% for males and 5.6 to 25.7% for females 
[27,28]. A meta-analysis from 2006 by Halbert et al reported a pooled prevalence of 
9.2% (95% CI: 7.7; 11.0) for studies using spirometry to diagnose COPD [29]. Pooled 
prevalence based on patient-report or physician diagnosis without spirometry resulted 
in lower estimates, 4.9% (95% CI: 2.8; 8.3) and 5.2% (95%CI: 3.3; 7.9), respectively, which 
may be an indication of under-diagnosis. Prevalence estimates are usually higher in men 
than in women [27-29], because the smoking epidemic started earlier in men than in 
women. In the Netherlands COPD prevalence based on general practitioner registra-
tions was estimated to be 4.1-5.4% for the population above 40 years, 4.6-5.9% for 
males and 3.7-4.7% for females [30-32].  A Dutch study using a COPD diagnosis based 
on the combined information of spirometry and/or physician-diagnosis found a COPD 
prevalence of 11.6% for the population above 55 years [33]. Under-diagnosis of COPD is 
very common and possibly as high as 50 to 75% [34-37]. Over- diagnosis may however, 
also be present. The often recommended fixed value of 0.7 for the FEV1/FVC ratio below 
which airflow obstruction is present may result in over-diagnosis in especially elderly 
patients, because the FEV1/FVC ratio decreases with age. Using the lower limit of normal 
of the FEV1/FVC ratio to identify patients with COPD would reduce this over-diagnosis 
[38,39]. Worldwide, the prevalence of COPD is expected to increase mainly due to age-
ing of the population and an increase in the prevalence of smoking, especially in the 
developing countries and among women. The general picture in the Netherlands and 
other Western countries seems to be that age-specific or age-adjusted prevalence rates 
are stable or even decreasing in men but still increasing in women [30,40-43]. However, 
due to demographic changes the absolute number of male and female COPD patients is 
still expected to increase in the coming decade.
Disability and mortality
COPD is a major cause of morbidity and mortality worldwide [44]. Because COPD is as-
sociated with a significant impairment in quality of life, especially in the more severe 
stages [45-48], COPD has a large impact in terms of morbidity. In 2004 COPD was the 7th 
leading global cause of years of life lost due to disability in high-income countries [26].
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Due to the expected increase in prevalence, the burden of COPD is expected to in-
crease [1,26,49]. The Global Burden of Disease Study 2004 projected COPD to be the fifth 
leading cause of disability worldwide in 2030. A study of Jemal et al showed that from 
six major causes of death COPD was the only condition for which mortality rates were 
increasing between 1970 and 2002 and expected to increase continuously [50]. In 2004 
about 3 million people died of COPD, 5% of all deaths worldwide in that year, making 
it the fourth leading cause of death [26]. A similar pattern was seen in the Netherlands, 
where in 2007 about 6,400 people died of COPD, making COPD the fourth leading cause 
of death in men and the eighth cause of death in women [51]. The excess mortality 
among patients with COPD is high, not only because of the presence of COPD but also 
because of the increased prevalence of other smoking-related diseases [52]. Therefore 
estimates of mortality due to COPD may be even higher, because COPD is often not 
recorded as the primary cause of death [53]. 
Economic burden
In line with the high burden in terms of disability, the economic impact of COPD is also 
considerable. Cost-of-illness studies provide insight into the costs related to COPD in 
society. Costs attributable to COPD can be divided into direct medical costs and cost 
due to productivity loss. Direct medical costs are costs directly related to diagnosis and 
treatment of the disease, such as spirometry, medication, physician visits and hospi-
talizations, while productivity costs are costs related to inability to perform work, such 
as work days off or early retirement. Table 1 shows the results of eleven cost-of-illness 
studies for COPD performed in ten different European countries [54-64]. All costs were 
converted to 2011 € using purchasing power parities (PPP) and national inflation rates 
[65,66]. Total direct COPD-related costs varied from €19 million for Iceland to €6,000 
million for Germany. Annual direct costs for COPD per patient ranged from €323 in 
Norway to €3,637 in Italy. Only four studies reported indirect costs varying from €82 to 
€1,044 per patient per year [55,57,60,63]. Comparison of cost estimates between studies 
is however difficult due to differences in methods, perspective, healthcare setting, unit 
costs and type of patients included. The studies differ for example in types of resource 
use included. Furthermore, most studies reported only COPD-related costs, while three 
studies reported the additional healthcare costs of a COPD patient compared to a 
healthy control or the costs of COPD and COPD-related co-morbidities [56,57,59]. The 
Confronting COPD survey performed in 2000/2001 was an international survey estimat-
ing the burden of COPD in seven North-American and European countries using the 
same methodology in each country. The annual direct costs per patient in this study 
ranged from $522 in France to $4,119 in the U.S [67]. 
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Differences in costs could not be explained by differences in unit costs only, but were 
thought to be the result of differences in patient characteristics and management of 
COPD in the individual healthcare systems. The total direct medical costs for COPD in 
the Netherlands in 2000 were estimated to be €280 million or €915 per patient [62]. An 
update of this study found estimates of €356 million and €1,110, respectively for the 
year 2007 [68]. The Confronting COPD survey reported a total cost estimate of €1,024 per 
Dutch patient of which €614 was for direct costs [69].Seven of the studies mentioned in 
Table 1 specified the cost by COPD severity showing a strong correlation between costs 
and disease severity [54,57-61,63]. The costs of a patient with very severe COPD were 
on average about 3 to 4 times higher than the costs of a patient with mild or moder-
ate COPD. The most important cost drivers in COPD are hospitalizations (40-45%) and 
medication (25-35%) [54,55,57-61]. As hospitalizations are mainly exacerbation-related 
and exacerbations often require an increase in use of medication, costs of treating ex-
acerbations are estimated to account for 50-75% of the total COPD-related costs [19]. A 
review of Toy et al showed a wide variation in the estimated cost per exacerbation, €95 
to €8,500 (2011 €) [70-72]. The cost of a severe exacerbation defined as a hospitalization 
ranged from €4,520 to €9,710 [12,73], while the costs of a mild or moderate exacerba-
tion varied between €44 and €650 [70,73,74]. The positive association between costs 
and increasing disease severity and the high exacerbation-related hospitalization costs 
show that besides primary prevention the economic burden of COPD can mainly be 
reduced by interventions and therapies that reduce disease progression and decrease 
the number of exacerbations resulting in a hospitalization.  
Treatment options
Once COPD has been diagnosed the most important goal is to prevent disease progres-
sion. Smoking cessation is still the most important and well-proven to be effective 
intervention to slow down the disease progression in COPD [75]. The Lung Health Study 
showed that COPD patients who quitted smoking had an improvement in lung function 
in the first year and the subsequent rate of decline was half the rate observed among 
continued smokers [76]. Therefore, current guidelines recommend that all smoking 
COPD patients should be offered the most intensive smoking cessation intervention 
feasible [1]. Next to smoking cessation therapy, all patients should receive an annual in-
fluenza vaccination to prevent the influenza virus from triggering a COPD exacerbation. 
Further management of COPD mainly focuses on relieve of symptoms, improvement of 
exercise tolerance and quality of life and prevention of exacerbations [1]. In addition, 
the commonly occurring COPD-related co-morbidities should be monitored and treated 
[77]. With respect to the management of stable COPD, treatment of mild COPD and 
moderate COPD is mainly limited to pharmacotherapy, i.e. bronchodilators to reduce 
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symptoms. Several bronchodilating agents are available, i.e. short- and long-acting 
β2-agonists and short- and long-acting anticholinergics. All these agents are proven to 
be effective, however, regular use of long-acting bronchodilators is most effective [1]. 
Treatment of mild COPD is limited to the use of short-acting bronchodilators if needed. 
In moderate COPD the addition of long-acting bronchodilators is recommended. When 
the disease progresses to severe COPD treatment with inhaled glucocorticosteroids in 
case of recurrent exacerbations is added [1]. Recent studies showed that inhaled cortico-
steroids might also have a beneficial effect in less severe COPD stages [78]. Effectiveness 
of inhaled corticosteroids in COPD has however been discussed for many years and is 
still the subject of an ongoing debate [79,80]. 
Non-pharmacological treatment of COPD consists of pulmonary rehabilitation and in 
case of very severe COPD oxygen therapy or surgery (lung volume reduction surgery 
or lung transplantation) [1,81]. Pulmonary rehabilitation consists of exercise training, 
education, self-management, psychological counseling and nutritional counseling. 
Exercise training aims to improve or maintain exercise capacity and the general con-
dition of patients. Education, self-management and psychological counseling focus 
on improvement of medication use, coping with the disease and adopting a healthy 
lifestyle. Nutritional counseling aims to improve the nutritional status of underweight 
or muscle-wasted patients by giving them nutritional advice and nutritional supple-
ments. The beneficial effects of exercise training with or without education in terms of 
improving exercise capacity, dyspnoea and quality of life are well proven in patients 
with more severe COPD [82,83]. Self-management programs including COPD education 
and/or self-treatment guidelines were also shown to be effective by having a significant 
effect on quality of life and hospitalizations [84]. Until recently pulmonary rehabilitation 
was mainly indicated for patients with severe COPD and provided in the setting of a 
hospital or respiratory rehabilitation centre. More and more guidelines now recognize 
the importance of reactivation by means of exercise training and nutritional counseling 
for patients with less severe COPD [1,83,85]. Programs for this patient population may 
well be implemented in a community-based setting provided by local physiotherapists 
and dieticians. 
Besides the above described therapies, specific treatment options for small groups of 
very severe patients are available, such as oxygen and lung surgeries. Oxygen therapy 
is usually prescribed for patients with very severe COPD with a reduced arterial oxygen 
pressure (PaO2<7.3 kPa) or an oxygen saturation of less than 88-90%. Long-term admin-
istration of oxygen has shown to reduce mortality [86]. Surgeries such as lung volume 
reduction surgery or lung transplantation are less often applied because of the high risk 
involved. 
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For patients in all severity stages treatment of exacerbations consists of an increase of 
regular bronchodilating medication, a course of antibiotics and/or systemic glucocorti-
costeroids and in severe cases additional oxygen or other types of ventilatory support.
Cost-effectiveness of treatment options
Although the clinical evidence for most treatment options of COPD has been well es-
tablished, data about costs and cost-effectiveness used to be limited. In the past decade 
however, the number of economic evaluations of treatments of COPD increased. For 
the most important preventive intervention, smoking cessation, effectiveness and cost-
effectiveness have been well proven in the general population [87-91]. However, there 
is only some evidence of effectiveness of smoking cessation interventions targeted to 
COPD patients and even when including the study reported in this thesis the informa-
tion about the cost-effectiveness of these interventions in this specific patient group 
is very limited. One study showed that the one-year cost-effectiveness of bupropion 
and nortriptyline compared to placebo was €2,100 and €10,600 per additional quitter, 
respectively [92]. The long-term cost-effectiveness of smoking cessation interventions 
for COPD patients was reported in a study included in this thesis [93]. This study showed 
that implementation of intensive counseling defined as more than 90 minutes counsel-
ing and intensive counseling plus pharmacotherapy (NRT, bupropion or nortriptyline) 
for patients with COPD was more effective than usual care. The costs per quality-
adjusted life year (QALY) gained for both interventions were below €10,000, comparable 
with ratios presented for smoking cessation interventions in the general population. 
Although influenza vaccinations for patients with COPD are shown to be effective in 
reducing exacerbations [94], information about the cost-effectiveness is also scarce. A 
study from Hak et al showed that influenza vaccinations were cost saving in patients 
with chronic lung disease aged 65 years and over [95]. A study in COPD patients from 
Thailand reported the costs and effects of influenza vaccinations in terms of the cost 
of the vaccination and the resulting reduction in healthcare use. In this study the cost 
benefit from influenza vaccination was shown to be higher in patients with more severe 
airflow obstruction, because the savings in costs for hospitalizations and especially 
mechanical ventilation were higher in these groups compared to the group with mild 
airflow obstruction [96]. 
Information about the cost-effectiveness of pharmacotherapy for COPD has increased 
in the past five to ten years. A review of Rutten-van Mölken et al found thirty-five stud-
ies reporting about the cost-effectiveness of pharmacological agents for maintenance 
treatment in COPD [97]. The review showed that short-acting bronchodilators used in 
combination (β2-agonist plus ipratropium) were found to be cost saving compared to 
either drug alone. Evidence for the cost-effectiveness of long-acting β2-agonists was 
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mainly based on studies comparing salmeterol with a comparator, such as placebo or a 
short-acting bronchodilator. The cost per QALY for salmeterol reported in these studies 
varied between cost saving and $197,000. Studies investigating the cost-effectiveness 
of the long-acting anticholinergic agent tiotropium compared to placebo, ipratropium 
or salmeterol reported cost savings in the majority of studies. The remaining studies 
reported costs per QALY gained up to $26,000. Results for the cost-effectiveness of 
treatment with inhaled corticosteroids compared to placebo, no treatment or standard 
care were not consistent with cost per QALY ranging from about $13,000 to $78,000 or 
even dominance for the comparator. Studies comparing inhaled corticosteroids with 
salmeterol showed that the latter was more cost-effective. Almost all studies investigat-
ing the cost-effectiveness of a combination of a long-acting β2-agonist in combination 
with an inhaled corticosteroid found better effects and higher costs compared to the 
group receiving placebo, standard care or one of the single components. The cost per 
QALY in these studies showed a wide variation, from $24,000 to $450,000. One of the 
conclusions of the review of Rutten-van Mölken et al was that due to differences in 
methodology, comparator and time horizon used, results of the studies are difficult to 
compare [97,98]. To improve comparability all future studies should be more consistent 
in study methodology, use the same comparator and use the QALY as effectiveness 
outcome [97,98]. 
For the non-pharmacological treatment options information with regard to cost-
effectiveness is limited. For pulmonary rehabilitation only three comprehensive eco-
nomic evaluations, including the one reported in this thesis, have been published, two 
in patients with severe and one in patients with moderate to severe COPD [99-101]. The 
study of Goldstein et al reported the cost-effectiveness of a 2-months inpatient program 
followed by 4 months of outpatient training to range between $29,000 and $51,000 per 
patient achieving a clinical important improvement in different components of a qual-
ity of life questionnaire [99]. The one-year study of Griffiths found a 6-week outpatient 
program to result in better effects and to be cost saving compared to standard care 
[100]. The study reported in this thesis investigating the cost-effectiveness of a two-year 
community-based COPD management program compared to usual care in patients with 
less severe airflow obstruction found a cost per QALY gained of about €32,500 [101]. 
Besides the three comprehensive economic evaluations several studies reported about 
the program costs or the impact of the program on healthcare utilization, such as hos-
pitalizations [102-105]. 
Evidence about cost-effectiveness was even more limited for the more specific treat-
ment options, oxygen therapy and surgeries. No studies were found reporting about 
the costs per QALY using oxygen as maintenance therapy. For oxygen use in relation to 
treatment of a severe exacerbation two studies reported a cost-effectiveness ratio, rang-
ing from cost saving to $45,000 per QALY [106,107]. The few other studies found only 
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reported about the savings in costs. Surgical procedures such as lung transplantation 
and lung volume reduction surgery are found to have very high cost-effectiveness ratios 
of $100,000 per QALY gained or higher [108,109]. 
Well-based information from economic evaluations is becoming more and more 
important for policy makers. The substantial current and increasing economic burden 
of COPD and the limited healthcare budgets increase the need for efficient treatment 
options in terms of both effects and costs.
Aim of this thesis 
In 2003 the GOLD guidelines raised the issue of the lack of information on economic 
aspects of treatment options for COPD [110]. In the previous paragraph it is shown 
that this issue is still valid. The overall aim of the studies presented in this thesis was to 
provide new and additional data about the cost and cost-effectiveness of treatment of 
COPD and to contribute to evidence-based policy making for COPD in two ways:
1)  by developing a decision analytic population-based COPD model, which can be used to 
estimate the (future) burden of COPD and the cost-effectiveness of a wide range of COPD 
interventions. As the epidemiology, burden and consequences of treating COPD are 
complex, a transparent model combining these elements can be a useful tool for policy 
making. A population-based COPD disease progression model has the potential to explore 
the implications of therapies for COPD over the whole spectrum from prevention to care, 
especially when direct information from long-term epidemiological studies or clinical trials 
is lacking. The model can be used to evaluate the short- and long-term effects of interven-
tions of different intensity or for different target groups. Furthermore, by using the same 
model to estimate the cost-effectiveness of different interventions, the model can provide 
policy makers with comparable information. 
2)  by performing an empirical economic evaluation linked to a clinical trial that evaluated 
the effectiveness of a COPD management program. Because pulmonary rehabilitation 
used to be mainly indicated for patients with severe and very severe COPD, little evidence 
was available about the effectiveness of this kind of programs in patients with less severe 
COPD. Besides the issue of effectiveness and cost-effectiveness, it was also necessary 
to explore other settings of providing pulmonary rehabilitation programs, such as 
community-based instead of hospital-based, because capacity of hospitals or respiratory 
rehabilitation centers would not be sufficient to treat all patients who could benefit from a 
reactivation program. The economic evaluation presented in the second part of this thesis 
therefore aimed to estimate whether an interdisciplinary, community-based pulmonary 
rehabilitation program (INTERCOM) was cost-effective in patients with less severe airflow 
obstruction than the patients usually attending pulmonary rehabilitation programs.  
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Outline of this thesis 
In the first part of this thesis, chapter two to seven, studies performed in relation to the 
development of the population-based COPD progression model are presented. The first 
version of the model was developed in 2002/2003 and presented in chapter three. The 
second updated and extended version of the model including exacerbations and proba-
bilistic sensitivity analysis (2008-2010) is presented in chapter seven. Both chapter three 
and seven explain the structure, and input parameters of the model and examples of 
the potential use of the model are given, using the first or second version of the model, 
respectively. 
Much effort was put into obtaining exacerbation-related input parameters. Chapter 
two, five and six show results of a thorough estimation of three types of model input pa-
rameters. In chapter two the severity distribution of COPD in the Dutch COPD population 
was estimated based on the GOLD classification. This distribution was used to distribute 
the prevalence in the model over the COPD severity stages. To include exacerbations 
in the second version of the model, the relation between exacerbations and lung func-
tion, mortality, lung function decline, quality of life and costs needed to be estimated. 
Results of the association with lung function and mortality were presented in separate 
manuscripts (chapter five and six). Chapter five shows the results of a review and meta-
analysis performed to estimate the exacerbation rate specified by GOLD stage. Rates 
were estimated separately for total exacerbations defined by an increase in healthcare 
use (event-based), total exacerbations defined by an increase in symptoms and severe 
exacerbations defined as a hospitalization for COPD. Because higher mortality risks after 
a severe exacerbation often exceed the period of hospitalization, the case-fatality of a 
severe exacerbation was defined as the excess mortality associated with the exacerba-
tion compared to the stable situation. Chapter six presents a meta-analysis estimating 
the case-fatality of a severe exacerbation. 
An application of the model is shown in chapter four. This chapter presents the cost-
effectiveness of smoking cessation interventions for COPD patients. Based on a litera-
ture review of trials evaluating a smoking cessation intervention in patients with COPD, 
the long-term effectiveness and cost-effectiveness of minimal counseling, intensive 
counseling and intensive counseling plus pharmacotherapy was estimated compared 
to usual care. 
The second part of this thesis, chapter eight and nine, reports the two studies related 
to the economic evaluation of the INTERCOM trial. Chapter eight addresses the question 
whether this interdisciplinary community-based COPD management program is cost-
effective for patients with less severe airflow obstruction. In this chapter, results of a 
comprehensive economic evaluation including all COPD as well as non-COPD related 
costs during the two years of the study are shown. Chapter nine reports a validation 
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study of the cost booklet that was used in the INTERCOM trial to collect resource use 
data. This booklet was validated against data from care-giver registrations. Furthermore, 
the impact of using costs based on the cost booklet or based on care-giver registrations 
on the cost-utility was calculated. Finally, in chapter ten the results of studies presented 
in chapter two to ten are discussed as well as the implications, methods used and the 
value of the results for policy making. 
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Abstract
The actual burden of chronic obstructive pulmonary disease (COPD) in terms of health-
care use and costs strongly depends on the distribution of disease severity. For the Neth-
erlands, the distribution of diagnosed COPD was estimated by classifying all patients 
with a physician diagnosis of COPD from two different sources of general practitioners 
(GP)-data into mild (27%), moderate (55%), severe (15%) or very severe COPD (3%) based 
on their post-bronchodilator FEV1% predicted, according to the GOLD-guidelines. This 
distribution will most likely shift to the less severe stages when under-reporting and 
under-diagnosis are reduced.
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Introduction
Worldwide, chronic obstructive pulmonary disease (COPD) causes serious health prob-
lems and disability. Models that project the future morbidity, mortality and costs of 
COPD show that the burden of COPD will increase during the next few decades [1, 2]. The 
actual burden in terms of costs strongly depends on the severity distribution of COPD 
in the population, as there is a powerful association between use of healthcare services 
and disease severity [3-5]. To project the future burden of COPD by disease severity and 
to evaluate the impact of different smoking cessation interventions for patients with 
COPD on the burden of COPD in the Netherlands, we have developed a population 
model that simulates disease progression over time according to severity stages [6]. To 
classify the prevalence of diagnosed COPD in the starting year of the simulation over 
the stages mild, moderate, severe and very severe COPD [7], it was necessary to know 
the distribution of COPD disease severity in the Dutch population of diagnosed COPD 
patients. Such data have not been reported in the literature before and are not routinely 
collected as part of any ongoing data registration. Because in the Netherlands virtu-
ally all people are registered with a general practice (GP), the prevalence of diagnosed 
COPD is generally derived from general practice databases. This study aimed to assess 
the severity distribution of COPD from GP databases in the Netherlands.
Methods
Two different sources of GP data were used. The first data source contained all patients 
with physician diagnosed COPD including those with co-existing asthma from five GP 
registrations in the Nijmegen Monitoring Project (NMP) [8]. These practices are part of 
the academic GP network of the University Medical Centre Nijmegen. In these practices, 
all patients with COPD are coded using International Classification of Primary Care [9] 
coding (R91/R95) and all available spirometric test results are stored electronically.
The second data source was a clinical trial that contained lung function data on COPD 
and asthma patients from 25 GP practices in the Amsterdam area [10]. All registered 
patients with a diagnosis of either COPD or asthma were asked to participate in the trial. 
To be enrolled in the trial, participants had to meet the following inclusion criteria: age 
16 to 75 years, capable of filling in a Dutch questionnaire, no specific pulmonary disease 
other than COPD or asthma and absence of any disease in a terminal phase. Known 
asthma patients were excluded from the dataset. All patients with physician diagnosed 
COPD (including COPD with coexisting asthma) and patients for whom the exact GP 
diagnosis for the respiratory condition was unknown entered our analysis. For the latter 
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group, the final decision whether or not patients had COPD was based on lung function 
indices.
For both datasets the classification of COPD severity was based on post-bronchodilator 
FEV1% predicted according to the class boundaries in the GOLD classification [7]. FEV1% 
predicted was calculated using ECCS/ ERS equations [11]. Patients aged < 45 years were 
excluded. 
For all NMP patients with a FEV1/FVC ratio <70%, the largest FEV1% predicted value 
of the two most recent consecutive years with measurements in the period 1997-2002 
was used for classification. When post-bronchodilator values were not available, pre-
bronchodilator values were multiplied by 1.095. This factor was based on the observed 
difference between pre- and post-bronchodilator values from NMP patients for whom 
both values were available (62%). All patients from the Amsterdam data with a FEV1/FVC 
ratio <70% were classified based on the baseline lung function measurements of the 
clinical trial performed in the period 1995-1998.
Results
Study populations
In the NMP practices 530 patients had physician-diagnosed COPD. For 307 (58%) of them 
sufficient spirometric data were available. Patients with and without spirometry did not 
differ with respect to sex, age, co morbid conditions and number of drug prescriptions 
for COPD. Eighty-five patients were excluded from further analyses because their FEV1/
FVC ratio was >70%. Six additional patients were excluded because they were aged < 
45 years. The remaining 216 patients (70% male) with a mean age of 67.7 years were 
classified according to the GOLD stages mild, moderate, severe and very severe COPD. 
In the Amsterdam study 1325 patients (65%) of the 2047 patients, who met the inclu-
sion criteria, were willing to participate. Patients who did not enter the clinical trial, were 
significantly younger and a higher percentage was male [10]. A total of 1308 patients 
had valid lung function measurements at baseline. From this group 607 patients with a 
diagnosis of asthma only, 400 patients with a FEV1/FVC ratio >70% and 36 patients aged 
< 45 years were excluded. In total 265 COPD patients (65% male) with a mean age of 63.8 
years remained for classification.
COPD severity distribution
Table 1 shows the results of the severity classification based on GOLD stages for both 
data sources separately as well as for both patient groups combined. Figure 1 shows 
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the frequency distribution of FEV1% predicted for the combined data. The bars show 
the empirical data, the continuous line the fitted normal distribution density function. 
Statistical testing demonstrated that the empirical data did not significantly deviate from 
a normal distribution with a mean FEV1% predicted of 68.3 and a standard deviation of 
19.9. For our simulation model we based the severity distribution on this normal distribu-
tion, truncated at 10 and 110 FEV1% predicted: mild COPD 27%, moderate COPD 55%, 
severe COPD 15% and very severe COPD 3%. 
Discussion
This study showed that in the Netherlands, in total, 80% of the patients with a physician diag-
nosis of COPD had mild or moderate disease whereas almost 20% had severe or very severe 
COPD. As virtually all people in the Netherlands, including those treated by pulmonologists, 
are registered with a GP practice, these data probably represent the population of physician-
Table 1: Distribution of disease severity among COPD patients known to the general practitioner 
COPD severity by GOLD criteria, FEV1/FVC<70%, Percentage (95%-confidence interval)
GOLD I GOLD II GOLD III GOLD IV
Mild: FEV1%
predicted ≥ 80%
Moderate: 50 ≤ FEV1% 
predicted < 80%
Severe: 30 ≤ FEV1% 
predicted < 50%
Very severe: FEV1% 
predicted < 30%
NMP 31% 47% 19% 3% 
Amsterdam 28% 55% 15% 2% 
Total 30% (26; 34%) 52% (47; 56%) 17% (13; 20%) 2% (1; 4%) 
FEV1: Forced expiratory volume in one second
FVC: Forced vital capacity
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Figure 1: Frequency distribution of FEV1% predicted of prevalent, diagnosed cases of COPD (n=481), 
defined as FEV1/ FVC<70%, based on the combined data sources
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diagnosed COPD patients fairly well. It does not reflect the COPD severity distribution in the 
entire Dutch community, as under-presentation and under-diagnosis is not accounted for.
Some of the patients also had a diagnosis of asthma. They were included. Excluding 
these patients has little impact; the proportion of patients with severe and very severe 
COPD changes from 19 to 22%.
The five NMP practices are known for keeping electronic records of spirometric test 
results. Nevertheless, spirometric data were absent in the electronic records for almost 
40% of the patients with a physician diagnosis of COPD. Although no significant dif-
ferences were found between the groups with and without spirometry on general 
characteristics, the lack of lung function data may have influenced the results. In the 
Amsterdam database the COPD and asthma patients who participated in the clinical 
trial were not completely representative for the total population of COPD and asthma 
patients in the 25 GP practices. Patients who refused to participate were significantly 
younger and a higher percentage was male. Whether this has influenced our results and 
to what extent is difficult to determine.
An interesting finding was that 32% of the patients with a physician diagnosis of COPD did 
not meet the criterion of airflow limitation as it is defined in the GOLD-guidelines (i.e., FEV1/
FVC ratio <70%). This indicates that in quite a few cases physicians do not base their diagnosis 
on lung function, but on criteria such as a history of smoking combined with chronic cough 
and dyspnoea over prolonged periods of time. As the systemic effects of COPD are increas-
ingly recognized, it is likely that in the future COPD severity will be based on a combination of 
variables, like the recently published BODE-index, which combines FEV1% predicted, dyspnoea 
score, 6-min walking distance and body mass index [12]. However, as this is only a recent de-
velopment, no routine registrations exist that generate these data for epidemiological use yet.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
Severity distribution of COPD in the Netherlands 35
References
 1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: 
Global Burden of Disease Study. Lancet .1997; 349:1498-504.
 2. Feenstra TL, Van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-van Molken MP. The impact 
of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model 
analysis in the Netherlands. Am J Respir Crit Care Med. 2001; 164:590-6.
 3. Jansson SA, Andersson F, Borg S, Ericsson A, Jonsson E, Lundback B. Costs of COPD in Sweden 
according to disease severity. Chest. 2002; 122:1994-2002.
 4. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 
2000; 118:1278-85.
 5. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year 
follow-up study. Chest. 2003; 123:784-91.
 6. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Genugten MLL, Rutten-van Molken MP. A health 
policy model for COPD: effects of smoking cessation. Rotterdam: iMTA, Erasmus Medical Center, 
2003. Available at http://www.imta.nl/publications/0368.pdf
 7. Pauwels RA, Buist AS, Calverley PM, et al. Global Inititiative for Chronic Obstructive Lung Disease. 
Workshop Report: Global Strategy for the Diagnosis, Management and Prevention of COPD: 
updated 2003. 2003. Available at: www.goldcopd.com (Accessed June 2004).
 8. Van Weel C, Smith H, Beasley JW. Family practice research networks. Experiences from 3 countries. 
J Fam Pract. 2000; 49:938-43.
 9. Lamberts H, Wood M. ICPC: International Classification of Primary Care. Oxford: Oxford University 
Press, 1987.
 10. Wijnhoven HA, Kriegsman DM, Hesselink AE, Penninx BW, de Haan M. Determinants of different 
dimensions of disease severity in asthma and COPD : pulmonary function and health-related 
quality of life. Chest. 2001; 119:1034-42.
 11. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced 
ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Com-
munity for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 
Suppl. 1993; 16:5-40.
 12. Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnoea, and exer-
cise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350:1005-12.

Chapter 3
A dynamic population model of disease 
progression in COPD
Martine Hoogendoorn
Maureen P.M.H. Rutten-van Mölken
Rudolf T. Hoogenveen
Marianne L.L. van Genugten
A. Sonia Buist
Emiel F.M. Wouters
Talitha L. Feenstra
Published in: Eur Respir J 2005; 26(2):223-33
 
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
38 Chapter 3
Abstract 
To contribute to evidence-based policy making, a dynamic Dutch population model of 
chronic obstructive pulmonary disease (COPD) progression was developed. The model 
projects incidence, prevalence, mortality, progression and costs of diagnosed COPD by 
the Global Initiative for Chronic Obstructive Lung Disease-severity stage for 2000-2025 
taking into account population dynamics and changes in smoking prevalence over time. 
It was estimated that of all diagnosed COPD patients in 2000 27% had mild, 55% had 
moderate, 15% had severe and 3% had very severe COPD. The severity distribution of 
COPD incidence was computed to be 40% mild, 55% moderate, 4% severe and 0.1% very 
severe COPD. Disease progression was modelled as decline in forced expiratory volume 
in one second (FEV1) % predicted depending on sex, age, smoking and FEV1% predicted. 
The relative mortality risk of a 10-unit decrease in FEV1% predicted was estimated at 
1.2. Projections of current practice were compared with projections assuming that 
each year 25% of all COPD patients receive minimal smoking cessation counseling or 
intensive counseling plus bupropion. In the projections of current practice prevalence 
rates between 2000-2025 changed from 5.1 to 11 per 1000 inhabitants for mild, from 
11 to 14 per 1000 for moderate, from 3.0 to 3.9 per 1000 for severe and from 0.5 to 1.3 
per 1000 for very severe COPD. Costs per inhabitant increased from €1.40 to €3.10 for 
mild, from €6.50 to €9.00 for moderate, from €6.20 to €8.50 for severe and from €3.40 
to €9.40 for very severe COPD (price level 2000). Both smoking cessation scenarios were 
cost-effective with minimal counseling generating net savings. In conclusion, the COPD 
progression model is a useful instrument to give detailed information about the future 
burden of COPD and to assess the long-term impact of interventions on this burden.
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Introduction
Worldwide, the increase in the prevalence, morbidity, mortality and costs of chronic ob-
structive pulmonary disease (COPD) that has been projected for future decades [1-3] has 
drawn the attention of healthcare policy makers. They realize that slowing down disease 
progression is one way to reduce the increasing healthcare costs, as there is a strong asso-
ciation between use of healthcare services and disease severity [4-7]. Currently the only 
available intervention proven to slow down disease progression before patients develop 
severe COPD is smoking cessation. The Lung Health Study (LHS) demonstrated that COPD 
patients who quit smoking had an improvement in lung function in the first year, and a 
subsequent rate of decline that was half the rate observed among continued smokers [8]. 
To project the future burden of COPD in the Netherlands by disease severity and to 
evaluate the impact of different smoking cessation interventions on the national burden 
of COPD, a population model has been developed that simulates COPD progression 
over four severity stages. The model builds further upon a dynamic multi-state life table 
model developed by the National Institute for Public Health and the Environment and 
described by Feenstra et al., which models the Dutch prevalence, incidence and mortal-
ity of COPD as a single disease state [3]. With this single-state model, the prevalence of 
COPD between 1994 and 2015 was projected to increase by 40% for males and 140% for 
females [3].
The objective of the present paper was to describe the design of the dynamic pop-
ulation-based COPD model with severity stages. The reason for developing this model 
was to provide healthcare policy makers, insurers and care-providers with detailed in-
formation about the future burden of COPD for the years 2000-2025 which can be used 
in planning public health strategies. The model is particularly suitable for comparing 
the impact of different interventions on the national burden of COPD on the long run. 
Therefore, the applicability of the model was illustrated by comparing two scenarios 
on increased use of smoking cessation interventions by COPD patients with current 
practice. Although the model is currently populated with Dutch data, it is likely that the 
trends represent other Western countries with an aging population and a history of a 
relatively high smoking prevalence (currently about 30% in the Netherlands).
Methods
General structure of the model
The COPD model is a dynamic population model that projects the incidence, prevalence, 
mortality, progression and healthcare costs of COPD per Global Initiative of Chronic 
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Obstructive Lung Disease (GOLD) severity stage as well as changes in the healthy popu-
lation, i.e. no COPD, as present in the entire Dutch population. The multi-state model is 
based on the life table method as it follows births cohorts over time. Each year a new 
birth cohort is added, while the existing birth cohorts age by one year. Dynamics of 
the general population are taken into account using prognoses of birth, mortality and 
migration as obtained from Statistics Netherlands (Voorburg/Heerlen, The Netherlands). 
Within each birth cohort people can move between smoking classes, be diagnosed with 
COPD, move to another COPD severity stage or die, all with a certain annual probabil-
ity. Changes in age and sex-specific smoking prevalence in the general population are 
computed by the model using the currently observed age and sex specific start, quit and 
restart rates that are based on data from the Dutch Foundation for Smoking and Health 
(STIVORO) and three Dutch cohort studies (table 1) [9-13]. 
COPD incidence and prevalence in the four severity stages are computed by sex and 
5-yr age classes, starting at age 45 yrs and ending with at an age of >85 yrs. Incidence 
also depends on smoking status, defined as current smoker, non-smoker or ex-smoker. 
Disease progression is modelled as annual decline in forced expiratory volume in one 
second (FEV1) % predicted, depending on sex, age, smoking status and FEV1% predicted. 
Disease progression is then transformed into an annual transition rate, i.e. the annual 
probability of moving to a worse COPD stage (table 1). The effects of smoking cessation 
are modelled as a one-time increase in FEV1% predicted and a reduced disease progres-
sion. COPD mortality rates (table 2) depend on FEV1% predicted, age, sex and smoking. 
Competing risks have been accounted for by including smoking-related causes of death 
as well as other unrelated causes of death in the model. The model assumes “conditional 
Mortality
Incidence
Mild 
COPD
Non-smokers
Smokers
Former smokers
Very 
severe 
COPD
Severe 
COPD
Moderate 
COPD
General 
population
Figure 1: The four severity stages of COPD and the three classes for the risk factor smoking are the 
building blocks of the model. The dynamic nature is illustrated by the arrows representing the annual 
disease incidence, mortality, the transitioning of patients to more severe disease states and the changes 
between risk factor classes
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independence”, i.e. within one age, sex and smoking class mortality rates for different 
diseases are assumed to be mutually independent. This implies for example, that given 
age and sex, the probability for a smoking COPD patient to die from lung cancer is the 
same as the probability for a smoking person without COPD. However, as there are more 
smokers and ex-smokers among COPD patients than among non-COPD patients, an av-
erage COPD patient has a higher risk of getting lung cancer and consequently, a higher 
risk of dying from it. Costs are calculated by multiplying the number of patients per sex, 
age and COPD severity stage with the annual costs per patient in the corresponding 
class. The structure, assumptions, input data and results of the model were discussed 
with an expert panel of scientists including pulmonologists. All mathematical details of 
the model have been described previously [14]. The main outcome parameters of the 
model were prevalence, mortality and costs specified by sex, age, smoking status, COPD 
severity and year. 
Table 1: Transition rates between smoking classes for the general population and the COPD population 
and transition rates between COPD severity stages for the year 2000 
Smoking transition rates§ Start Quit Restart
General population 0.8% 3.6% 6.5%
COPD patients 0% 4.7% 2.6%
Severity stage transition rates# Non-smokers Smokers Former smokers
Mild to moderate COPD 1.8% 2.5% 2.1%
Moderate to severe COPD 3.0% 3.7% 3.4%
Severe to very severe COPD 2.6% 3.1% 3.0%
§ Mean current observed smoking transition rates over all sex and age classes
# Proportion of COPD patients transitioning to another severity stage associated with yearly decline in 
lung function
Table 2: Prevalence#, incidence#, excess mortality^ and costs for 2000
Prevalence Incidence Excess mortality Costs per patient, € 
Men
Mild COPD 6.4 0.9 22.4 260
Moderate COPD 13.3 1.2 35.5 570
Severe COPD 3.7 0.1 54.0 1,900
Very severe COPD 0.6 0.003 77.3 6,400
Women
Mild COPD 3.9 0.6 22.5 310
Moderate COPD 8.1 0.7 35.6 680
Severe COPD 2.3 0.06 54.3 2,300
Very severe COPD 0.4 0.002 77.4 7,600
# per 1000 people in the Dutch population
^ per 1000 chronic obstructive pulmonary disease (COPD) patients in that specific severity stage
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Input data
Prevalence by severity
COPD prevalence by sex and age was obtained from general practitioner (GP) registra-
tions [15-17], indicating that it refers to “physician-diagnosed COPD”. The mean preva-
lence rate for people aged >45 yrs was 67 per 1000 for males and 37 per 1000 for females. 
To estimate the severity distribution of the prevalence of COPD in the Netherlands 
in the year 2000, two different sources of GP-data were used [15, 18]. The first database 
consisted of data from five general practices, which are part of an academic general 
practice network [15]. In these practices all available spirometric test results were stored 
in electronic patient files. The second database contained the lung function data of 
asthma and COPD patients from 25 GP practices at baseline of a clinical trial [18]. No 
specific criteria other than having a physician diagnosis of asthma or COPD and not 
having another pulmonary or terminal disease were used to allow patients to enter the 
trial. The FEV1% predicted of all patients with a physician diagnosis of COPD, ≥45 yrs of 
age and airflow limitation (FEV1/forced vital capacity <70%), from both data sources, was 
used to distribute COPD over mild, moderate, severe or very severe COPD according to 
the lung function boundaries in the GOLD-guidelines [1]. Both sources together con-
tained a total of 481 COPD patients. The frequency distribution of their FEV1% predicted 
did not significantly deviate from a normal distribution with a mean (SD) of 68.3 (19.9). 
From this distribution, truncated at 10 and 110 FEV1% predicted, it was estimated that 
27% (95% CI: 23; 31%) of the patients had mild COPD, 55% (95% CI: 51; 60%) moderate 
COPD, 15% (95% CI: 12; 19%) severe COPD and 3% (95% CI: 1; 4%) very severe COPD. This 
distribution was applied to each subgroup of COPD patients defined by sex, age and 
smoking status in the base year. 
Incidence by severity 
Total COPD incidence by age and sex was obtained from the same GP registrations as 
the prevalence data. The mean annual incidence rate for people aged >45 yrs was 6 per 
1000 for males and 3 per 1000 for females. The distribution of the incidence over the 
severity stages was estimated mathematically such that given the prevalence, disease 
progression and mortality in 2000, the distribution of FEV1% predicted in the entire 
COPD population in the year 2001 was not different from the distribution in the year 
2000, when keeping smoking prevalence rates and population numbers constant. This 
resulted in a normal distribution for the incidence with a mean FEV1% predicted of 76.4 
(15.6). Using these normal distribution characteristics and the cut-off points of the COPD 
stages, the distribution of the incidence was estimated to be 40% in mild, 55% in moder-
ate, 4% in severe and 0.1% in very severe COPD. This distribution was applied to the sex, 
age and smoking-specific incidence numbers in each year after 2000. 
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Decline in lung function by severity
Disease progression was modelled as annual decline in FEV1% predicted, which depends 
on sex, age, smoking and FEV1% predicted. Estimates of the decline in FEV1%predicted 
were based on the Lung Health Study [8]. The original 5-year follow-up data from the 
5887 COPD patients were re-analyzed using a random effect model with year, smoking 
cessation, sex, age, age2, baseline FEV1% predicted and all statistically significant second 
order interactions as explanatory variables (see Appendix I). The increase in FEV1% 
predicted associated with smoking cessation was included in this same model. Increase 
and decline outside the range of the age and lung function values observed in the Lung 
Health Study were based on the equation given in appendix I. No data were available 
for non-smoking COPD patients. Therefore, decline among non-smoking COPD patients 
was assumed to be equal to the decline among the ex-smokers. Annual decline was 
transformed into stage transition rates indicating the probability of moving to a worse 
severity stage, from a given severity stage, e.g. from mild to moderate (see table 1). COPD 
patients who quit smoking could move to a less severe stage, but total remission from 
COPD was impossible. In the first year 0.6% of the moderate, smoking patients moved to 
mild COPD, 1.7% of the severe patients moved to moderate COPD and 1.8% of the very 
severe patients moved to severe COPD because of smoking cessation. 
Mortality by severity
In the model, all cause mortality among COPD patients was divided into “excess mortal-
ity” and “mortality from other causes”. Excess mortality was defined as the difference 
in mortality between COPD patients and the general population, which includes the 
increased risk of dying from other smoking related diseases. 
In order to obtain a well-documented estimate of the relative risk for all-cause mor-
tality per unit change in FEV1% predicted, a meta-analysis was performed on papers 
published between 1970 and 2002, which reported the association between FEV1% 
predicted and all-cause mortality in COPD patients (Appendix II). Other selection criteria 
were a follow-up of at least 3 yrs and a correction of the proportional hazard rate for 
at least age and smoking. The relative risks obtained from the different studies were 
combined into a weighted average, using the precision of the estimates in the study (i.e. 
the size of the 95% confidence intervals) as weights. Assuming a log-linear risk function, 
this meta-analysis resulted in an estimate of the RR per 10-unit decline of 1.20 (95% CI: 
1.16; 1.23) for studies in COPD patients [19-23]. Hence, for each 10-unit decline in FEV1% 
predicted, a 20% increase in excess mortality was modelled. As mortality increases with 
COPD severity, a 20% increase among patients with severe COPD has much more impact 
on absolute mortality than a 20% increase among patients with less severe COPD. Non-
COPD related mortality was assumed not to depend on COPD severity, but only on sex, 
age and smoking. 
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COPD-related healthcare costs by severity
A Dutch prevalence-based cost of illness study for the year 2000 was performed. National 
and regional ongoing registrations or surveys were used from which the costs of GP-
visits, outpatient visits, home care, day-care treatment in hospital, inpatient hospital care, 
nursing home and residential care, influenza vaccination, medication, oxygen therapy 
and lung transplantation were estimated (Appendix III). As there were no Dutch data on 
resource use per severity stage, a Swedish study was used to obtain ratios for the direct 
medical costs of a patient with moderate (2.22), severe (7.51) or very severe COPD (24.67) 
compared with the costs of a patient with mild COPD (1.0) [5]. These ratios were used to 
assign total Dutch costs within each sex and age class to the different severity stages.
Projections
Running the model for the period 2000-2025 resulted in projections of the COPD 
population and its cost of care for current practice. Prevalence and mortality rates were 
expressed as rates per 1000 inhabitants. The projections of current practice were an 
extrapolation of currently observed trends in smoking behaviour and disease progres-
sion. It was assumed that the age and sex specific incidence and mortality rates for each 
severity and smoking class remained constant. Throughout the projections, the costs 
per mild, moderate, severe and very severe patient were also assumed constant at the 
level of the year 2000. 
Sensitivity analysis
To study the robustness of the projections of the model, extensive one-way sensitivity analy-
ses were performed (SA1-SA8). In the first sensitivity analysis the severity distribution of the 
COPD prevalence was assumed to be age-dependent. For each year < 66 yrs (the mean age 
of the COPD patients the distribution was based on), the normal distribution shifted 0.5% 
predicted to the less severe stages, while for each year > 66 yrs it shifted 0.5% to the more 
severe stages. The second sensitivity analysis assumed the severity distribution of the inci-
dence to be the same as the distribution of the prevalence, i.e. 27% of the incidence in mild 
COPD, 55% in moderate COPD, 15% in severe COPD and 3% in very severe COPD. The effect 
of the assumption that 60% of the incidence occurred in mild COPD and 40% in moderate 
COPD was investigated in the third sensitivity analysis. The fourth sensitivity analysis tested 
the effect of a 10% lower decline in FEV1% predicted than predicted from the Lung Health 
Study, while the fifth sensitivity analysis tested the effect of a 10% higher decline. In the 
sixth sensitivity analysis the one-time increase in lung function of the COPD patients who 
stop smoking was assumed to be zero. The seventh sensitivity analysis assumed the decline 
in non-smoking COPD patients to be equal to the decline in smoking instead of former 
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smoking COPD patients. In sensitivity analysis eight, a more than exponential association 
between lung function and mortality risk (i.e. log-quadratic) was tested, because results of 
the meta-analysis gave indications for a deviation from the exponential model. 
Evaluation of two scenarios on increased implementation of two smoking 
interventions
In the projections of current practice, annual changes in the number of non-smokers, 
smokers and ex-smokers, both in the general population and the COPD population, 
were modelled assuming that current age and sex-specific start, quit and restart rates 
for smoking remain constant over time. The current cessation probability among COPD 
patients was estimated to be on average 4.7% for both males and females. This current 
cessation rate was calculated by applying the sex and age specific cessation rates in the 
general population to the sex and age distribution of the COPD patients [9, 10]. 
To illustrate the potential use of the model in setting public health priorities, the 
cost-effectiveness of two smoking cessation scenarios was assessed. The first scenario 
assumed that smoking COPD patients were offered minimal counseling by the general 
practitioner, with a 12-months continuous abstinence probability of 7.9% [24, 25]. The 
second scenario assumed that smoking COPD patients were offered intensive counsel-
ing in combination with bupropion (IC+Bupr). The 12-months continuous abstinence of 
this intervention was 17.2% [26]. In both scenarios it was assumed that, each year, 25% 
of all COPD patients used the intervention. This implied that 25% of all smoking COPD 
patients had a higher smoking cessation probability of either minimal GP counseling 
(7.9%) or intensive counseling plus bupropion (17.2%). The remaining 75% of the smok-
ing COPD patients kept the current cessation probability. Intervention costs of both 
smoking cessation interventions were based on bottom up estimates of resource use 
and costs per unit [27]. Estimates of resource use were based on practice guidelines and 
the original clinical trials from which the effectiveness data were taken. Intervention 
costs were €21 per patient for minimal GP counseling and €334 per patient for IC+Bupr. 
Both scenarios were compared with the projections made for current practice. The 
evaluation was performed over the period 2000-2025 and for different implementation 
periods of the interventions: 1, 10 or 25 yrs. Increasing the number of quitters resulted 
in less progression to worse severity stages, less mortality and less COPD-related costs. 
To calculate quality-adjusted life years (QALYs), life years were corrected for the quality 
of life during these years by means of the COPD severity stage specific QALY weights 
published by Borg et al [28]. To compute costs per life year and costs per QALY gained, 
the savings in COPD-related healthcare costs were subtracted from the additional costs 
of the smoking intervention. These net costs were divided by the gain in life years or the 
gain in QALYs. A discount rate of 4% was applied to both costs and effects. 
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Results
Prevalence and mortality
The model projected that between 2000 and 2025 the absolute number of diagnosed 
COPD patients increased from 188,000 to 270,000 for males and from 117,000 to 224,000 
for females. The prevalence of COPD in the Dutch population of all ages was projected 
to increase from 24 to 33 per 1000 inhabitants for males and from 15 to 27 per 1000 
inhabitants for females. The prevalence increased both in males and females, but the 
increase was higher for females. Figure 2 shows prevalence rates per severity stage over 
time. When prevalence rates for males and females were combined, they increased from 
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Figure 2A-B: Projections of the prevalence rates per severity stage over time for a) males and b) females. 
mild COPD (grey solid); moderate COPD (black dashed); severe COPD (black solid); very severe COPD (grey 
dashed)
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5.1 to 11 per 1000 for mild COPD, from 11 to 14 per 1000 for moderate COPD, from 3.0 
to 3.9 per 1000 for severe COPD and from 0.5 to 1.3 per 1000 for very severe COPD. This 
resulted in an increase of the total prevalence rate from 19 to 30 per 1000 inhabitants.
The absolute number of deaths among COPD patients increased from 15,000 to 
23,000 for males and from 8,000 to 16,000 for females. For males the total mortality 
rate changed from 1.9 to 2.9 per 1000. This indicates that per 1000 males in the general 
population in 2025 2.9 men with COPD will die during that specific year. For females the 
total mortality rate increased from 1.0 to 1.9 per 1000. Figure 3 shows the absolute num-
ber of deaths among COPD patients for the different severity stages for the years 2000 
and 2025. When mortality rates for males and females were combined, they increased 
from 0.3 to 0.7 per 1000 for mild COPD, from 0.8 to 1.1 per 1000 for moderate COPD, 
from 0.3 to 0.4 per 1000 for severe COPD and from 0.1 to 0.2 per 1000 for very severe 
COPD, resulting in an increase of the total mortality rate from 1.4 to 2.4 per 1000. These 
rates are expressed per 1000 inhabitants, thus reflecting that prevalence was highest for 
moderate COPD, followed by mild, severe and very severe COPD.
Healthcare costs
Total COPD-related healthcare costs in 2000 were estimated to be €280 million, €161 
million for males and €119 million for females. The model projected the costs to increase 
to €495 million in 2025, €248 and €247 million for males and females, respectively. Be-
cause costs per patient in a severity class were kept constant over time, this increase in 
total costs was caused by the increase in prevalence combined with the change in the 
severity distribution of the COPD population. Figure 4 presents the total COPD-related 
healthcare costs per severity stage for the years 2000 and 2025. When expressed per 
0
2,000
4,000
6,000
8,000
10,000
12,000
mild moderate severe very
severe
mild moderate severe very
severe
Males Females
COPD severity stage
A
bs
o
lu
te
 
n
u
m
be
r 
o
f d
e
a
th
s
 
a
m
o
n
g 
CO
PD
 
pa
tie
n
ts
 
Figure 3: Absolute number of deaths among COPD patients in 2000 (black bar) and projections for 2025 
(grey bar) by sex and severity stage
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Dutch inhabitant, costs increased from €1.40 to €3.10 for mild COPD, from €6.50 to €9.00 
for moderate COPD, from €6.20 to €8.50 for severe COPD and from €3.40 to €9.40 for very 
severe COPD, resulting in an increase of the total costs per inhabitant from €18 to €30.
Sensitivity analysis
Table 3 summarizes the results of the sensitivity analysis. All projections of total preva-
lence numbers in 2025 were within a range of 5% of the projections of the base-case. 
Table 3: Sensitivity analyses on the projections of prevalence, mortality and total costs (2000, €) for 2025 
Total number of 
COPD patients 
Percentage of COPD patients 
with mild, moderate, severe and 
very severe COPD 
All-cause mortality 
(number of patients)
Total COPD-related 
healthcare costs (million €)
Base-case 494,300 36, 47, 13, 4 39,600 495
SA 1 501,200 37, 47, 12, 4 39,300 496
SA 2 475,400 26, 45, 21, 9 40,400 691
SA 3 514,000 51, 43, 4, 2 38,600 348
SA 4 496,600 37, 48, 12, 4 39,500 464
SA 5 491,900 35, 47, 13, 5 39,700 527
SA 6 492,700 35, 47, 13, 5 39,600 514
SA 7 493,900 36, 47, 13, 4 39,600 500
SA 8 492,400 36, 47, 13, 4 39,600 492
SA: sensitivity analysis; SA 1:severity distribution of the COPD prevalence is age-dependent; SA 2: severity 
distribution of incidence equals the distribution of the prevalence, i.e. 27% in mild, 55% in moderate, 15% 
in severe and 3% in very severe COPD; SA 3: severity distribution of incidence is 60% in mild and 40% in 
moderate COPD; SA 4: decline in FEV1% predicted is 10% lower than estimated from the LHS; SA 5: decline 
in FEV1% predicted is 10% higher than estimated from the LHS; SA 6: No increase in FEV1% predicted after 
smoking cessation; SA 7: Never smoking COPD patients have the same decline as smoking COPD patients; 
SA 8: The association between lung function and mortality is more than exponential. 
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Figure 4: Total COPD-related health care costs in 2000 (black bar) and projections for 2025 (grey bar) by 
sex and severity stage
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Variations in assumptions regarding the severity distribution of the prevalence by age 
(SA1), the decline in lung function (SA4 and 5), the decline in lung function among non-
smoking COPD patients (SA7), increase after smoking cessation (SA6) or the association 
between lung function and mortality (SA8) hardly affected the estimates of prevalence 
by severity. Estimates of the COPD prevalence, mortality and costs were most sensitive 
to the assumption on the severity distribution of the incidence. The two assumptions 
regarding the distribution of incidence resulted in a shift of the severity distribution 
to either less severe stages (SA3) or more severe stages (SA2) compared to the base 
case. Projections of the costs in 2025 ranged from -30% (SA3) to +40% (SA2) of the costs 
projected for the base case model. When lung function decline was either 10% lower 
or 10% higher than predicted from the LHS data, the costs were 6% lower or higher 
compared to the base case. 
Cost-effectiveness of smoking cessation in COPD
Increased implementation of minimal GP counseling for one year resulted in 1200 addi-
tional quitters compared to the projections of current practice. The intervention costs for 
1-yr implementation were €800,000; €700 per additional quitter. In total, 4,700 additional 
quitters were gained after 1-yr implementation of IC+Bupr. The intervention costs for 
one-year implementation were €12.6 million, €2,700 per additional quitter. Table 4 shows 
the discounted cumulative costs and effects over a period of 25 years and the resulting 
cost-effectiveness ratios in terms of costs per life-year gained and costs per QALY gained. 
Regardless of the implementation period, minimal GP counseling was a dominant 
strategy compared with current practice, because effects were higher and costs savings 
were higher than intervention costs. For a 25-yr implementation period at 4% discount-
Table 4: Number of (quality-adjusted) life years (Lys or QALYs) gained, total intervention costs, total savings and 
cost-effectiveness: cumulative over the years 2000-2025, discounted at 4% for both costs and effects (2000, €)
Duration of 
implementation
LYs gained QALYs 
gained
Intervention costs 
(million)
Savings in COPD-
related costs 
(million)
Costs per LY 
gained
Costs per QALY 
gained
1 year
MC# 100 170 0.8 1.8 # #
IC+Bupr§ 500 790 12.6 6.9 10,600 7,300
10 years
MC 1,100 1,700 7.1 15.2 # #
IC+Bupr 4,000 6,200 104.6 56.6 12,000 7,700
25 years
MC 1,400 2,500 15.3 24.5 # #
IC+Bupr 5,400 9,300 219.1 88.0 24,500 14,100
# MC = minimal GP counseling
§ IC+Bupr = intensive counseling plus bupropion
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ing, 1,400 life years or 2,500 QALYs were gained. Subtracting the savings in COPD-related 
costs from the intervention costs over the 25-year period resulted in a net saving of €9.2 
million. IC+Bupr is more effective. Over the 25-year period 5,400 life years or 9,300 QALYs 
were gained, but the intervention costs were much higher and not fully offset by extra 
savings. Costs per QALY gained were estimated to be €14,100 for IC+Bupr.  
Discussion
Whenever it is important to inform policy makers about the expected future trends in 
the epidemiology of a disease and the long-term impact of implementation of certain 
interventions, modelling is required. In the present study a dynamic population model 
for COPD was developed that included progression of COPD over time from diagnosis 
of the disease to death. This model was used to project the prevalence, mortality and 
COPD-related healthcare costs by severity stage and to assess the long-term impact of 
two smoking cessation interventions. 
The projections of current practice have shown that over a period of 25 years, an 
increase of 6 mild, 3 moderate, 0.9 severe and 0.8 very severe patients per 1000 inhabit-
ants in the Netherlands can be expected. This increases total COPD-related healthcare 
costs from €280 to 495 million in 2025, an increase of almost 80%. Costs of COPD per 
Dutch inhabitant increase from €18 to 30. Of every 1000 inhabitants in the year 2025, 
2.4 COPD patients will die compared with 1.4 in the year 2000. In absolute terms, 
prevalence, mortality and costs were highest for moderate COPD, but the proportional 
increase in these parameters between 2000 and 2025 was highest for very severe COPD 
and second highest for mild COPD. The latter is explained by the relative high incidence 
in this stage in combination with the slow progression of the disease. The first can partly 
be explained by the increasing number of Dutch inhabitants, especially females with a 
long smoking history, in the highest age categories.
The main reason to develop such a COPD model is to have an instrument with which 
to compare the success of various interventions in reducing the expected increase in 
the burden of COPD. This can only be done with a model that incorporates disease pro-
gression over time. To illustrate its use, projections of current practice were compared 
with two scenarios in which it was assumed that COPD patients more often get minimal 
counseling by a GP or IC+Bupr. The model showed that offering minimal GP counseling 
to 25% of all diagnosed, smoking COPD patients resulted in a gain in health and life years 
and net cost savings irrespective of whether the intervention was implemented for 1, 10 
or 25 years. The combination of IC+Bupr to 25% of all smoking COPD patients each year, 
for a period of 10 years, resulted in costs per life-year gained of about €12000 (€7,700 
per QALY), which is relatively low compared with other healthcare interventions.
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The COPD model is embedded in a population model so that outcomes represent the 
Dutch setting. The Dutch COPD population, as in other high-income countries reflects 
the smoking epidemic of the past decades. Short-term developments depend on age-
ing and the effects of past smoking behaviour [3]. The current model describes these 
developments in detail and enables evaluation of policy measures to reduce the burden 
of COPD. For other countries with similar populations and comparable under-diagnosis, 
similar results might be expected. However, whether the cost effectiveness outcomes 
have validity for other countries also depends on the relative costs of different types 
of care. The model structure would allow translating the model to different countries 
using country specific data on costs, smoking behaviour and the severity distribution of 
incidence and prevalence. 
It is important to stress that this is a model of physician-diagnosed COPD patients, 
since undiagnosed subjects are not modelled. Under-diagnosis is a well-known problem 
in COPD. However, because the model is intended to be a policy model, only diagnosed 
COPD is described and modelled. Undiagnosed patients may also use care for their COPD, 
but this care can never be related to COPD. An interesting topic for future research is the 
evaluation of case finding. Case finding efforts would shift the incidence distribution to 
the less severe cases, over time also shifting the prevalence distribution. 
It is further important to note that because the model is a dynamic population model 
and not a cohort model that follows a group of COPD patients over time until they have 
all died, it does not suffer from cohort or survival effects. 
In order to validate the model, outcomes of total COPD prevalence for the years 2000-
2003 were compared to the prevalence as found in the Continuous Morbidity Registration 
(CMR) [15]. As differences in prevalence rates per 1000 between the model projections 
and the CMR data varied from 0.42 for females in 2003 to 3.71 for men in males, we con-
cluded that our model projections compare quite well with this GP registration. As the 
CMR does not contain prevalence rates by disease severity, this registration could not be 
used to validate the severity distribution. The severity distribution of COPD was therefore 
validated with data from a Dutch study on a new regional patient management program 
in the Maastricht area (The Netherlands) in which all known COPD patients, treated either 
in primary care or by pulmonologists, underwent spirometry testing at baseline [29]. This 
study estimated the severity distribution of COPD in 2002/2003 to be 30% in mild, 48% in 
moderate, 17% in severe and 5% in very severe COPD. The current model projections for 
the year 2003 were 29, 52, 16 and 3%, respectively. Hence, they were quite close to the 
estimates from Maastricht. It is not possible to validate the model to historical data, as 
the severity distributions of incidence and prevalence were not available in the past, as 
lung function measurements did not routinely take place in GP practices. 
Although modelling is a powerful tool to estimate the long-term effects of interven-
tions that cannot be studied in clinical trials, it certainly has limitations. Due to limited 
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availability of suitable epidemiological data to generate robust estimates, making as-
sumptions was inevitable. The most important assumptions will now be discussed. 
For simplification of the model the progression of COPD was assumed to be primarily 
dependent on decline in FEV1% predicted, which in turn, depends on sex, age, smoking 
status and FEV1% predicted. Of course, the progression of COPD is influenced by many 
other factors, such as smoking history, susceptibility to smoking and exacerbations. As 
the current model primarily concentrates on disease progression, it omits COPD exacer-
bations. Recently two studies have found indications that exacerbations accelerate the 
decline in lung function with about 8 ml/yr [30, 31], which seems to be relatively modest. 
Hence, the results presented above would probably not change much after inclusion of 
exacerbations. However, in order to model the cost-effectiveness of interventions that 
reduce the number, duration and/or severity of exacerbations, exacerbations will be 
included in future versions of the model. Currently, it is impossible to explicitly include 
treatment-related variables with a possible influence on COPD progression or survival, 
such as oxygen therapy or nutritional and exercise interventions, into the model, be-
cause the size of the effect in terms of lung function decline is still unknown. However, 
their effect is already present in the estimates of the input parameters of the model, as 
these were largely obtained from registries or studies that allowed patients to obtain 
treatment deemed necessary.  
The sex- and age-specific estimates of COPD prevalence and incidence, which were 
obtained from regional GP registrations, were assumed to be representative for the 
Dutch population of diagnosed COPD patients. This assumption is reasonable, because 
virtually all people in the Netherlands, including those treated by pulmonologists, are 
registered with a GP practice. Nevertheless, the recording of spirometric results in the 
electronic patient records is far from perfect and when, for example, results of severe 
patients are more likely to be missing, the prevalence of severe and very severe COPD 
might be underestimated. Furthermore, data were too limited to enable specification of 
the severity distribution by sex, age and smoking status. In the sensitivity analysis the 
severity distribution by age (SA1) was varied, but the projections did not change much.
Although the Lung Health Study is the best and largest study on the effects of smoking 
and smoking cessation on lung function in COPD, it has limitations for the current studies 
purpose [8]. The study population mainly consisted of subjects with mild-to-moderate 
airflow obstruction aged 40-60 years. Decline (and increase after smoking cessation) 
for patients outside the observed age and lung function range had to be based on ex-
trapolation of the data using the random effect model. Changing the annual decline in 
lung function with plus or minus 10% did not influence the outcomes greatly (SA4, 5). As 
non-smokers did not participate in the Lung Health Study, the decline in lung function 
among non-smokers was assumed to equal the decline among ex-smokers. This was 
thought to be more realistic than assuming that the decline equals the decline in non-
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smokers in the general population. As the number of never smoking COPD patients is 
rather small, assuming the decline of non-smokers to be equal to the decline in smoking 
COPD patients did not change the results much (SA7). 
Results from the sensitivity analyses show that the model projections are most sensi-
tive to changes in the assumption about the severity distribution of the incidence. It 
is important to stress that the two assumptions tested in the sensitivity analysis were 
extremes. Such extremely different assumptions were not applied to other variables in 
the sensitivity analyses. The choice of these sensitivity analyses resulted from very dif-
ferent views of the expert panel on the incidence distribution. The assumption that 60% 
of the incidence occurs in mild and 40% in moderate COPD reflects the optimistic view 
that COPD is increasingly diagnosed in earlier stages. The assumption that the severity 
distribution of the incidence equals the distribution of the prevalence represents a pes-
simistic view with relatively many patients diagnosed when they already have advanced 
COPD. The real distribution is somewhere in between and probably close to what was 
estimated i.e. 40% in mild, 55% in moderate, 4% in severe COPD and 0.1% in very severe 
COPD. 
In conclusion, a dynamic COPD model has been constructed that summarizes much 
of the current epidemiological knowledge about COPD. This model is a valuable tool for 
policy making, because it can represent and identify trends in the future burden and 
costs of COPD and assess the cost-effectiveness of interventions offered to patients with 
COPD in different severity stages.  
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Appendix I: Calculation of annual decline in lung function
Table A1 shows the regression coefficients of the random effect model based on the 
original 5-yr follow-up data of the Lung Health Study. This model was used to calculate 
sex, age, smoking status and FEV1% predicted dependent values of annual decline in 
lung function.  
Annual decline was calculated by subtracting the calculated FEV1% predicted in year 0 
(given certain sex, age, smoking status and baseline FEV1% predicted) of the FEV1% pre-
dicted in year 1 (given certain sex, age+1, smoking status and baseline FEV1% predicted) 
Table A1: Regression coefficients of the random effect model used to calculate annual decline in lung 
function
Dependent variable: FEV1% predicted β-Coefficient p-value
Intercept -20.9546 0.26
Year 0.2394 0.33
Smoking cessation (0=no, 1=yes) 14.3188 <0.0001
Sex (0=male, 1=female) 7.3174 0.10
Age 1.1132 0.13
Baseline FEV1% predicted 1.3646 <0.0001
Year*smoking cessation 0.4556 <0.0001
Year*sex -0.1562 <0.0001
Year*age -0.03144 <0.0001
Year*baseline FEV1% predicted 0.006027 <0.01
Smoking cessation*sex 1.7297 <0.0001
Smoking cessation*baseline FEV1% predicted -0.1242 <0.0001
Sex*age -0.4038 <0.05
Sex*baseline FEV1% predicted 0.02723 <0.05
Age*baseline FEV1% predicted -0.01818 <0.05
Age2 -0.01213 0.10
Age2*smoking cessation -0.00086 <0.0001
Age2*sex 0.004299 <0.05
Age2*baseline FEV1% predicted 0.000197 <0.05
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Appendix II: Meta-analysis on lung function and mortality
To estimate the relationship between FEV1% predicted and all-cause mortality, a meta-
analysis was performed on papers published between 1970 and 2002 reporting this 
association in a general or COPD population. Papers had to meet the following in- and 
exclusion criteria:
•	 ≥	3	yrs	of	follow-up
•	 Caucasian	population
•	 Association	corrected	for	at	least	age	and	smoking
•	 Association	not	corrected	for	dyspnoea	and	decline	in	lung	function
•	 Not	in	patients	hospitalized	for	a	COPD	exacerbation
•	 Reporting	standard	errors	(SE)
For each paper that directly reported the relative risk (RR) per unit of change in FEV1% 
predicated, the relative change in mortality rate associated with a 10-unit decline in 
FEV1% predicted was calculated. For each paper that reported the RRs per class of FEV1% 
predicted a log-linear risk function was first fitted on the data, before the RR of a 10-unit 
decline in FEV1% predicted was calculated. The RRs of all papers were combined into a 
weighted mean, using the precision of the estimate in each paper as a weight.
In total, 17 studies were found. Of these 11 directly reported the RRs per unit change 
in FEV1% predicted [32-42] and six reported the RRs by class of FEV1% predicted [43-
48]. Only 5 of these 17 were done in COPD patients [36, 38, 39, 42, 43]. Table A2 shows 
the results for COPD and the general population. Two additional studies in COPD were 
available, but they did not report SE [49,50]. When the two studies not reporting SE 
were included, the mean RR in seven COPD studies, weighted for the sample size in each 
study, was 1.28.
Among COPD patients each 10-unit decrease in FEV1% predicted increased the mor-
tality risk by at least 20%. This is a significantly higher increase than the 11% increase 
among the general population.  
Table A2: Relative mortality risks of a 10-unit decline in FEV1% predicted
COPD General population
RR (95% confidence interval) 1.20 (1.16; 1.23) 1.11 (1.10; 1.12)
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Appendix III: Cost of illness for COPD
A prevalence-based cost of illness study for the year 2000 was performed. Only direct 
medical costs were taken into account. Data on healthcare use were, as much as pos-
sible, obtained from representative national registries to obtain age- and sex-specific 
data. Costs per unit of resource use were also estimated. Resource use was multiplied 
with unit costs to calculate total costs for COPD care in the Netherlands (table A3). All 
costs were valued in € (price level 2000).
Table A3: Data source, unit costs and total costs per type of care
Unit Data source Unit costs 
2000 €
Total costs in 
million €
General practitioner Visit Confronting COPD Survey 17 13
Specialist Outpatient visit Confronting COPD Survey 50 27
Home care Hour Patient Panel Chronic Diseases 8.70 54
Hospital
Day-care Day National Medical Registration 177 0.17
Inpatient care Day National Medical Registration 271 75
Nursing home - Study on Cost of illness in the Netherlands - 34
Influenza vaccination Vaccination Evaluation National Influenza Vaccination 
Campaign 
15 3.5
Medication Prescription Foundation for Pharmaceutical Statistics - 60
Oxygen therapy Day Netherlands Organisation for Health Research and 
Development
4.20 11
Lung transplantation Transplantation Eurotransplant 186,000 1.3
Total 280
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Abstract 
The aim of this study was to estimate the long-term (cost-)effectiveness of smoking ces-
sation interventions for patients with chronic obstructive pulmonary disease (COPD). A 
systematic review was performed of randomized controlled trials on smoking cessation 
interventions in patients with COPD reporting the 12-months biochemical validated 
abstinence rates. The different interventions were grouped into four categories: usual 
care, minimal counseling, intensive counseling and intensive counseling plus pharma-
cotherapy (=”pharmacotherapy”). For each category the average 12-month continuous 
abstinence rate and intervention costs were estimated. A dynamic population model for 
COPD was used to project the long-term (cost-)effectiveness (25 years) of 1-year imple-
mentation of the interventions for 50% of the smoking COPD patients compared with 
usual care. Uncertainty and one-way sensitivity analyses were performed for variations 
in the calculation of the abstinence rates, the type of projection, intervention costs and 
discount rates. Nine studies were selected. The average 12-month continuous absti-
nence rates were estimated to be 1.4% for usual care, 2.6% for minimal counseling, 6.0% 
for intensive counseling and 12.3% for pharmacotherapy. Compared with usual care, 
the costs per quality-adjusted life year (QALY) gained for minimal counseling, intensive 
counseling and pharmacotherapy were €16,900, €8,200 and €2,400, respectively. The 
results were most sensitive to variations in the estimation of the abstinence rates and 
discount rates. Compared with usual care intensive counseling and pharmacotherapy 
resulted in low costs per QALY gained with ratios comparable to results presented for 
smoking cessation in the general population. Compared with intensive counseling, 
pharmacotherapy was cost saving and dominated the other interventions. 
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
Cost-effectiveness of smoking cessation interventions in COPD patients 63
Introduction
Smoking cessation is still the most important intervention to slow down the disease 
progression of chronic obstructive pulmonary disease (COPD) [1-3]. It decreases the 
annual decline in lung function [4], reduces symptoms of cough and sputum, improves 
health status and reduces exacerbations of COPD [5]. Because of the strong associa-
tion between use of healthcare services and disease severity [6], slowing down disease 
progression is likely to reduce annual COPD-related healthcare costs. 
Current treatment guidelines recommend that all smoking COPD patients should 
be offered the most intensive smoking cessation intervention feasible [7,8]. A review 
of five smoking cessation interventions offered to COPD patients by Wagena et al 
showed that only pharmacotherapy combined with intensive counseling seemed to 
be effective in this patient group. The effects of less intensive strategies did not reach 
statistical significance [9]. A more recent review concluded that counseling plus nicotine 
replacement therapy (NRT) had the greatest effect on prolonged abstinence rates in 
smokers with COPD [10]. Although almost all smoking cessation interventions targeted 
at smokers in the general population are cost-effective [11,12], little is known about 
the cost-effectiveness of smoking cessation interventions offered to patients who al-
ready have a smoking-related disease like COPD. Since information on the short-term 
cost-effectiveness of these interventions in COPD is already scarce, information on the 
long-term cost-effectiveness is virtually absent. It is however highly relevant to know 
the long-term cost-effectiveness, because the health benefits are small in the first year 
after the intervention, but will continue to increase over time. 
The aim of this study was to estimate the impact of smoking cessation interventions 
offered to COPD patients on the future burden of COPD using a previously published 
dynamic population-based model of COPD disease progression [13].
Methods
Study selection
All randomized controlled trials published in English investigating the effectiveness 
of a smoking cessation intervention in patients with COPD confirmed by spirometry 
or physician-diagnosis were included if the follow-up was at least twelve months. The 
smoking cessation intervention or therapy had to be the primary intervention and not 
part of a disease management or education program and abstinence of smoking had to 
be biochemically validated. 
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
64 Chapter 4
Search strategy
We performed a literature search in MEDLINE using the following MeSH headings 
or words in the title or abstract: COPD or “chronic obstructive pulmonary disease” or 
“chronic bronchitis” in combination with smoking, tobacco, nicotine or smok* or nicotin* 
and one of the following terms: smoking cessation or tobacco use or quit* or stop* or 
cessat* or abstin* or abstain*. The search was performed in February 2009 and limited to 
randomized controlled trials published in English. We also searched the reference lists 
of retrieved articles and checked the systematic reviews for further references. If the 
search in MEDLINE resulted in studies reporting 6-month results, but the authors were 
aware of other publications in which the 12-month results were presented the study 
was included.
Methodological quality
The methodological quality of the selected studies was evaluated using the Jadad scale 
and the Delphi list [14,15]. The Jadad scale consists of five questions with respect to 
randomization and blinding. Each positive answer to a question was valued with one 
and a negative answer with zero, resulting in a sum score ranging from zero to five [14]. 
The Delphi-list consists of nine aspects regarding randomization, study population, 
blinding and presentation of results. Possible answers were scored as one point (“yes”) 
or zero points (“no” or “don’t know”), resulting in a sum score ranging from 0 to 9 [15]. 
Both scores were assigned independently by two reviewers (MH, TF, MRM). Points of 
disagreement were discussed until consensus was reached. Both scores were used in 
combination to assess the methodological quality of the studies.
Combination of abstinence rates and intervention costs
The interventions performed in the different arms of the selected trials were grouped 
into four categories: 1) care as usual, defined as no counseling or pharmacotherapy or 
any other type of smoking intervention offered as part of the trial (=”usual care”), 2) 
minimal or brief counseling, < 90 minutes in total (=”minimal counseling”), 3) intensive 
counseling, ≥90 minutes without pharmacotherapy (=”intensive counseling”) and 4) 
intensive counseling in combination with any type of pharmacotherapy (=”pharma-
cotherapy”). Interventions offering pharmacotherapy on a non-compulsory basis were 
included in the category with pharmacotherapy if this was used by >50% of the patients. 
Patients in the placebo-arms of drug trials often received some form of counseling and 
were therefore grouped into the categories minimal or intensive counseling depending 
on the duration of counseling. For our model calculations we needed absolute quit rates 
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for at least one of the four intervention categories. We therefore used random effect 
meta-analysis [16] to account for study heterogeneity and estimated mean abstinence 
rates for all four categories. The rates were calculated separately for 12-month continu-
ous abstinence and 12-month point prevalence abstinence. Twelve months continuous 
abstinence was defined as biochemical validated abstinence at all measurements up 
to 12 months including the 12-months measurement. Twelve months point prevalence 
abstinence was defined as biochemical validated abstinence at 12 months. We recalcu-
lated the abstinence rates to the intention-to-treat population assuming subjects with 
missing data to be smokers when this was not done in the main analysis of the article. 
For studies providing sufficient details about the intervention, the costs of the 
intervention were estimated using Dutch unit costs for the year 2007. Based on these 
estimates average intervention costs for all four intervention categories were calculated 
as the weighted means over the studies using the numbers of patients as weights.
Model 
A dynamic population model for COPD was used to estimate the impact of increased 
implementation of smoking cessation interventions compared with usual care [13]. The 
model is representative for the total Dutch COPD population (306,000 patients in 2000) 
and is dynamic because changes in the population, such as birth, mortality, ageing and 
changing smoking patterns in the population are taken into account. The model distin-
guishes six states: no COPD, four COPD severity stages (mild, moderate, severe and very 
severe COPD based on the GOLD classification) [8] and dead. The prevalence of COPD for 
the first year of simulation was distributed over the four COPD severity stages according 
to the observed severity distribution of physician-diagnosed patients in the Netherlands 
[17]. For each following year the model simulates the changes in the number of COPD 
patients, the severity distribution and annual COPD-related healthcare costs due to 
incidence, mortality and disease progression, i.e. annual decline in FEV1% predicted. 
Incidence, mortality and disease progression are specified by sex, age, smoking status 
and COPD disease severity. COPD-related healthcare costs are specified by sex, age and 
COPD severity. The most important input parameters of the model are shown in table 1. 
An extensive description of the model can be found elsewhere [13]. The model can be 
used for projections of the Dutch COPD population over time, but more importantly, to 
evaluate the long-term costs and health benefits of interventions as was done for this 
study. The effects of smoking cessation were modelled as a one-time increase in FEV1% 
predicted in the year of smoking cessation followed by a lower annual decline in FEV1% 
predicted based on the Lung Health Study [4] and reduced mortality due to COPD and 
other smoking-related diseases. The implementation of smoking cessation interven-
tions for COPD patients was modelled by replacing the smoking cessation rates of usual 
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care by the higher smoking cessation rates of the intervention for a certain period of 
time, for a certain (part of ) the COPD population. A higher cessation rate compared to 
usual care results in more COPD patients quitting smoking, slower progression to worse 
COPD severity stages, less mortality and a reduction in COPD-related healthcare costs. 
The model uses 12-month abstinence rates and accounts for annual probabilities to 
relapse in former smokers, so former smokers may start smoking again also more than 
one year after quitting [13].  
Outcome parameters
The long-term effectiveness of the interventions was expressed in terms of the cumula-
tive number of life years and quality-adjusted life years (QALYs) gained and the cumula-
tive reduction in mortality. QALYs were calculated by weighting life years for the quality 
of life during these years in each COPD severity stage using EQ-5D utility weights (Table 
1). The cumulative number of life years, QALYs and deaths over the entire time horizon 
was calculated as the sum of the annual number of patients alive, the annual number of 
QALYs and the annual number of deaths, respectively, discounting future outcomes. The 
cumulative COPD-related healthcare costs were calculated as the properly discounted 
sum of the annual COPD-related healthcare costs over the time horizon. Finally, the cost 
per (quality-adjusted) life year gained was calculated as the ratio of total intervention 
costs minus savings in COPD-related healthcare costs compared with usual care divided 
by the cumulative (quality-adjusted) life years gained compared with usual care.  
Table 1: Main input parameters of the COPD disease progression model [13]
Mild 
COPD
Moderate 
COPD
Severe 
COPD
Very severe 
COPD
Prevalence per 1000 people in the general population* 5.1 10.7 3.0 0.5
Incidence per 1000 people in the general population* 0.71 0.94 0.08 0.003
Annual decline in FEV1% predicted# Smokers -1.13 -1.50 -1.84 -2.13
Ex-smokers -0.79 -1.17 -1.51 -1.79
One-time increase in FEV1% predicted 
associated with smoking cessation
0.03 2.91 5.56 7.76
Total mortality per 1000 COPD patients in a 
specific severity stage* Smokers 61 73 91 114
Ex-smokers^ 51 64 82 104
COPD-related healthcare costs (2007 €) 318 700 2,389 7,847
EQ-5D utility weights [18] 0.8971 0.7551 0.7481 0.5493
*Data from the year 2000, the first year of the simulation
# Data presented as the average for males and females with a mean age of 68 years, the mean age of the 
total Dutch COPD population
^ Standardized for the sex, age and COPD severity distribution of the smokers
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Base case analysis
In the base case analysis we modelled the impact of offering minimal counseling, in-
tensive counseling or pharmacotherapy to 50% of the Dutch smoking COPD patients 
(76,000 patients) for one year compared with usual care. Fifty percent was chosen 
because this percentage of smoking COPD patients reported a willingness to stop smok-
ing within six months [19,20]. The base case analysis was performed using the mean 
12-month continuous abstinence rates as calculated in the meta-analysis. Analyses were 
performed from a healthcare perspective. Effects and costs were evaluated over a time 
horizon of 25 years and were discounted at 1.5% and 4%, respectively, as recommended 
by Dutch guidelines for pharmacoeconomic evaluations [21]. 
Uncertainty and sensitivity analyses
The uncertainty around the outcomes due to the uncertainty around the calculated 
abstinence rates and intervention costs was assessed using the 95% lower and upper 
limit of the difference in abstinence rate compared with usual care and the minimum 
and maximum estimate of the intervention costs. Furthermore, a series of one-way 
sensitivity analyses was performed to estimate the impact of the choice of input param-
eters on the outcomes. In the first sensitivity analysis the impact of using the 12-months 
point prevalence rate was assessed. In the second analysis effects and costs were not 
discounted. For our base case analyses we used absolute quit rates based on random ef-
fect meta-analysis. In sensitivity analysis three we replaced these by estimating the odds 
ratio (OR) of minimal counseling, intensive counseling and pharmacotherapy versus 
usual care using a network meta-analysis approach [22] and applied these OR’s to the 
average 12-months continuous abstinence rate for usual care. In the fourth sensitivity 
analysis the model was run for the cohort of Dutch COPD patients present at the start of 
the simulations assuming no new incidence of COPD. In contrast to the Netherlands, in 
many countries nortriptyline is not considered and/or used for pharmacological smok-
ing cessation support, because it is not registered as such. In the fifth sensitivity analysis 
we therefore estimated the outcomes for pharmacotherapy excluding the studies on 
nortriptyline. 
Results
The literature search identified 39 publications of which 26 were rejected in the first se-
lection based on the title and abstract only. The remaining 13 references were reviewed 
in full, resulting in the further exclusion of three papers. One reported abstinence rates 
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which were not biochemically validated. The other two studies had a follow-up of six 
months, and to our knowledge, no other publication was available that reported the 12 
months results. Two publications concerned the same study. This resulted in inclusion of 
ten papers reporting nine different studies [2,20,23-30]. Characteristics of these studies 
are shown in Table 2.  The methodological quality of the selected studies is described in 
the Appendix. The highest scores were observed for studies comparing pharmacologi-
cal treatments, because these studies score positive on items about “double-blinding”. 
In studies comparing counseling with, for instance, usual care double-blinding is not 
feasible, so they received a lower quality score. All nine studies were included in the 
analyses. The table in the online supplement also shows the definitions of abstinence, 
the method of biochemical validation and the reported abstinence rates for the inter-
ventions in the different arms of the nine selected studies. Nineteen different estimates 
of 12-month continuous abstinence were reported, one estimate for usual care [20], 
three for minimal counseling [20,23,24], six for intensive counseling [24-29,31] and nine 
for pharmacotherapy (three for NRT, three for bupropion and three for nortriptyline) 
[23-29,31]. The weighted average 12-month continuous abstinence rates for intensive 
counseling (6.0%) and for pharmacotherapy (12.3%) were significantly higher than for 
usual care (1.4%). This was not the case for minimal counseling, with an abstinence rate 
of 2.6% (Table 3). Six studies provided sufficient details to estimate the additional costs 
of the interventions, minimal counseling (three estimates [20,23,24]), intensive counsel-
ing (five estimates [24-27]) and pharmacotherapy (eight estimates [23-27]), compared 
with usual care. Table 3 shows the weighted average intervention costs as well as the 
minimum and maximum costs observed within the intervention category. 
Table 4 shows the results for the base case analysis, one year implementation of the 
intervention for 50% of the smoking COPD patients and evaluation of outcomes over a 
25-year time horizon. Compared with usual care the discounted cumulative number of 
QALYs gained among this group of COPD patients in the Netherlands was 280 for minimal 
counseling, 960 for intensive counseling and 2,240 for pharmacotherapy. Figure 1 shows the 
undiscounted number of QALYs gained per year over the 25-year time horizon of the base 
case analysis. For each of the interventions, the maximum gain in QALYs was observed ten 
to fifteen years after implementation. Compared with usual care the net costs (difference 
in intervention costs minus savings in COPD-related healthcare costs) were €4.8 million for 
minimal counseling, €7.9 million for intensive counseling and €6.3 million for pharmaco-
therapy. Estimates of the cost-effectiveness compared with usual care, ranged from €2,400 
for pharmacotherapy to €16,900 per QALY gained for minimal counseling. If each interven-
tion was compared to the next most effective intervention, the cost per QALY of intensive 
versus minimal counseling was €4,600, while pharmacotherapy versus intensive counseling 
was cost saving.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
72 Chapter 4
Uncertainty and sensitivity analyses
Figure 2 shows the uncertainty around the difference in total costs and the difference in 
QALYs compared with usual care as a result of the uncertainty around the 12-month con-
tinuous abstinence rates and the intervention costs. For minimal counseling the results 
varied from less effective than usual care with higher costs to more effective with cost 
savings. The results for intensive counseling ranged from more effective and cost saving 
to a maximum possible cost per QALY gained of €44,800, while for pharmacotherapy 
results ranged from more effective and cost saving to a maximum of €15,700 per QALY 
gained. The results of the different sensitivity analyses for all interventions compared 
with usual care are shown in Table 4. Using the 12-months point prevalence rates for each 
of the three types of interventions and usual care resulted in a slightly lower estimate 
of the cost per QALY gained for minimal counseling and slightly higher estimates for 
intensive counseling and pharmacotherapy versus usual care compared with the base 
case analysis. No discounting for both effects and costs also resulted in lower estimates 
of the cost per QALY gained with pharmacotherapy even being cost saving. The third 
sensitivity analysis resulted in OR’s of 2.4, 4.7 and 9.8 for minimal counseling, intensive 
counseling and pharmacotherapy compared with usual care, respectively. Applying 
these to the 12-month continuous abstinence rate of usual care (1.4%) resulted in the 
following abstinence rates of 3.3%, 6.4% and 13.2% for minimal counseling, intensive 
counseling and pharmacotherapy, respectively. Consequently, the cost-effectiveness of 
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Figure 1: Annual number of quality-adjusted life years (QALYs) gained over time for 1-year 
implementation of minimal or brief counseling, intensive counseling without pharmacotherapy and 
intensive counseling with pharmacotherapy (‘pharmacotherapy’) compared with usual care, 0% 
discounting
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all three interventions was (slightly) better than the base case analysis. Outcomes based 
on a cohort of COPD patients instead of using the dynamic version of the model did not 
have much influence on the results. The fifth sensitivity analysis based on the 12-months 
continuous abstinence rate and the weighted average intervention costs excluding the 
studies on nortriptyline (12.0% and €403, respectively) showed an increase of the cost 
per QALY for pharmacotherapy compared with usual care from €2,400 to €6,100.    
Discussion
This study estimated the impact of offering different types of smoking cessation inter-
ventions to patients with COPD. Meta-analysis showed that both intensive counseling 
(defined as >90 minutes counseling) as well as intensive counseling with any type of 
pharmacotherapy were significantly more effective than usual care. The cost-effective-
ness ratio’s for both types of intervention were low and below €20,000 per QALY gained, 
the often mentioned threshold for an intervention to be considered cost-effective in the 
Netherlands [32]. Comparison of pharmacotherapy with intensive counseling resulted 
in cost savings making pharmacotherapy the most favourable intervention. The cost per 
QALY gained for minimal or brief counseling (defined as counseling <90 minutes) was 
also below €20,000, but the effectiveness was not significantly different from usual care. 
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Figure 2: Uncertainty around the difference in total costs and the difference in quality-adjusted life years 
(QALYs) for the base case analysis, 1-year implementation of the intervention compared with usual care over a 
time horizon of 25 years, discount rate for effects 1.5% and for costs 4%. ( = minimal or brief counseling,  = 
intensive counseling and  = intensive counseling + pharmacotherapy)
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Our literature search on studies reporting the effectiveness of smoking cessation 
interventions in patients with COPD resulted in nine studies. It was therefore impossible 
to group the interventions into more than three or four categories, although we ac-
knowledge that differences in methods and interventions within one category existed. 
Minimal and intensive counseling are commonly used classifications in smoking ces-
sation studies and reviews. The pharmacotherapy category was too small to subdivide 
by type, intensity or duration of pharmacotherapy. Longer duration or greater intensity 
of pharmacotherapy would probably lead to higher abstinence rates, although it is not 
clear whether this is also true for COPD patients. With regard to type of pharmaco-
therapy, the meta-analysis included three estimates on each type of pharmacotherapy 
(bupropion, nortriptyline and NRT). If, despite the low numbers, the category pharma-
cotherapy was subdivided into intensive counseling plus NRT and intensive counseling 
plus antidepressant, the cost per QALY gained would have been €10,400 for NRT and 
€600 for antidepressants, both low ratios. However, more research on the effective-
ness of pharmacotherapies in COPD patients is needed to give better estimates of the 
cost-effectiveness specified by type, intensity of supportive counseling and duration of 
pharmacotherapy. Our estimate of pharmacotherapy included the results of studies of-
fering pharmacotherapy on a non-compulsory basis, if this was used by more than 50% 
of the patients. This might have resulted in a potential underestimation of the effect of 
pharmacotherapy. Exclusion of the two trials with non-compulsory pharmacotherapy, 
however, only had a small effect on the incremental cost-effectiveness ratio of pharma-
cotherapy (€1,900 instead of €2,400 per QALY gained). 
Our estimates of the 12-month continuous abstinence rates of intensive counseling 
(6.0%) and pharmacotherapy (12.3%) were still relatively low and lower than observed 
in the general population (10 and 17%, respectively) [33,34]. These results suggest that 
abstinence rates in patients with COPD are lower than in “healthy” smokers. This finding 
was also observed in a study by Wagena et al which showed that patients with COPD 
had a 30% higher chance of relapsing than smokers at risk of COPD [27]. By increasing 
the intensity and duration of counseling and/or pharmacotherapy, the abstinence rates 
in COPD may possibly increase as shown by the Lung Health study also included in our 
meta-analysis [2]. This study is unique in terms of intensity of the intervention, monitor-
ing of patients and follow-up, which resulted in remarkably high abstinence rates for 
the smoking intervention group but also for the usual care group. Although the current 
guidelines advocate the most intensive smoking cessation intervention, it is question-
able whether an intervention with such a high intensity as the Lung Health Study is 
feasible in daily practice. 
Results for the cost-effectiveness of pharmacotherapy and intensive counseling in 
COPD were comparable with the cost per QALY gained for smoking cessation support 
in the general population. For the general population studies on nicotine replacement 
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therapy (NRT), bupropion and nortriptyline have showed cost-effectiveness ratios con-
sistently below €10,000 per (quality adjusted) life year [12,35-38]. The cost-effectiveness 
ratio for minimal counseling in COPD is somewhat higher than in studies in the general 
public [11,12]. This is probably a result of the lower abstinence rate and the relatively 
high intervention costs compared with other studies on minimal counseling. In our 
study minimal counseling for COPD patients still consisted of an average of about 25 
minutes counseling, while in most general population studies minimal counseling is 
defined as less than 10 minutes of cessation advice.
The common approach in reviews evaluating the effectiveness of smoking cessation 
interventions is to report the RR or OR of one comparator with the other [9,33,34]. The 
best method to retain randomization would be a network meta-analysis. However, in 
addition, for a cost-effectiveness analysis the absolute quit rate for at least one of the in-
terventions or usual care need to be estimated. We decided instead to use the averages 
of the absolute quit rates as obtained from random effect meta-analysis in our base case 
analysis. Estimating OR’s and applying them to the absolute quit rate of usual care would 
have resulted in slightly more favourable cost per QALY estimates for all interventions, 
but would not have changed the conclusions much (third sensitivity analysis). 
In conclusion, compared with usual care implementation of both intensive counseling 
with and without pharmacotherapy for COPD patients resulted in low costs per QALY 
gained with ratios in the range of results presented for smoking cessation support in 
the general population. Implementation of minimal counseling was also cost-effective, 
but the effectiveness was not significantly different from usual care. Pharmacotherapy in 
combination with intensive counseling was cost saving compared with intensive coun-
seling alone and dominated the other interventions. These results confirm the advice 
given in the guidelines that COPD patients should be offered the most intensive smok-
ing cessation intervention feasible, not only from a clinical, but also from an economic 
perspective.  
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Abstract 
The objective of this study was to quantify the relationship between severity of chronic 
obstructive pulmonary disease (COPD) as expressed by GOLD stage and the annual 
exacerbation frequency in patients with COPD. We performed a systematic literature 
review to identify randomized controlled trials and cohort studies reporting the exac-
erbation frequency in COPD patients receiving usual care or placebo. Annual frequen-
cies were determined for: total exacerbations defined by an increase use of healthcare 
(event-based), total exacerbations defined by an increase of symptoms and severe 
exacerbations defined by a hospitalization. The association between the mean FEV1% 
predicted of study populations and the exacerbation frequencies was estimated using 
weighted log linear regression with random effects. The regression equations were ap-
plied to the mean FEV1% predicted for each GOLD stage to estimate the frequency per 
stage. Thirty-seven relevant studies were found with 43 reports of total exacerbation 
frequency (event-based: n=19, symptom-based: n=24) and 14 reports of frequency of 
severe exacerbations. Annual event-based exacerbation frequencies per GOLD stage 
were estimated at 0.82 (95% uncertainty interval (UI): 0.46; 1.49) for mild, 1.17 (0.93; 
1.50) for moderate, 1.61 (1.51; 1.74) for severe and 2.10 (1.51; 2.94) for very severe COPD. 
Annual symptom-based frequencies were 1.15 (95% UI: 0.67; 2.07), 1.44 (1.14; 1.87), 1.76 
(1.70; 1.88) and 2.09 (1.57; 2.82), respectively. For severe exacerbations, annual frequen-
cies were 0.11 (95% UI: 0.02; 0.56), 0.16 (0.07; 0.33), 0.22 (0.20; 0.23) and 0.28 (0.14; 0.63), 
respectively. Study duration or type of study (cohort versus trial) did not significantly 
affect the outcomes. This study provides an estimate of the exacerbation frequency per 
GOLD stage, which can be used for health economic and modelling purposes.
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Introduction
The progression of chronic obstructive pulmonary disease (COPD) is often accompanied 
by periods of increasing symptoms, such as dyspnoea, cough and sputum production 
known as exacerbations. Exacerbations are important events because they are associ-
ated with an increase in mortality [1,2], significant impairment of health-related quality 
of life [3-5] and an increase in healthcare use and associated costs [6,7], especially the 
event of a hospitalization [8]. The exacerbation frequency is therefore an important 
outcome parameter in COPD [9,10]. 
However, quantification of the average exacerbation frequency is difficult. Many stud-
ies report the exacerbation frequency but results can not be compared directly, because 
different definitions are used, exacerbations are measured in different seasons [9]  or 
data come from different types of studies, e.g. clinical trials or cohort studies, each using 
specific inclusion criteria [10]. Use of different definitions in particular seems to have a 
large influence. 
Definitions of exacerbations can be roughly divided into two groups: i.e. the symp-
tom-based definitions and event-based definitions. Studies defining exacerbations 
as self-reported changes in symptoms (symptom-based definition) generally result in 
higher estimates than studies using event-based definitions, because they also include 
exacerbations which do not present to physicians [11]. When symptoms are closely 
monitored using diaries, these “unreported” exacerbations are thought to account for 
about 50% of all exacerbations [4]. Event-based definitions use more objective criteria, 
such as a doctor’s visit, use of antibiotics and/or systemic steroids or hospitalization. 
However, event-based definitions are sensitive to differences in treatment patterns 
between settings. 
Another source of variation between studies is the method used to classify the severity 
of an exacerbation. Most studies classify exacerbations based on the treatment required, 
i.e. either an increase of short-acting bronchodilator or maintenance medication use, 
additional antibiotics and/or systemic corticosteroids or hospitalization [12]. 
Despite the difficulties in measuring exacerbations, the general pattern is that the fre-
quency of exacerbations increases with decreasing lung function [9,10,13]. However, as 
far as we know no studies have quantified this relationship. The present study aimed to 
quantify the relationship between degree of airflow obstruction expressed as the FEV1% 
predicted, and the annual exacerbation frequency, using previously published data. The 
association was estimated separately for symptom-based and event-based exacerba-
tions and for total and severe exacerbations. Furthermore, we explored the impact of 
study duration and type of study, i.e. clinical trial or cohort study, on this relationship. 
This study arose out of the need to estimate the average exacerbation frequency for the 
different COPD severity stages as defined by the Global Initiative for Chronic Obstructive 
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Lung Disease (GOLD) that were used as input parameters in a COPD disease progression 
model [14,15]. Because this model aims to simulate the long-term cost-effectiveness of 
interventions which successfully prevent exacerbations compared with minimal care, 
the exacerbation frequency in patients receiving minimal care was essential.  
Methods
A systematic literature review was performed to identify randomized controlled trials 
and cohort studies reporting the exacerbation frequency in patients receiving care as 
usual or placebo. MEDLINE, EMBASE and the Cochrane database were searched using 
the key words “chronic obstructive pulmonary disease” or COPD or “chronic bronchitis” 
in combination with exacerbat* and the specification “cohort or survey or observation* 
or the selection ”clinical trial”. Studies were included if they were published after 1990, 
had a follow-up of at least three months, used an event- or symptom-based definition 
for an exacerbation and, included a group of patients that received either usual care or 
placebo (e.g. the placebo arm of a long-acting bronchodilator trial or a combination 
treatment trial). Studies that included a subgroup of COPD patients selected based on 
criteria other than lung function were excluded (e.g. studies only including patients 
admitted to hospital or patients with an acute exacerbation at baseline). Retrospective 
studies based on administrative or claims data were excluded because the algorithms to 
identify exacerbations in these databases are often quite different from the definitions 
used in prospective cohort studies or clinical trials.  Finally references of the studies that 
met the inclusion and exclusion criteria were checked. 
Primary outcomes 
The three main outcomes of the study were the annual frequency of total exacerbations 
using an event-based definition, the annual frequency of total exacerbations using a 
symptom-based definition and the annual frequency of severe exacerbations as defined 
by a hospitalization. One study could provide more than one estimate of the exacerba-
tion frequency by presenting separate rates for total and severe exacerbations or rates 
based on both a symptom- and an event-based definition or by presenting rates for 
different lung function classes. 
Data extraction 
Because the comparator arm in our model needed to reflect minimal care, we only 
extracted exacerbation data for the groups of patients that received either usual care 
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or placebo. The following data were extracted: percentage males, mean age, mean 
lung function (in FEV1% predicted of the study population), follow-up duration, defi-
nition of exacerbation used (symptom- or event-based) and the annual exacerbation 
frequency. If the mean FEV1 was only given in liters, the mean FEV1% predicted of the 
study population was calculated using the association between the absolute value and 
percentage predicted from other studies. If the exacerbation frequency was presented 
for different classes of the FEV1% predicted and the mean within-class FEV1% predicted 
was not specified, the mean FEV1% predicted was estimated based on the mean and the 
standard deviation of the FEV1% predicted in the total population assuming a normal 
distribution or it was assumed to be the middle FEV1% predicted of that specific class.  
Data on the exacerbation frequency were recalculated to annual exacerbation rates, 
if necessary. The annual exacerbation rate was calculated by dividing the total number 
of exacerbations by the total number of patient years on the assumption that drop-outs 
count for half of the follow-up time. 
Data analysis
As almost all studies provided only point estimates of exacerbation rates, uncertainty 
around the exacerbation rates was estimated assuming the exacerbations to follow a 
Poisson distribution within each study. To quantify the relationship between the FEV1% 
predicted and the annual exacerbation frequency, weighted log linear regression 
analysis with random effects was performed. Log linear regression was chosen in order 
to symmetrize the skewed distribution of the exacerbation rates and approximate a 
normal distribution of the residuals in the linear regression analysis. A random effect 
model was chosen to account for study heterogeneity. The logarithm of the annual 
exacerbation frequency was used as dependent variable and the mean FEV1% predicted 
of the study as independent variable. The regression analysis was performed using 
the S-plus routine general linear model for mixed-effects models [16]. Analyses were 
performed separately for total event-based, total symptom-based and severe exacerba-
tions. From the resulting regression equation the predicted log exacerbation rate for a 
specific FEV1% predicted could be calculated. Simply taking the exponential function of 
the logarithm of the exacerbation rate, in order to re-transform the data into a normal 
exacerbation rate introduces bias and inconsistency [17]. Therefore we have used the 
non-parametric smearing factor, which was calculated following the method of Duan 
et al [17,18]. According to this method, the smearing factor φ can be calculated as the 
weighted mean of the exponential of the differences between the logarithm of the 
observed and predicted exacerbation rates in the selected studies using the number 
of exacerbations in a study as a weight. This smearing factor is then multiplied by the 
uncorrected predicted exacerbation rates to find corrected predicted exacerbation rates 
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for a given FEV1% predicted. As a result, the relationship between the annual exacerba-
tion frequency and the FEV1% predicted is:
Annual exacerbation frequency = φ * exp[ a+b*FEV1% predicted] whereby
φ = smearing factor
a = intercept (estimated in the regression analysis)
b= coefficient for FEV1% predicted (estimated in the regression analysis)
This equation was used to calculate the annual exacerbation frequency in the four COPD 
severity stages according to the GOLD classification [19] using a mean FEV1% predicted 
of 90 for mild, 65 for moderate, 42 for severe and 23 for very severe COPD [20]. To in-
clude the uncertainty around the smearing factor jointly with the uncertainty around 
the regression coefficients, the uncertainty around the exacerbation rates per GOLD 
stage was estimated by Monte Carlo simulation, i.e.1000 random draws were taken from 
the joint distribution of the intercept and the coefficient for FEV1% predicted. For each 
combination of intercept and coefficient the accompanying smearing factor was calcu-
lated using the formula described above. The mean FEV1%predicted per GOLD stage 
was then applied to each of the 1000 combinations of intercept, coefficient for FEV1% 
predicted and smearing factor, resulting in 1000 estimates of the exacerbation rate per 
GOLD stage. The 2.5% and 97.5% percentiles of these 1000 estimates formed the 95% 
uncertainty interval. 
Additional regression analyses were performed adding follow-up duration (in months) 
and type of study (cohort versus trial) to FEV1% predicted as dependent variables. The 
analyses were performed with Splus 8.1 (TIBCO Spotfire S+ Version 8.1.1 HF-001 for 
Microsoft Windows, 2008). 
Results
The literature review identified 86 references for trials and cohort studies published after 
1990 that seemed eligible based on the title. Of these 86 references that were obtained 
in full another 44 studies were excluded because they did not present exacerbation 
frequencies or numbers (n=13), were based on a selective subgroup of COPD patients 
(n=11), were based on a cross-sectional study or on administrative or claims data (n=8), 
had a follow-up less than 3 months (n=9) or used a deviant definition for an exacerba-
tion (n=3). The final 42 references referred to 37 unique studies, 28 trials [21-48] and 
nine cohort studies [3,6,49-55]. This resulted in 43 estimates for the total exacerbation 
frequency and 14 estimates of the frequency of severe exacerbations. Of the 43 esti-
mates of the total exacerbation frequency, 19 used the event-based definition and 24 
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the symptom-based definition. Characteristics of all included studies with their annual 
exacerbation rates are presented in Table 1. The left three graphs in figure 1 show the 
logarithm of the annual total and severe exacerbation frequency plotted against the 
mean FEV1% predicted of each study, as well as the estimated relation between the two 
obtained from the regression analyses. The estimated coefficients for the relationship 
between the mean FEV1% predicted and the exacerbation frequency are shown in Table 
2. Lung function was a predictor of borderline significance (p=0.053) for event-based 
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Figure1A-F: Left graphs: Logarithm of the annual total or severe exacerbation frequency plotted against 
the mean FEV1% predicted of the study, line= estimated relation obtained from the log-linear regression. 
Right graphs: Annual total or severe exacerbation frequency plotted against the mean FEV1% predicted of 
the study, line= relation based on the re-transformed exacerbation rates using the smearing factor
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exacerbations only (symptom-based: p=0.19, severe exacerbations: p=0.51). The final 
association between the FEV1% predicted and the exacerbation frequency after retrans-
forming the predicted log exacerbation rate into normal exacerbation rate, are shown 
in the right three graphs in figure 1. Results for the mean exacerbation frequencies for 
the different GOLD stages based on the regression equations are presented in Table 3. 
Using an event-based definition the total exacerbation frequency was significantly 
higher in patients with an FEV1% predicted below 50% compared with patients having 
an FEV1% predicted above 50%. Regression analyses with additional covariates showed 
no significant effect of duration of follow-up of the study or type of study (cohort versus 
trial) was found. The duration of follow-up was of borderline significance for total exac-
erbations using the symptom-based definition with longer follow-up resulting in lower 
rates (Table 4). 
Table 2: Estimates of the regression coefficients, covariance and smearing factors for the relation between 
FEV1% predicted and annual exacerbation rate described as: Annual exacerbation frequency = φ * exp[ 
a+b*FEV1% predicted] 
Total exacerbations: 
event-based definition#
Total exacerbations: 
symptom-based definition#
Severe exacerbations#
Intercept: a 1.181 (0.351), p=0.004 0.981 (0.364), p=0.01 -1.043 (0.904), p=0.27
Coefficient FEV1% predicted: b -0.014 (0.007), p=0.053 -0.009 (0.007), p=0.19 -0.013 (0.020), p=0.51 
Covariance intercept and coefficient -0.00227 -0.00227 -0.0176
Smearing factor: φ 0.893 0.960 1.072
# Values are mean (SE), p-value
Table 3: Estimated annual exacerbation frequency per GOLD stage based on the regression equations 
(95% uncertainty interval)
GOLD stage Mean 
FEV1% 
predicted
Total exacerbations: 
event-based 
definition
Total exacerbations: 
symptom-based 
definition
Severe 
exacerbations
I, Mild COPD (FEV1% pred ≥80%) 90 0.82 (0.46; 1.49) 1.15 (0.67; 2.07) 0.11 (0.02; 0.56)
II, Moderate COPD (50%≤ FEV1% pred< 80%) 65 1.17 (0.93; 1.50) 1.44 (1.14; 1.87) 0.16 (0.07; 0.33)
III, Severe COPD (30%≤ FEV1% pred<50%) 42 1.61 (1.51;.74)) 1.76 (1.70; 1.88) 0.22 (0.20; 0.23)
IV, Very severe COPD (FEV1% pred<30%) 23 2.10 (1.51; 2.94) 2.09 (1.57; 2.82) 0.28 (0.14; 0.63)
Table 4: Random effect regression analysis of FEV1%predicted and annual exacerbation frequency: 
significance of the covariates, type of study and duration of follow-up  
P-value for type of study (cohort 
versus trial)
P-value for duration of 
follow-up
Total exacerbations, event-based definition 0.80 0.57
Total exacerbations, symptom-based definition 0.24 0.05
Severe exacerbations 0.86 0.99
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Discussion
Although many trials and cohort studies report on the important outcome i.e. exacer-
bation frequency, the association between lung function and exacerbation frequency 
is less often investigated. The current study systematically reviewed the information 
contained in the literature and combined it into an estimate of exacerbation frequency 
as a function of FEV1% predicted. The coefficient for lung function showed borderline 
significance for total exacerbations using the event-based definition (p=0.053), and 
was insignificant for total exacerbations using a symptom-based definition and severe 
exacerbations. Based on the estimated equation the final estimates of the total exacer-
bation frequency per GOLD severity stage using the event-based definition were 0.82 
for mild, 1.17 for moderate, 1.61 for severe and 2.10 for very severe COPD. In spite of 
the overlapping uncertainty intervals, these estimates are useful for health economic/
modelling purposes, as long as they are accompanied by an appropriate uncertainty 
probabilistic sensitivity analysis. In this way, the 95% confidence intervals vary substan-
tially per GOLD stage, which would be ignored using a single exacerbation frequency 
for all GOLD stages. 
In accordance with the general finding that using the symptom-based definition 
results in higher estimates of the total exacerbation frequency, we found slightly higher 
estimates for mild, moderate and severe COPD using the symptom-based definition 
compared with the event-based definition. However, this difference was not significant 
and seemed to get smaller with increasing severity of COPD.  We also did not see an 
effect of follow-up duration. The mean follow-up in the studies in this review was 14 
months, ranging from three to 36 months.
The study had a couple of limitations and strengths. A reason why the relationship be-
tween lung function and exacerbation frequency in our study was relatively weak may 
be our use of published data. Regression on study summary estimates, as done in this 
study, has substantially less power than regression on patient-level data [56]. It is likely 
that variation in lung function across studies is lower than variation in lung function 
across patient-level data within studies. By plotting the mean exacerbation frequency 
against the mean FEV1% predicted of a particular study, the within study variation was 
not accounted for. Thus, a limitation of our study was that the heterogeneity in mean 
lung function between the studies in our review was relatively limited, especially for 
severe exacerbations. The majority of studies had a mean FEV1% predicted between 35 
and 60% and studies with a very low (<30%) and a very high mean FEV1% predicted 
(>80%) were scarce or completely lacking. However, using a systematic review, the cur-
rent study reflects the full evidence present in the current literature. This is preferable to 
using a single patient-level study, which may be biased towards the specific population 
under study. 
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Another limitation may be that most of the data were obtained from patients par-
ticipating in clinical trials each using specific inclusion criteria. We included data from 
28 clinical trials with in total 6780 patients and nine cohort studies with in total 2211 
patients. Trial populations may be biased towards a lower exacerbation frequency 
because they include clinically stable patients with no other major co morbidities and 
who are motivated to participate in a trial. However, an overestimation could also be 
possible because a large number of trials included only patients with at least one or 
two exacerbations in the year before inclusion. The cohort studies included in our re-
view used similar inclusion criteria as the trials and therefore probably included similar 
patient populations. No systematic difference in exacerbation rate was found between 
the cohort studies and trials. How these compare with the COPD population seen in 
daily practice is difficult to determine. One indication may be found in large retrospec-
tive database analyses [57-59]. These studies used event-based definitions and usually 
found lower exacerbation frequencies than our study, which gives us confidence that we 
did not underestimate exacerbation frequencies. 
Exacerbations depend on the season and are more likely to occur in winter [3]. There-
fore, according to recommendations [12], studies need to have a follow-up of at least 
twelve months or recruitment should be spread throughout the year to give reliable 
estimates of the exacerbation frequency. One of the strengths of our study is that the 
majority of studies, 89%, had a follow-up of at least six months and 65% had a follow-up 
of at least one year. Conversion of exacerbation rates from studies with a follow-up less 
than 12 months to annual rates may however have overestimated or underestimated 
the exacerbation frequency. However, we did not find a significant difference between 
studies with a follow-up duration shorter and longer than 12 months.  
To validate the exacerbation frequencies found in our study, they may be compared 
with the limited patient-level data on the exacerbation frequency specified by subgroup 
of lung function. The cohort study of Andersson et al, which was included in the review, 
was the only study providing estimates for four COPD severity stages, using almost the 
same cut-off points for the stages as the GOLD classification [6]. The study used an event-
based definition for exacerbations and found an annual exacerbation frequency of 0.67 
for mild, 0.70 for moderate, 1.06 for severe and 2.56 for very severe COPD, which was 
somewhat lower than our estimates, except for very severe COPD. Vestbo et al reported 
on the exacerbation frequencies in several cohort studies and placebo-arms of trials in 
relation to the FEV1% predicted and also found exacerbation frequencies below 1.0, for 
patients with an FEV1% predicted above 50%. The average values for exacerbations for 
patients with an FEV1% predicted between 40 and 50% ranged between 1.0 and 1.5, 
which was comparable with our results [10]. Burge et al showed the number of exacerba-
tions per year in the placebo-arm of the ISOLDE trial using an event-based definition and 
specified the frequency for three lung function categories: <1.25, 1.25-1.54 and >1.54 
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liter (about comparable with <45%, 44-55% and >55% predicted). Below 45% predicted 
a mean of 2.6 exacerbations was found, while above >55% the average value was about 
1.2 [13]. From the above described studies the general picture seems to be that above 
50% predicted the total annual exacerbation frequency is around or slightly below 1.0, 
while below 40-45% predicted the exacerbation rate increases significantly, to about 
two or more exacerbations per year. The results of our study showed the same picture.  
In conclusion, the current study provides an estimate of the association between an-
nual exacerbation frequency and FEV1% predicted in COPD, based on aggregated, sum-
mary data from individual studies. Results were in line with the few studies reporting on 
this relationship using patient-level data. The resulting GOLD stage specific exacerba-
tion frequencies show overlapping uncertainty intervals, and hence any analysis based 
on these rates should be accompanied by a proper sensitivity analysis. 
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Abstract 
The aim of our study was to estimate the case-fatality of a severe exacerbation from 
long-term survival data presented in the literature. A literature search identified stud-
ies reporting≥1.5 year survival after a severe chronic obstructive pulmonary disease 
(COPD) exacerbation resulting in hospitalization. The survival curve of each study was 
divided into a critical and a stable period. Mortality during the stable period was then 
estimated by extrapolating the survival curve during the stable period back to the time 
of exacerbation onset. Case-fatality was defined as the excess mortality that results 
from an exacerbation and was calculated as 1 minus the (backwardly) extrapolated 
survival during the stable period at the time of exacerbation onset. The 95% confidence 
intervals (CI) of the estimated case-fatalities were obtained by bootstrapping. A random 
effect model was used to combine all estimates into a weighted average with 95%-CI. 
The meta-analysis based on six studies that fulfilled the inclusion criteria resulted in a 
weighted average case-fatality rate of 15.6% (95% CI: 10.9%; 20.3%), ranging from 11.4% 
to 19.0% for the individual studies. A severe COPD exacerbation requiring hospitaliza-
tion not only results in higher mortality risks during hospitalization, but also in the time 
period after discharge and contributes substantially to total COPD mortality. 
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Introduction
Worldwide, mortality due to chronic obstructive pulmonary disease (COPD) is high. Ac-
cording to the World Health Organization (WHO), at least 2.7 million deaths every year are 
due to COPD [1]. The 30-yr projections from the Global Burden of Disease Study show a 
striking increase in COPD as a cause of death to the third place worldwide in 2020 [2]. This 
increase largely results from a worldwide increase in the prevalence of smoking - espe-
cially in the developing countries and among females - and ageing of the population. The 
excess mortality among patients with COPD is high, not only because of the presence of 
COPD but also because of the increased prevalence of other smoking-related diseases [3].
Many studies have analyzed predictors of mortality in COPD. Among the factors 
independently associated with mortality in COPD are age, lung function (forced expira-
tory volume in 1 second, inspiratory capacity divided by total lung capacity), dyspnoea, 
co-morbidity, body mass index (BMI), fat-free mass, exercise capacity, arterial oxygen 
tension, C-reactive protein, the BODE-index (BMI, the degree of airflow obstruction, 
dyspnoea, and exercise capacity) and the number of previous hospitalizations [4,5]. 
Because patients with COPD are often recorded as dying from other causes, it has 
been suggested that all-cause mortality is probably the best mortality measure to use 
in COPD [5]. Nevertheless, it is well known that many patients dying do so during a 
severe COPD-exacerbation, when they experience acute respiratory failure [6]. However, 
there is a relative scarcity of knowledge on mortality rates from COPD exacerbations. 
Unlike in myocardial infarction and stroke [7] no estimates of the case-fatality of a COPD 
exacerbation exist. This may be associated with the absence of consensus on the length 
of the critical period during which the mortality risk is increased. 
The most frequently reported outcome of death due to COPD exacerbations is short-term, 
in-hospital mortality [8]. Previous studies have estimated in-hospital mortality after hospital-
ization for a COPD exacerbation to range from 2.5% to 14% [9,10]. Mortality among patients 
admitted to intensive care units is much higher, i.e. up to 30% [11]. In-hospital mortality is 
insufficient to assess case-fatality for at least two reasons. There is a selection bias towards 
patients with longer hospital stays and it does not incorporate the mortality that occurs after 
hospital discharge but is still attributable to the index exacerbation. Therefore, our study 
aimed to estimate the case-fatality of a severe COPD exacerbation including the time period 
after hospitalization. This study arose out of our need to capture the impact of exacerbations 
on mortality within the context of a dynamic COPD progression model [12,13] used to evalu-
ate the impact of different COPD interventions. To fully simulate the potential long-term 
impact of interventions which successfully prevent or treat exacerbations the impact of 
severe exacerbations on mortality needed to be estimated. As the COPD population in the 
model is specified by age, which is a significant predictor of mortality in COPD [5], we also 
investigated the association between age and mortality after a severe exacerbation. 
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Methods 
We performed a comprehensive literature search in MEDLINE and EMBASE for journal 
articles published after 1990 reporting mortality or survival during and after hospitaliza-
tion for an exacerbation of COPD using the MESH (sub) headings “chronic obstructive 
pulmonary disease or COPD or chronic bronchitis” in combination with “mortality or 
dead or death* or life expectancy or survival or prognosis” and “hospital* or admission* 
or admitt* or exacerbation* or disease episodes”. We also searched references listed from 
articles retrieved. Studies were excluded if the patient population was a subgroup of 
hospitalized COPD patients, such as patients requiring mechanical ventilation. Inclusion 
criteria were: European, American or Australian study population; a follow-up period 
that started at hospital entry and lasted ≥1.5 year and presenting mortality rates at three 
or more time-points after hospital admission, or presenting a survival curve. Studies that 
fulfilled all inclusion criteria except for a follow-up of 1.5 year or the presence of three 
data points were used to complete the information on the average mortality rates at 
different time-points after a severe exacerbation as presented in the literature. In addi-
tion to information on the average mortality rates at different time-points, data on the 
association between mortality and age was extracted from the studies. 
Our general approach was as follows (figure1). For each study, we extracted the 
survival curve presented in the article or estimated the curve from the presented data 
ourselves. We roughly distinguished between the critical and the stable period after 
hospital admission with the survival curve during the stable period being flatter than 
the one during the critical period. Several data points from the curve during the stable 
period were extracted to estimate survival during this period. Only data points well after 
 
‘Case 
fatality’ 
Critical 
phase 
Stable 
phase 
1 
Time 
0 
Survival 
Figure 1: Survival curve after hospitalization for an exacerbation of COPD. The dotted line represents the 
extrapolated curve during the stable phase
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the critical period were included. For each study, the survival function during the stable 
period was then parameterized using three parameters:
S(t)  = (1-g) Exp[- α t - β t2]
with t time, with t=0 being time of hospital admission
 S(t) survival probability
 α, β parameters that define the non-linear change in survival over time
 g case-fatality of the exacerbation
The survival curve was fitted by minimizing the sum of squared differences with the 
points that were extracted from the curve, or given in the publication. We then extrapo-
lated the survival curve during the stable period back to the time of hospital admission 
and calculated where the curve intersected the vertical axis (i.e. the start of hospital 
admission). The case-fatality was defined as the excess mortality that results from an ex-
acerbation and equals g=1-S(0). Uncertainty intervals for each parameter were obtained 
from bootstrapping. Based on the given initial sample size and the calculated survival 
probabilities for each interval during the follow-up period, we randomly draw new sur-
vival numbers assuming binomial distributions. In this way we generated new survival 
curves, resulting in newly calculated values for the model parameters. The 2.5% and 
97.5% percentile values correspond with the 95% uncertainty interval. Finally, estimates 
from all studies were combined to calculate the weighted average for g, using random 
effect meta-analysis [14]. The weights were based on a combination of the sampling 
error (variance of case-fatality within each study) and the random-effect variance (vari-
ance of case-fatality between all studies). 
To estimate the association between age and mortality after a severe exacerbation, 
the relative risks of age on mortality within a study, if reported, were extracted from the 
retrieved references. The association with age within each separate study was investi-
gated, because there was little difference in the mean age between the different studies. 
The weighted average relative risk was calculated using the variance in the individual 
studies as a weight.
Results
After first selection 60 references were obtained in full (figure 2). An entire review of 
these remaining publications resulted in the exclusion of another 44 studies for different 
reasons (figure 2). The main reasons for exclusion were that the association between 
hospitalization for COPD and mortality was not reported (13 studies) and that the study 
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population consisted of a selective subgroup of hospitalized patients (13 studies). Of 
the latter 13 studies, six studies included patients admitted to ICU or requiring (non-) 
mechanical ventilation only, three included patients treated in ER or pre-hospital setting 
only, two included hospitalizations for diagnoses other than COPD, while two studies 
included patients with a first admission or a very mild exacerbation only. Of the remain-
ing 16 studies, 10 studies met all inclusion criteria except for the 1.5 years of follow-up. 
Hence, a total of six studies were finally included in the meta-analysis to calculate the 
case-fatality rate [15-20]. None of these studies evaluated the effect of an intervention as 
they were all cohort studies. For one of these six studies, the study of Brekke et al [20], we 
had access to the patient level data. For the other five studies results were based on the 
data presented in the article. Characteristics of the studies included are shown in Table 1. 
 
Total references 
identified n=148 
 
Unique references 
identified n=96 
 
Total references 
studied n=60 
 
 
References rejected based on: 
- Title review: not relevant (n=24) 
- Country of the study population (n=12) 
(not European, American or Australian) 
Studies included in the 
meta-analysis n=6 
 
References rejected based on: 
- Not reporting the association between 
hospitalization for COPD and mortality (n=13) 
- Exclusion of patients dying during the 
hospitalization (n=8) 
- Patient population was subgroup of all 
hospitalized COPD patients (n=13) 
- Same study population already included in the 
meta-analysis (n=10) 
Relevant studies 
identified n=16 
Studies which follow-up was too short to estimate 
the case-fatality that were used to complete the 
information on mortality rates at different time 
points after a severe exacerbation as presented 
in the literature  (n=10) 
 
Figure 2: Results of the systematic literature search
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Case-fatality
Table 2 presents the results of the curve fitting procedure for each of the six selected 
studies. Details about the parameter values for each study are presented in the Appen-
dix. The estimated average case-fatality rate for the individual studies varied between 
11.4% and 19.0%. The overall weighted mean value of the case-fatality of an exacerba-
tion was 15.6% (95% CI: 10.9; 20.3%). 
Association between mortality and age
All of the six studies included in the meta-analysis reported on the association between 
mortality after a hospitalization for an exacerbation and age. Age was a significant 
predictor of mortality in univariate analyses (five studies) and remained an independent 
predictor after correction for other explanatory variables in multivariate analyses (4 
studies). On average the probability of dying after a hospitalization for an exacerbation 
increased by 4.1% per year increase in age (RR=1.041 95%CI: 1.037; 1.045) (six studies). 
Average mortality rates at different time-points presented in the literature
Characteristics of the ten studies with an insufficient length of follow-up are shown in 
table 3 [9,10,21-28]. Table 4 shows the average mortality probabilities at different time-
points for both these ten studies as well as the six studies that were included in the 
meta-analysis. Based on all sixteen studies combined, the average in-hospital mortality 
rate was 6.7%. The average mortality rates at three and six months were 18% and 26%, 
respectively.
Table 2: Estimated case-fatality of a COPD exacerbation
1st author of the study, year of publication N Estimated mean
case-fatality (95% confidence limits)
Connors, 1996 1,016 17.2% (11.5; 23.1%)
Vestbo, 1998 487 12.3% (5.8; 18.4%)
Groenewegen, 2003 171 17.7% (10.2; 25.8%)
Gunen, 2005 205 16.7% (7.9; 25.4%)
McGhan, 2007 54,269 11.4% (10.6; 12.2%)
Brekke, 2008 996 19.0% (18.7; 19.3%)#
Overall estimate* 15.6% (10.9; 20.3%)
# Based on patient-level data
*Overall weighted average case-fatality based on random effects analysis. 
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Discussion
In this study the case-fatality of an exacerbation was calculated by extrapolating the 
survival curve during the stable period to the time of exacerbation onset. The weighted 
average case-fatality rate was estimated to be 15.6%, with the individual studies varying 
from 11.4% to 19.0%. The average in-hospital mortality rate was 6.7%, which strongly 
supports the notion that the critical period indeed exceeds the duration of the hospi-
talization. 
However, we would like to emphasize that the estimated case fatality can not be 
compared with the mortality rates at different time-points as these represent different 
concepts. The case fatality was calculated as one minus the survival that would have 
been expected if the patient would have been stable (Figure 1), while mortality at a 
certain time-point was calculated as one minus the survival at that specific point in time. 
This also implies that the exact distinction between the critical and stable period after 
exacerbation onset however, could not be determined by comparing the case fatality 
rate with mortality rates at different points in time. The critical period was defined as the 
period in which mortality is increased compared to the stable situation. Therefore, this 
period ranges from the hospital admission until the point were the estimated survival 
curve during the stable period approaches the actual observed survival curve (figure 1). 
Estimating the point where the two survival curves approach each other is only possible 
if patient-level data are available or when we make additional assumptions on how the 
case-fatality changes over time within the critical period. We had patient-level data from 
one study, the study of Brekke et al [20]. For this study the critical period was estimated 
to last 4.4 months. The length of the critical period is likely to vary according to the 
population studied; in patients with several co-morbidities the exacerbation may have 
both more severe [9,19] and longer lasting impact and similarly the critical period could 
last longer in the elderly.
Due to limited data and the homogeneity of the different studies we were not able 
to specify the case-fatality by subgroups such as COPD severity (defined by lung func-
tion), sex or age. Therefore we searched for information about the association of these 
variables with mortality within the extracted studies. Within the studies the relation 
of mortality due to an exacerbation with disease severity or sex was less clear. Mortal-
ity after a hospitalization for an exacerbation was however highly dependent on age 
(RR=1.041 per increase in year of age). 
As the study populations of the six studies selected for the meta-analysis were al-
most the same with respect to the mean age, 65 to 71 years, age did no influence the 
between-study comparison of case-fatalities. The studies included have sampled data 
spanning a time period of more than 10 years but no obvious pattern of change over 
time in case-fatality can be seen. This could be the result of the variation in treatment 
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and management between the different countries but was actually also observed in 
within one of the included studies [16]. In contrast, a very recent study found indications 
of a slight improvement of exacerbation-related mortality over time [29].
Despite the homogeneity between the studies with respect to age, the study popula-
tions may have differed on other aspects. Although we selected studies from Western 
countries, the criteria used for hospitalization for example are not similar across coun-
tries. This is related to local treatment patterns, which in turn may be driven by local 
guidelines, medical traditions, cultural aspects, financing and reimbursement schemes 
etc. In our selected studies the mean length of stay was significantly longer in the 
European studies compared to studies from the USA, 11 versus 7 days. However, the 
mean in-hospital mortality rate did not differ. One study aspect which seemed to have 
an influence on the results was whether patients included in the study had physician- or 
spirometry-confirmed COPD. Studies including patients with confirmed COPD reported 
higher mortality rates than studies including patients with hospitalization for COPD 
based on ICD-coding. The mean in-hospital mortality rate for both groups were 9.2% 
(95% CI: 7.4; 10.9) and 4.8% (95% CI: 3.5; 6.1), respectively. Two of the studies used in the 
meta-analysis included patients with a hospitalization for COPD based on ICD-coding. 
If the largest of these two studies, the study of McGhan [19], was excluded from the 
meta-analysis, the average case fatality rate would have been higher, i.e. 17.9% (95% 
CI: 15.8; 20). Studies using ICD-coding only to define COPD may report lower mortality 
rates because they also included mild patients or patients with for example asthma that 
were wrongly coded.  
In conclusion, mortality in COPD is common and severe exacerbations of COPD are 
one of the major causes of death in COPD. In this study the case-fatality rate of a severe 
exacerbation resulting in hospitalization was estimated to be 15.6%, showing the sub-
stantial impact of exacerbations on mortality. 
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Appendix
The survival function during the stable period for each study was parameterized using 
three parameters:
S(t)  = (1-g) Exp[- α t - β t2]
with t time, with t=0 being time of onset of exacerbation
 S(t) survival probability
 α, β parameters that define the non-linear change over time
 g case-fatality of an exacerbation
Table A1: Median parameter values (95% uncertainty interval) of the survival function 
1st author of the study, year of 
publication
α β g
Connors, 1996 [1] 0.482 (0.353;0.608) -0.117 (-0.164; -0.071) 0.174 (0.115;0.231)
Vestbo, 1998 [2] 0.132 (0.055;0.204) 0.001 (-0.013;0.018) 0.126 (0.058;0.184)
Groenewegen, 2003 [3] -0.006 (-0.087;0.069) 0.016 (0;0.033) 0.179 (0.102;0.258)
Gunen, 2005 [4] 0.135 (0.058;0.228) -0.014 (-0.03;0.002) 0.17 (0.079;0.254)
McGhan, 2007 [5] 0.229 (0.22;0.238) -0.01 (-0.012;- 0.008) 0.114 (0.106;0.122)
Brekke, 2008 [6]# 0.191 (0.187;0.195) -0.017 (-0.018;-0.016) 0.190 (0.187;0.193)
# Based on patient-level data
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Abstract 
The objective of the study was to develop a stochastic population model of disease 
progression in COPD that includes the impact of COPD exacerbations on health-related 
quality of life, costs, disease progression and mortality and can be used to assess the 
impact of a wide range of interventions. The model is a multistate Markov model with 
time varying transition rates specified by age, sex, smoking status, COPD disease sever-
ity, and/or exacerbation type. The model simulates annual changes in COPD prevalence, 
due to COPD incidence, exacerbations, disease progression (annual decline in FEV1% 
predicted) and mortality. The main outcome variables are (quality-adjusted) life years 
(QALYs), total exacerbations and COPD-related healthcare costs. Exacerbation-related 
input parameters were based on quantitative meta-analysis. All important model pa-
rameters are entered into the model as probability distributions. To illustrate the poten-
tial use of the model, costs and effects were calculated for three-year implementation 
of three different COPD interventions, one pharmacological, one on smoking cessation 
and one on pulmonary rehabilitation using a time horizon of ten years for reporting 
outcomes. Compared with minimal treatment the cost per QALY gained was €8,300 for 
the pharmacological intervention, €10,800 for the smoking cessation therapy, €8,700 
for the combination of the pharmacological intervention and the smoking cessation 
therapy and €17,200 for the pulmonary rehabilitation program. The probability of the 
interventions to be cost-effective at a ceiling ratio of €20,000 varied from 58 to 100%. 
The COPD model provides policy makers with information about the long-term costs 
and effects of interventions over the entire chain of care, from primary prevention to 
care for very severe COPD and includes uncertainty around the outcomes. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow 
limitation, which is not fully reversible [1]. The main risk factor is smoking and the most 
important symptoms are chronic dyspnoea, cough and sputum production. The pro-
gression of COPD is often accompanied by periods of increasing symptoms, known as 
exacerbations, which were found to be associated with increased mortality, impaired 
health-related quality of life and increased healthcare use [2,3].
The worldwide burden of COPD in terms of morbidity, mortality and healthcare costs 
is substantial and is expected to increase in the future, mainly due to ageing and con-
tinuing tobacco use. A US study showed that from six major causes of death COPD was 
the only condition for which mortality rates have increased between 1970 and 2002 
and these rates were expected to increase continuously [4]. Furthermore, COPD was 
projected to be one of the leading causes of mortality and disability in 2020 worldwide 
[5]. Against this background health policy makers need information about the options 
for prevention and treatment of COPD in terms of both effects and costs. 
In a slowly progressing disease such as COPD, modelling can be a useful tool to estimate 
the medium and long-term effects and costs of interventions. Next to that, modelling is 
also useful to combine existing knowledge from various sources in a consistent way. In 
the past decade nine different COPD progression models have been published [6-14]. 
All these models are Markov models and comparable with respect to COPD severity 
based on FEV1% predicted, progression based on decline in lung function and inclusion 
of exacerbations. Structural differences between the models exist regarding the number 
of COPD severity stages, duration of the Markov cycles, inclusion of the risk factors age 
and smoking, distinction in severity of exacerbations and inclusion of COPD incidence. 
Furthermore, the models substantially differ in utility values assigned to COPD stages 
and utility decrements assigned to exacerbations [15]. Finally, not all the models take 
into account the uncertainty around the input parameters, which is currently regarded 
as essential in cost-effectiveness analyses [16,17]. 
Because most of the COPD models were built to evaluate a specific intervention in a 
specific population, mostly to support reimbursement negotiations of new medications, 
they may be less suitable to evaluate other types of interventions. This is for example 
reflected in the fact that model parameters such as transition probabilities and exac-
erbation rates were often obtained from one or a few clinical trials investigating the 
medication of interest. In such models, disease progression is often similar regardless 
sex, age and smoking status which make these models less suitable to simulate the 
impact of for example smoking cessation interventions on disease progression.    
The aim of this study was to develop a dynamic population model of disease progres-
sion in COPD from diagnosis of the disease until death. In contrast to our earlier model 
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[9,18], the new model includes the impact of COPD exacerbations, allows for probabilis-
tic sensitivity analysis and can be used to evaluate a wide range of COPD interventions, 
from prevention to treatment. This paper primarily describes the structure of the new 
model and the estimation of the new exacerbation-related input parameters. The po-
tential use of the new model is illustrated by calculating the cost-effectiveness of three 
different COPD interventions compared with minimal treatment.
Methods
Description of the model structure 
The COPD model is not a straightforward simple discrete stage Markov model, but it 
may be classified as a Markov-type model, because the Markov property is a prominent 
aspect of the entire model. The model has six main health states, no COPD, four COPD se-
verity stages based on the Global Initiative for chronic Obstructive Lung Disease (GOLD) 
classification [1] and death, which are further stratified by sex, age and smoking status. 
COPD severity stages are further characterized by their distribution of lung function, the 
forced expiratory volume in one second (FEV1) as percentage of the predicted value. The 
cycle length of the model is one year and the time horizon of the analyses can vary be-
tween one year and life-time. Figure 1 illustrates the structure of the model. The model 
follows birth cohorts over time. Each year a new birth cohort is added, while the existing 
cohorts age with one year. Within each birth cohort people can move between smoking 
classes, be diagnosed with COPD, move to another COPD severity stage or die, all with a 
certain annual probability. These probabilities depend on the relevant co variables age, 
sex, lung function and smoking status. The model starts with the Dutch general popula-
tion and the COPD patient population in 2007 specified by sex, one-year age classes, 
smoking status (smokers/ former smokers/never smokers) and COPD severity. COPD 
patients are divided into four severity stages according to their lung function, expressed 
as the FEV1% predicted. The model then simulates the annual changes in the general 
population as well as the COPD population. The dynamics in the Dutch general popula-
tion are taken into account using prognoses of birth and mortality as well as estimates 
of the start-, stop and restart rates of smoking, while changes in the COPD population 
are the result of incidence, changes in smoking status, disease progression and mortality 
(figure 1). In each severity stage COPD patients have an annual probability to experi-
ence exacerbations. Exacerbations in the model were defined based on an increase in 
healthcare use, i.e. an event-based definition. A distinction was made between moder-
ate (non-severe) and severe exacerbations. A moderate exacerbation was defined as an 
exacerbation leading to a prescription of systemic corticosteroids and/or antibiotics and 
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a severe exacerbation was defined as a hospitalization for COPD. Total exacerbations 
were calculated as the sum of both moderate and severe exacerbations. Exacerbations 
were modelled to affect disease progression, mortality, quality of life and costs. 
Mortality among COPD patients consists of mortality attributable to COPD and mortality 
due to other causes. COPD-attributable mortality was defined as the independent mortal-
ity risk related to having COPD, i.e. which is adjusted for the mortality risk from smok-
ing. This adjusted COPD-related mortality risk is smaller than the unadjusted risk, since 
having COPD is largely correlated with smoking, and smoking increases the mortality risk 
through many more chronic diseases other than COPD. COPD-attributable mortality was 
modelled as being dependent on sex, age and FEV1% predicted (RR=1.2 (95% CI: 1.16; 
1.23) per 10-unit decline [19] and was further divided into exacerbation-related mortality 
and remaining COPD attributable mortality. Mortality from other causes was modelled to 
depend on sex, age and smoking status and included the mortality from other smoking-
related diseases. To avoid double counting, COPD attributable mortality was not modelled 
to depend on smoking status because the impact of smoking on mortality due to COPD is 
already captured by the increased incidence and prevalence of COPD among smokers and 
former smokers. This means that a smoking and former smoking patient with the same sex, 
age and COPD severity stage were assumed to have the same risk to die of COPD. Smoking 
patients, however, have a higher COPD-attributable mortality risk over time, because they 
progress faster to more severe COPD stages, which are associated with a higher mortality 
risk. More details about the model structure can be found in [20]. 
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Figure 1. Description of the Dutch COPD population model
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Outcomes
The main outcome variables of the model are the total annual number of life years, qual-
ity-adjusted life years (QALYs), moderate and severe COPD exacerbations, total mortality 
and total COPD-related healthcare costs. The annual number of life years is calculated 
as the annual number of patients alive. The annual number of QALYs is calculated as the 
annual number of life years weighted by their quality of life during these years using 
EQ-5D utility weights specified by COPD severity [6]. For each exacerbation a decrement 
in utility weights is applied [21,22]. Total mortality is defined as the annual number of 
deaths with a COPD-related cause plus the annual number of deaths due to other causes. 
The annual COPD-related healthcare costs are calculated by multiplying the number of 
patients alive with the COPD-related maintenance costs per patient specified by sex, age 
and COPD severity and adding the additional costs of exacerbations. 
Demographic, smoking and COPD non-exacerbation related input parameters 
Data on demography and prognoses of birth and mortality for the year 2007 were 
obtained from Statistic Netherlands [23], while prevalence of smoking and changes in 
smoking status in the population, i.e. start, stop and restart rates, were based on data 
from STIVORO [24-26],  all specified by sex and one-year age classes.  
Data on COPD prevalence, incidence and mortality for 2007 including uncertainty 
were obtained from GP registrations [27,28]. As almost all Dutch citizens are registered 
at a GP, the model is representative of the Dutch population of diagnosed COPD patients. 
Prevalence, incidence and mortality by sex and age were further specified by smoking 
status using the relative risks of smokers and former smokers to die of COPD [29,30]. The 
COPD prevalence within each subclass by sex, age and smoking status was then further 
divided over the four GOLD stages of COPD severity [1] using the estimated normal 
distribution of the FEV1% predicted of COPD patients in two Dutch GP practices (mean: 
68.3, SD: 19.9), which led to the following distribution: 27% mild (FEV1 predicted ≥80%), 
55% moderate (FEV1 predicted <80% and ≥50%), 15% severe (FEV1 predicted <50% and 
≥30%) and 3% very severe COPD (FEV1 predicted <30%) [31]. The severity distribution of 
the incidence was estimated by the model and defined as the distribution that -given 
disease progression and mortality- would not change the FEV1% predicted among the 
prevalent cases in the first year of the model. Based on this estimated normal distribu-
tion (mean: 76.4, SD: 15.6), the severity distribution of the incidence was estimated to be 
40% in mild, 55% in moderate, 4% in severe and 0.1% in very severe COPD.  
Disease progression was modelled as the annual decline in FEV1% predicted based on 
a re-analysis of the original 5-yr Lung Health Study data [32,33]. A random effect model 
was used to estimate the annual decline in FEV1% predicted depending on sex, age, 
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Table 1: Main input parameters for the model for the reference scenario specified by sex and/or COPD 
severity stage
COPD severity stage
Mild Moderate Severe Very severe
Prevalence (2007) as % of general population >45yrs: 
- Males Never smokers 0.03 0.06 0.02 0.003
Smokers 0.41 0.85 0.24 0.04
Former smokers 0.98 2.05 0.57 0.10
- Females Never smokers 0.12 0.25 0.07 0.01
Smokers 0.36 0.74 0.21 0.04
Former smokers 0.64 1.34 0.37 0.06
Incidence (2007) as % of general population >45yrs:
- Males Never smokers 0.005 0.007 0.0005 0.00001
Smokers 0.08 0.11 0.008 0.0002
Former smokers 0.17 0.24 0.02 0.0004
- Females Never smokers 0.02 0.03 0.002 0.00005
Smokers 0.07 0.10 0.007 0.0002
Former smokers 0.11 0.15 0.01 0.0003
Annual decline in FEV1% predicted#:
- Males Never smokers/former smokers -0.83 -1.20 -1.56 -1.85
Smokers -1.16 -1.54 -1.89 -2.18
- Females Never smokers/former smokers -0.79 -1.17 -1.52 -1.81
Smokers -1.13 -1.51 -1.86 -2.15
COPD attributable mortality (2007)#:
- Males 2.8% 4.5% 6.9% 9.6%
- Females 1.9% 3.0% 4.6% 6.3%
Mortality due to other causes (2007) #:
-Never smokers Males:1.0%, females: 0.6%
-Smokers Males: 2.4%, females: 1.4%
-Former smokers Males: 1.2%, Females: 0.7%
Utilities: 0.8971  
(0.1117)
0.7551  
(0.2747)
0.7481  
(0.2991)
0.5493 
(0.3129)
COPD costs for maintenance per patient (€, 2007)#:
- Males €135 (20)  €169 (25)  €187 (28) €277( 42)
- Females  €326 (49) €405 (61) €452 (68) €671 (101)
Smoking prevalence in the general population 
>45yrs:
- Never smokers Males: 18%, females: 39%
- Smokers Males: 27%, females: 22%
- Former smokers Males: 54%, females: 39%
Smoking transition rates in the general population 
>45yrs: 
- Start Males: 0.5%, females: 0.1%
- Stop Males: 6.5%, females: 6.5% 
- Restart Males: 1.3%, females:1.4%
# Data has been specified by age. The table presents values for age 69 years, the mean age of the COPD 
population in the model
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smoking status and baseline FEV1% predicted [9]. The values found were not translated 
into transition rates as is common in all other models, but modelled directly as the 
change in the distribution of FEV1% predicted for the total group of patients within a 
certain COPD state. A new division over the severity stages was made at each annual 
step after all changes had been simulated using the cut-off points for the different GOLD 
severity stages (FEV1predicted of 80%, 50% and 30%).  
The main input parameters for mortality were all-cause mortality obtained from Sta-
tistic Netherlands [34] and COPD excess mortality [28]. The COPD-attributable mortality 
was calculated as the COPD excess mortality adjusted for smoking status. Mortality due 
to other causes was estimated as the total mortality among COPD patients minus the 
COPD-attributable mortality. 
The total direct medical costs for COPD in the Netherlands specified by sex and age 
were obtained from a previous cost of illness study for the year 2000 [35]. These costs 
were updated to the year 2007 using consumer price indices [36]. We did not update 
these data using newer cost of illness studies, because we aimed to represent minimal 
treatment and the resource use estimates of 2000 best reflected this type of treatment. 
The COPD-related maintenance costs were calculated as the total direct medical cost 
per sex and age class minus the exacerbation-related costs per sex and age class. The 
maintenance costs within each sex and age class were further divided over the severity 
stages using ratios for the total COPD costs of a patient with moderate (1.24), severe 
(1.39) or very severe COPD (2.06) compared to the costs of a patient with mild COPD (1.0) 
as observed in Dutch studies [10,37]. The main input parameters of the model are shown 
in Table 1 and further specified in reference [20]. 
COPD exacerbation-related input parameters
The new exacerbation-related parameters were based on quantitative meta-analyses. 
These parameter estimates can be regarded as results of this study, but are presented in 
the methods section because it concerns input parameters.
Exacerbation frequency by COPD severity
The frequency of total and severe exacerbations by GOLD severity stage was based on 
a systematic literature review and meta-analysis of randomized controlled trials and 
cohort studies reporting altogether 19 different estimates of the total exacerbation 
frequency and 14 different estimates of the severe exacerbation frequency in patients 
receiving usual care or placebo. The association between the mean FEV1% predicted of 
the study populations in the selected studies and the annual exacerbation frequencies 
was estimated. The estimated equations were used to calculate the total number and the 
number of severe exacerbations per GOLD stage. Based on the mean FEV1% predicted 
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per GOLD severity stage in the first year, the average number of total exacerbations in 
the first year was estimated to be 0.82 (95% CI:0.46; 1.49) for mild, 1.17 (0.93; 1.50) for 
moderate, 1.61 (1.51; 1.74) for severe and 2.10 (1.51; 2.94) for very severe COPD. The 
severe exacerbations rates were 0.11 (95% CI: 0.02; 0.56), 0.16 (0.07; 0.33), 0.22 (0.20; 
0.23) and 0.28 (0.14; 0.63), respectively. The estimated regression equations were built 
into the model to capture the impact of changes in mean FEV1% predicted over time 
within a severity stage on the exacerbation frequency.  All details about the estimation 
of the exacerbation frequencies specified by GOLD severity stage have been reported in 
a separate manuscript [38].
Case-fatality of exacerbations
Mortality was assumed to be increased after a severe exacerbation only, not after a 
moderate exacerbation. The case-fatality was calculated as the probability of mortal-
ity after a severe exacerbation corrected for the mortality probability during a stable 
disease period. This was based on six studies reporting at least 1.5 year survival after a 
severe exacerbation that allowed us to separate the survival curve after hospital admis-
sion into a critical and a stable period. The case-fatality of a severe exacerbation was 
estimated to be 15.6% (95% CI: 10.9; 20.3%) on average. This case-fatality was applied 
to the mean age of the COPD population in the papers selected from the literature, i.e. 
69 years. The relation between age and mortality was also estimated (RR=1.041 (95% CI: 
1.037; 1.045) per year increase in age) and used in the model to make the case-fatality 
rate age-dependent. Further details about the estimation of the case-fatality of a severe 
COPD exacerbation have been reported in a separate manuscript [39]. 
Exacerbations and lung function decline
Five studies were found reporting the relation between exacerbations and lung function 
decline [40,41-44]. Only one study directly reported the decline in lung function per 
lower respiratory illness [42]. For the other studies the decline in lung function due to an 
exacerbation was estimated by dividing the difference in lung function decline between 
patients with infrequent and frequent exacerbations as defined in the specific study by 
the difference in exacerbations between the two groups. The average decline in lung 
function per exacerbation was estimated to be 0.19% predicted (95% CI: 0.092; 0.29).
Exacerbations and quality of life
Only two studies reported about exacerbations and quality of life using the EuroQol 
(EQ-5D), one for severe and one for moderate exacerbations. O’Reilley et al presented 
utility values at admission and discharge for a COPD hospitalization based on the UK 
value set [22]. Based on these values, -0.077 and 0.576 respectively, the mean length of 
hospitalization of 11 days, the assumption that the utility value would have returned to 
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normal, i.e. 0.689, after 4.5 months [39] and the assumption of a linear increase between 
admission and discharge and discharge and baseline, the annual utility loss due to a 
severe exacerbation was estimated to be 4.82% (95% CI: 3.11; 6.53) from the baseline 
utility value. The annual utility loss due to a moderate exacerbation, 1.66% (95% CI: 1.23; 
2.09) of the baseline value, was derived from a study of Goossens et al, who measured 
utility scores during a moderate exacerbation at four different time points over a period 
of six weeks [21].
Costs of exacerbations 
The costs per moderate and severe exacerbation were based on a study from Oosten-
brink et al [45]. Because of the difference in exacerbation definition with our model we 
slightly modified the cost estimate of a moderate exacerbation by deleting the inpatient 
hospital costs for a non-severe exacerbation. The final cost estimates were updated to 
the year 2007 resulting in a cost estimate of €94 (95% CI: 80; 108) for a moderate and 
€4100 (95% CI: 2348; 5852) for a severe exacerbation.
Intervention scenarios
All reference values of the input parameters were as far as possible estimated from data 
sources in which patients received minimal treatment. Data were obtained from cohorts 
receiving usual care in older studies or from the placebo-arm of a trial or the arm re-
ceiving a non-intensive intervention. Therefore a model simulation using the reference 
values of the input parameters reflects the situation in which patients receive minimal 
treatment (“minimal treatment scenario”). To illustrate the possibilities of the model we 
calculated the cost-effectiveness for four scenarios (three different interventions) com-
pared with minimal treatment. For ease of interpretation, all cost-effectiveness analyses 
were performed for a fixed cohort of patients, that is setting COPD incidence to zero. 
The first scenario evaluated was the implementation of a pharmacological combina-
tion therapy of a long-acting β2 agonist with an inhaled corticosteroid (ICS/LABA). 
Effects of this therapy were modelled as a reduction in lung function decline, exacerba-
tion frequency and all-cause mortality. The size of these benefits was obtained from 
the TORCH trial [44,46] and given in Table 2. Directly applying the RR’s to all three 
parameters independently would overestimate the effect of the intervention, because 
lung function, exacerbation rate and mortality are related to each other in the model. 
Therefore the effect of the intervention was modelled in three steps. In step one the 
effect on lung function decline was applied. If the effect of the decrease in decline on 
exacerbation frequency was smaller than the effect seen in the trial, the effect of the 
intervention on exacerbation frequency was adjusted till the magnitude of the effect 
observed in the trial (step two). After that, the effect of the first two steps on all-cause 
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mortality was determined. Finally, in step three the effect on mortality was adjusted 
till the effect seen in the trial. The second scenario assumed increased implementation 
of intensive counseling plus pharmacotherapy for smoking COPD patients, leading to 
increased smoking cessation rates (Table 2) [18]. In the model, increased smoking ces-
sation leads to a one-time increase in FEV1% predicted, a lower annual decline in lung 
function (based on the Lung Health Study [33]) and reduced mortality due to COPD and 
other smoking-related diseases. In scenario three implementation of the combination of 
the first two interventions, ICS/LABA for all patients with moderate and severe COPD and 
intensive counseling plus pharmacotherapy for all smoking COPD patients was evalu-
ated. Because the TORCH trial did not found a significant interaction between treatment 
and smoking status [46], we assumed no interaction effect between the pharmacologi-
cal intervention and the smoking cessation therapy, i.e. effects were assumed additive. 
In scenario four, implementation of an interdisciplinary community-based pulmonary 
rehabilitation program was simulated, using a trial-based estimate of its costs and effect 
on quality of life (Table 2) [47]. 
Table 2 also shows the type and percentage of patients receiving the intervention 
and the intervention costs. All interventions were assumed to be implemented for three 
years and evaluated using a time horizon of ten years. A three-year implementation 
period implied that the benefits and costs of the interventions were applied for three 
years and that after three years all input parameters returned to the reference values, 
representing minimal treatment.  The four intervention scenarios were compared with 
the minimal treatment scenario to estimate the number of QALYs gained, the number 
of exacerbations avoided, the incremental intervention costs and the savings in COPD-
related healthcare costs. Health outcomes were discounted by 1.5%, costs by 4% [48]. 
Table 2: Input data for the intervention scenarios (95% confidence interval)
Combination of a long-acting 
bronchodilator and an inhaled 
corticosteroid 
Intensive counseling plus 
pharmacotherapy for smoking 
cessation
Pulmonary rehabilitation
Target population Moderate and severe COPD Mild, moderate, severe and very 
severe COPD
Moderate and severe COPD
Percentage of patients 
receiving the intervention
50% 50% 15% 
Annual smoking cessation 
rate  
- +10.9% (6.0;15.0%) -
Annual decline in lung 
function
RR=0.60 (0.45;0.76) - -
Total exacerbation frequency RR=0.75 (0.69;0.81) - -
All-cause mortality at three 
year
HR=0.825 (0.681;1.002) - -
Annual change in utility - - +0.043 (-0.005;0.090) 
Annual intervention costs €773 €305 €745 
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The costs per QALY gained and exacerbation avoided for each intervention scenario 
were calculated as the total incremental intervention costs minus savings in COPD-
related healthcare costs divided by the gain in QALY or the number of exacerbations 
avoided, respectively. 
Sensitivity analyses 
To estimate the impact of the uncertainty around the different input parameters on the 
outcomes a probabilistic sensitivity analysis was performed. The parameters included 
in the sensitivity analysis with their mean and SE and applied distribution have been 
described in appendix I. Monte Carlo simulation was conducted by drawing random 
values from all parameters distributions, after which the model was run for each set 
of parameters and results of each run were collected. Monotonicity was enforced for 
the utility weights and COPD-related maintenance costs by COPD severity. For utility 
values for example this means that in each simulation the randomly drawn value for 
mild COPD needed to be higher than the value drawn for moderate COPD and the value 
for moderate needed to be higher than for severe COPD etc. The current analyses were 
based on 1000 simulations, providing the 95% uncertainty interval around the effects 
and costs. The uncertainty was displayed in cost-effectiveness planes and acceptability 
curves [49-51]. 
In addition to the probabilistic sensitivity analyses we performed several one-way 
sensitivity analyses for all intervention scenarios for a number of key model parameters 
and for model parameters for which a probabilistic approach was not appropriate, 
such as discount rate. In the first sensitivity analysis we investigated the effect of a 50% 
higher or lower annual decline in FEV1% predicted. In sensitivity analysis two to six we 
investigated the impact of using either the 95% lower limit or the 95% upper limit of the 
five exacerbation-related parameters: the baseline exacerbation frequencies per sever-
ity stage, the case-fatality, the decline in lung function, the utility loss and the costs. 
In sensitivity analysis seven the 95% CI limits for the utility values by COPD severity 
stage were applied. In sensitivity analysis eight we investigated the impact of using a 
lower smoking cessation rate for COPD patients in the reference scenario, 1.4% [52]. 
The impact of a ten percent reduction or increase in intervention costs was assessed in 
sensitivity analysis nine. Using discount rates of 0% or 4% for both costs and effects was 
investigated in sensitivity analysis ten and in sensitivity analysis eleven we performed 
analyses using a time horizon of five and twenty years. 
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Results
The COPD population in 2007, the starting year of the simulation, consisted of 321,000 
patients above 45 years of age. Forty-six percent of the patients were female and the 
mean age was 69 years. Thirty percent of the patients were estimated to be current 
smokers, while 64% were former smokers. The majority of patients (82%) had mild or 
moderate COPD. About two-third of the total COPD-related healthcare costs of €352.8 
million in 2007 for a minimal treatment scenario were exacerbation-related. The results 
for the four interventions scenarios are shown in table 3. The mean cost per QALY gained 
compared with minimal treatment varied between €8,300 and €17,200. The costs per 
exacerbation avoided varied between €2,600 for the ICS/LABA intervention and around 
€400,000 for the smoking cessation scenario. The latter ratio is high because smoking 
cessation extends life expectancy and patients are therefore longer at risk to get an ex-
acerbation. Pulmonary rehabilitation was not assumed to affect exacerbation frequency, 
so the costs per exacerbation avoided were not calculated.  
Scenario 1: ICS/LABA
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Scenario 2: smoking cessation therapy
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Scenario 3: ICS/LABA + smoking cessation therapy
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Scenario 4: Pulmonary rehabilitation
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Figure 2A – 2D: Cost-effectiveness planes for three year implementation of 1) inhaled corticosteroid 
(ICS) with long-acting bronchodilator (LABA), 2) pharmacotherapy plus intensive counseling for smoking 
cessation, 3) combination of ICS/LABA and pharmacotherapy plus intensive counseling for smoking 
cessation and 4) pulmonary rehabilitation program. All compared with minimal treatment, time horizon 
ten years, discount rates: 1.5% effects, 4% costs
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The results of the probabilistic sensitivity analysis are shown in figure 2 and 3. For sce-
nario one to three, i.e. implementation of ICS/LABA, intensive counseling plus pharma-
cotherapy for smoking cessation or a combination of these two interventions, 100% of 
all model replications fell in the upper right quadrant indicating more QALYs and higher 
costs compared to minimal treatment. For scenario four on pulmonary rehabilitation 
this percentage was 96%. The probability to be cost-effective at a willingness-to-pay 
value of €20,000 per QALY gained was 99.9% for ICS/LABA, 97.3% for pharmacotherapy 
for smoking cessation, 99.8% for the combination of ICS/LABA and smoking cessation 
and 58% for pulmonary rehabilitation (Figure 3).  
The one-way sensitivity analyses showed that for the first three scenarios the cost per 
QALY gained was most sensitive to the time horizon chosen and the baseline exacer-
bation frequencies (Appendix II). For the scenario on pulmonary rehabilitation a 10% 
reduction or increase in intervention costs or changes in utility values for the COPD 
severity stages had the highest impact on the cost per QALY. 
Discussion 
This study aimed to develop a dynamic, stochastic population model of disease progres-
sion in COPD including the impact of exacerbations. The paper described the structure 
of the model and showed the potential of the model by evaluating three different COPD 
interventions. One of the strengths of the model is that many of the input parameters 
of the model were obtained from systematic reviews, using quantitative analysis to 
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Figure 3: Acceptability curves ICS/LABA=black solid, pharmacotherapy for smoking cessation=grey 
solid, combination of ICS/LABA and pharmacotherapy for smoking therapy=grey dashed, pulmonary 
rehabilitation=black dashed
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combine data from multiple sources. The annual frequency of moderate and severe 
exacerbations, the case-fatality of a severe exacerbation, and the impact of exacerba-
tions on lung function decline and quality of life were all estimated by quantitative 
meta-analysis, which improves the quality of the parameter estimates. 
The model is also up-to-date as it can generate uncertainty around the estimated 
results using probabilistic sensitivity analyses. The uncertainty around estimates of all 
important parameters has been included. We did not take into account structural model 
uncertainty [16]. This means for example that a reduction in the number of severe exac-
erbations always results in a reduction of the case-fatality and a gain in utility. However, 
these assumptions are clinically very plausible. 
A limitation of the model is that the severity and progression of COPD are only based 
on lung function, i.e. FEV1% predicted. It is well-know from the literature that the sever-
ity of COPD is also determined by the severity of symptoms, especially breathlessness 
and fatigue, the level of exercise impairment and the existence of co-morbidities [1]. 
Composite measures, such as the BODE, DOSE or ADO, which include variables such as 
BMI, airflow obstruction, dyspnoea,  exercise capacity, age, smoking status or exacerba-
tion frequency are better predictors of disease severity than lung function alone [53-55]. 
The progression of COPD is also not only influenced by the decline in lung function 
[56]. It is however very difficult if not impossible to obtain detailed data for so many 
different variables from national registries and hospital and GP databases. For reasons of 
availability and simplicity the severity and progression of COPD in the model is therefore 
only based on lung function as is done in all other available COPD models.
Up to now, besides our model, eight other COPD models have been published 
[6-8,10-14]. Seven of the models take into account uncertainty around input param-
eters in a more or less elaborate way [6-10,12,14] and three are population-based, i.e. 
representative for a total nationwide COPD population [9,11,13]. The majority of the 
models has been developed with financial support of pharmaceutical companies and 
six models were built to evaluate a specific pharmacological treatment. Five models 
were used to investigate the impact of implementation of inhaled corticosteroids with 
or without long-acting β2-agonist bronchodilator for a (sub-)group of COPD patients 
[7,8,11,12,14], while one model was used to evaluate implementation of the long-acting 
anticholinergic bronchodilator, tiotropium [10]. Because these models have been built 
to evaluate a specific intervention, input parameters not relevant for the intervention 
under evaluation, such as disease progression are often modelled as one single value of 
FEV1 decline that is not depending on sex, age or smoking. This type of simplifications 
in input parameters and assumptions can make a model less suitable to evaluate other 
types of interventions.  
The potential of our model was demonstrated by showing the results for four inter-
vention scenarios. By choosing three completely different interventions we tried to 
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emphasize that the model can be used to evaluate a wide range of interventions. The 
model can be used to evaluate interventions that have an effect on COPD incidence 
rates, smoking rates, lung function decline, quality of life, mortality and/or frequency 
and severity of exacerbations. To make the results of the scenarios as realistic as pos-
sible, we applied the intervention to a realistic target population in terms of disease 
severity and percentage of patients receiving the intervention. To make the results of the 
scenarios more valid, effectiveness should have been taken from a systemic review, and 
not from one trial as was done for two interventions. This will be part of future research. 
To increase comparability between the scenarios we applied the same implementation 
duration and time horizon for all scenarios. The optimal time horizon was however 
different for each scenario. For pharmacotherapy a time horizon of ten years seemed 
plausible, but for the smoking cessation scenario that was too short to capture all health 
gains because the annual gain in QALYs was maximal around ten years. Extensive one-
way sensitivity analyses showed that results of the scenarios were very sensitive for the 
time horizon used. It is therefore very important to use a well-based estimate of the 
most realistic time horizon for each intervention. For the scenarios on pharmacotherapy 
and smoking cessation baseline exacerbation frequencies also influenced the results 
substantially. We are however rather confident about the exacerbation frequencies as 
these were obtained from a systematic review. 
Although a large part of the input data of the model are based on international data, the 
model as described in this paper is representative for the Dutch COPD population, because it 
filled with Dutch data on epidemiology of COPD and costs. To transfer the model to another 
country, setting-specific input data on prevalence, incidence, mortality, smoking prevalence 
and costs should replace the Dutch data (if they are expected to differ). All of these input data 
are listed in separate files that are imported into the model and are therefore easy to adapt.
In conclusion, this paper described the structure of an up-to-date COPD progression model, 
with input parameters as much as possible based on systematic reviews. The model can be 
used to provide policy makers with information about the long-term costs and effects of 
interventions over the entire chain from primary prevention to care for very severe COPD. 
Furthermore it also gives insight into the uncertainty around the outcomes. The model has 
been developed without any industry support and hence provides an independent tool for 
evaluation.
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Appendix I: Details about the probabilistic sensitivity analysis
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Appendix II: Results of the one-way sensitivity analyses
€ 0 € 5,000 € 10,000 € 15,000
Usual care stop rate smoking COPD patients 1.4%
Utility decrement due to exacerbations 95% CI limits
Lung function decline due to exacerbation 95% CI limits
Case fatality 95% CI limits
Utility value COPD severity stages 95% CI limits
Cost of exacerbations 95% CI limits
0% or 4% discounting of effects and costs
Costs of intervention +/- 10%
Annual decline in lung function +/- 50%
Exacerbation frequencies 95% CI limits
Time horizon of 5 or 20 years
Cost per QALY
Figure A1: Sensitivity analyses for the cost per QALY gained of three year implementation of a 
combination of ICS/LABA for 50% of the COPD patients with moderate or severe COPD in 2007, time 
horizon ten years
€ 0 € 10,000 € 20,000 € 30,000 € 40,000
Lung function decline due to exacerbation 95% CI limits
Cost of exacerbations 95% CI limits
Case fatality 95% CI limits
Utility decrement due to exacerbations 95% CI limits
Utility value COPD severity stages 95% CI limits
Annual decline in lung function +/- 50%
Costs of intervention +/- 10%
Usual care stop rate smoking COPD patients 1.4%
0% or 4% discounting of effects and costs
Exacerbation frequencies 95% CI limits
Time horizon of 5 or 20 years
Cost per QALY
Figure A2: Sensitivity analyses for the cost per QALY gained of three year implementation of intensive 
counseling plus pharmacotherapy for smoking cessation for 50% of the smoking COPD patients in 2007, 
time horizon ten years
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€ 0 € 5,000 € 10,000 € 15,000 € 20,000
Utility decrement due to exacerbations 95% CI limits
Usual care stop rate smoking COPD patients 1.4%
Lung function decline due to exacerbation 95% CI limits
Utility value COPD severity stages 95% CI limits
Case fatality 95% CI limits
Cost of exacerbations 95% CI limits
Annual decline in lung function +/- 50%
Costs of intervention +/- 10%
0% or 4% discounting of effects and costs
Exacerbation frequencies 95% CI limits
Time horizon of 5 or 20 years
Figure A3: Sensitivity analyses for the cost per QALY gained of three year implementation of a 
combination of ICS/LABA for 50% of the COPD patients with moderate or severe COPD, and three year 
implementation of intensive counseling plus pharmacotherapy for smoking cessation for 50% of the 
smoking COPD patients in 2007, time horizon ten years
€ 15,000 € 16,000 € 17,000 € 18,000 € 19,000 € 20,000
Annual decline in lung function +/- 50%
Case fatality 95% CI limits
Lung function decline due to exacerbation 95% CI limits
Cost of exacerbations 95% CI limits
Usual care stop rate smoking COPD patients 1.4%
Time horizon of 5 or 20 years
Utility decrement due to exacerbations 95% CI limits
Exacerbation frequencies 95% CI limits
0% or 4% discounting of effects and costs
Utility value COPD severity stages 95% CI limits
Costs of intervention +/- 10%
Cost per QALY
Figure A4: Sensitivity analyses for the cost per QALY gained of three year implementation of an 
interdisciplinary community-based pulmonary rehabilitation program for 15% of the COPD patients with 
moderate or severe COPD in 2007, time horizon ten years
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Abstract 
The study aimed to estimate the cost-effectiveness of interdisciplinary community-
based chronic obstructive pulmonary disease (COPD) management in patients with 
COPD.  We conducted a cost-effectiveness analysis alongside a two-yr randomized 
controlled trial in which 199 patients with less advanced airflow obstruction and im-
paired exercise capacity were assigned to the INTERCOM program or usual care. The 
INTERCOM program consisted of exercise training, education, nutritional therapy and 
smoking cessation counseling offered by community-based physiotherapists and dieti-
cians and hospital-based respiratory nurses. All-cause resource use during two yrs was 
obtained by self-report and from hospital and pharmacy records. Health outcomes were 
the St George’s Respiratory Questionnaire (SGRQ), exacerbations and quality-adjusted 
life years (QALYs). The INTERCOM group had 30% (95% CI: 3; 56%) more patients with 
a clinically relevant improvement in SGRQ total score, 0.08 (95% CI: -0.01; 0.18) more 
QALYs per patient, but a higher mean number of exacerbations, 0.84 (95% CI: -0.07; 1.78). 
Mean total two-yr costs were €2,751 (95% CI: -632; 6,372) higher for INTERCOM than for 
usual care, which resulted in an incremental cost-effectiveness ratio of €9,078 per ad-
ditional patient with a relevant improvement in SGRQ or €32,425 per QALY. INTERCOM 
significantly improved disease-specific quality of life, but did not affect exacerbation 
rate. The cost per QALY ratio was moderate, but within the range of what is generally 
considered to be acceptable. 
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Introduction
The importance of pulmonary rehabilitation [1] in treating chronic obstructive pulmo-
nary disease (COPD) is increasingly recognized as COPD is becoming more and more 
regarded as a systemic disease, that does not only affect the lungs [2]. In patients with 
severe COPD the beneficial effects of both in-patient and hospital-based outpatient 
pulmonary rehabilitation programs have been well established in terms of improving 
exercise capacity, dyspnoea and quality of life [3].  With regard to the cost-effectiveness 
of pulmonary rehabilitation the evidence is still very limited. Nevertheless, it is often 
stated in the literature that pulmonary rehabilitation is cost-effective, because it reduces 
healthcare costs [1, 4]. However, most studies only reported the program costs or the 
impact on just a limited number of healthcare services such as hospital admissions 
[5-10]. Only two comprehensive economic evaluations of pulmonary rehabilitation pro-
grams have been published [11,12]. Both studies included patients with severe COPD 
and were performed in the inpatient or outpatient setting of a hospital. Evidence of 
cost-effectiveness in less severe patients or in community settings is not available. In 
general it is assumed that the substitution of hospital care by community care reduces 
total costs and improves cost-effectiveness. We aimed to conduct a comprehensive 
cost-effectiveness analysis (CEA) of a community-based multidisciplinary rehabilitation 
program for COPD patients with less severe airflow obstruction than that of patients 
traditionally included in secondary-care or tertiary-care pulmonary rehabilitation pro-
grams. This CEA was performed alongside a two-year randomized controlled trial evalu-
ating the effect of an INTERdisciplinary COMmunity-based COPD management program 
(INTERCOM) compared to usual care. Full clinical results of this trial have been reported 
elsewhere [13-15]. In brief, results over the total two-year period showed that there were 
statistically significantly better effects in the INTERCOM group than for usual care in St. 
George’s Respiratory Questionnaire (SGRQ) total score, Medical Research Council (MRC) 
dyspnoea score, 6-min walking distance (6MWD) and cycle endurance time in a constant 
work rate test at 70% of peak exercise capacity. No significant differences were found 
for exacerbations, muscle function and body composition. Both patient and caregiver 
assessment of effectiveness significantly favoured the INTERCOM program. 
Methods
Patients and design
One hundred ninety-nine patients with GOLD stage 2 or 3 COPD and impaired exercise 
capacity (maximum work (Wmax) <70% predicted), recruited by respiratory physicians 
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of two general hospitals in the Netherlands, were randomized to the INTERCOM program 
(n=102) or to usual care (n=97) (Figure 1). Patients did not have prior rehabilitation or 
serious co-morbidity that precluded exercise training. At inclusion, they were judged by 
their respiratory physician to be clinically stable and pharmacotherapy was optimized. 
The time horizon of the study was two years and disease-specific and generic quality of 
life and functional parameters were single-blinded evaluated at baseline and, 4, 12 and 
24 months. All patients gave written informed consent and ethical approval was granted 
by the Medical Ethical Committee of the two hospitals. 
INTERCOM program
The core elements of the INTERCOM program were exercise training, education, nutri-
tional therapy and smoking cessation counseling (the latter two upon indication) [13]. 
During the 4-month standardized, supervised, intensive intervention phase individual 
exercise training sessions were given twice a week by physiotherapists in the proxim-
ity of the patients’ home. Patients were also instructed and motivated to perform the 
exercises at home and to walk and cycle twice a day. Smoking cessation counseling, if 
applicable, as well as education to improve the knowledge of COPD and its treatments 
and to teach self-management skills was provided by respiratory nurses in the hospital 
(average of four sessions). Nutritionally depleted patients were scheduled to visit a local 
dietician four times in the first four months. Nutritional therapy consisted of counseling 
to improve nutritional intake and three oral liquid (3x125ml) supplements (Respifor®, 
Nutricia BV, Zoetermeer, the Netherlands) per 24 hours for a period of four months. Dur-
 
Randomized (n=199) 
INTERCOM 
program n=102 
Usual care 
 n=97 
Included in the ITT 
cost-effectiveness 
analysis (n=87) 
Included in the ITT 
cost-effectiveness 
analysis (n=88) 
 
Included in the 
cost-effectiveness 
analysis among 
completers (n=77) 
Included in the 
cost-effectiveness 
analysis among 
completers (n=81) 
 
Premature 
discontinuation (n=10) 
 
Withdrew consent n=2 
Co-morbidity n=3 
Died n=5 
Premature 
discontinuation (n=7) 
 
Withdrew consent n=1 
Co-morbidity n=1 
Died n=5 
 
Failed to complete at 
least one cost booklet 
and one follow-up 
measurement (n=9) 
 
Failed to complete at 
least one cost booklet 
and one follow-up 
measurement (n=15) 
Figure 1: Patient disposition. INTERCOM: interdisciplinary community-based chronic obstructive 
pulmonary disease management program; ITT=intention-to-treat.
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ing the less intensive, less-standardized 20-month maintenance phase, patients visited 
the physiotherapist once a month. In case of insufficient recovery from an exacerbation, 
additional training sessions (maximum of six) could be started. During the maintenance 
phase, patients visited the dietician four times, while they visited the respiratory nurse 
according to an individualized schedule. 
Usual care
Patients assigned to usual care received pharmacotherapy according to accepted 
guidelines, a short smoking cessation advice from their respiratory physician and short 
nutritional advice to eat more and better in case they were nutritionally depleted. 
Perspective
The cost-effectiveness study was performed according to the good research practices 
for cost-effectiveness analyses alongside clinical trials [16]. The study was conducted 
from a societal perspective, including all COPD and non-COPD related healthcare costs, 
travel expenses and cost of productivity losses. A separate analysis was done from a 
third party payers’ perspective. All costs related to conducting the trial and developing 
the intervention have been excluded. 
Healthcare utilization and unit costs
In both treatment groups, patients kept a weekly record of contacts with healthcare 
providers, “over-the-counter medication”, medical devices, hospital admissions, time 
lost from paid work, hours of (un)paid household help, travel expenses and nutritional 
supplements using cost booklets. Each booklet covered a period of four weeks and 
was collected every two months. Whenever necessary, patients were contacted by 
telephone for further clarification. To ensure that no hospitalizations were missed, data 
on hospital admissions were extracted from the electronic hospital records of the two 
hospitals involved in the study. Information on the dispense and costs of outpatient 
medication was obtained from each patients’ local pharmacy. For twelve patients using 
oxygen during exercise, the start and stop date of oxygen supply were obtained from 
their oxygen supplier. Resource utilization was valued in euros (€) using Dutch guideline 
prices updated to the year 2007 (Table 1) [17]. Because of the small number of patients 
with a paid job and the homogeneity of this group, the weekly number of hours absent 
from paid work was valued with the average gross hourly earnings weighted for sex and 
age, €46.61 per hour. The calculation of productivity loss was based on the friction cost 
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approach [18], using a friction period of 154 days [17]. No discounting was applied to 
costs or effects, because of the limited study period.  
Health outcomes
It was pre-specified which of the wide range of health outcome measures applied in 
the clinical trial would be used in the cost-effectiveness study. These were: 1) the net 
proportion of patients with a clinically relevant improvement (≥ four units) in disease 
specific quality of life as measured by the SGRQ total score [19, 20]; 2) the total number of 
COPD-exacerbations (moderate plus severe); and 3) the number of quality-adjusted life 
years (QALYs) based on EuroQol-5D (EQ-5D) utility values [21, 22]. SGRQ and exacerba-
tions were the co-primary outcomes of the clinical study, whereas QALYs is the outcome 
preferably used in economic evaluations. The SGRQ and the EQ-5D were administered 
at baseline and, 4, 12 and 24 months, while exacerbations were measured continuously 
over the 2-yr period. 
The net proportion of patients with an improvement of four or more units in SGRQ 
total score was calculated as the proportion of patients with four or more units improve-
ment between baseline and 24 months minus the proportion of patients with four or 
more units deterioration. A moderate exacerbation was defined as a visit to the general 
 Table 1: Unit costs for the most important types of resource utilization (2007, €)
Type of healthcare Unit Unit costs 
Contacts with care providers:
General practitioner Contact 21
Medical specialist, general hospital Contact 59
Physiotherapist Contact 24
Dietician Contact 31
Respiratory nurse Contact 27
Other therapists Contact 24-75
Hospital care
General hospital Day 356
University hospital Day 502
Daycare treatment Day 242
Emergency Department Visit 147
Ambulance Ride 359
Pulmonary rehabilitation centre 
Inpatient day Day 379
Paid and unpaid help
Home care Hour 32
Informal care/ unpaid household help Hour 8.70
Oxygen therapy Day 4.00
Respifor® Unit 2.76
Travel expenses, public transport/ car Km 0.17
Productivity cost Hour 46.61
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practitioner or respiratory physician in combination with a prescription of antibiotics 
and/or prednisolone or a visit to the emergency department or day care of a hospital, 
which according to the patient, was related to a COPD exacerbation. A severe exacerba-
tion was defined as a hospitalization for a COPD exacerbation. The number of QALYs for 
each patient was calculated by summing the days under observation weighted by their 
EQ-5D utilities [21, 22] using linear interpolation. 
Cost-effectiveness
Cost-effectiveness was expressed as the incremental cost-effectiveness ratio (ICER), 
which was calculated as the difference in mean costs between the INTERCOM and usual 
care group divided by the difference in mean health outcome. Three different ICERs 
were planned: costs per additional patient with a relevant improvement in SGRQ total 
score, costs per exacerbation avoided and costs per QALY.
Statistical analyses
The analysis was performed according to the intention-to-treat (ITT) approach. All 
randomised patients who had at least one outcome measurement after the start of 
treatment and who completed at least one cost booklet were included in the cost-
effectiveness analysis. Differences in baseline characteristics of patients completing the 
trial and drop-outs were statistically tested using independent sample unpaired t-tests 
for continuous, normally distributed data, Wilcoxon Mann-Whitney U tests for continu-
ous non-normally distributed data and Chi-square tests for categorical variables. 
To account for costs and health outcomes that were missing after patients prema-
turely dropped out from the trial and the additional uncertainty that these missing 
values introduced, the multiple imputation technique was used [23]. Each missing 
value was replaced by ten simulated values using the propensity score method in SAS 
V8 [24, 25]. In summary this method implied that for patients who dropped out values 
were imputed that were randomly drawn from the data of patients who did not drop 
out, but had a similar probability to have missing data given several baseline and other 
variables. This meant that for patients with a worse health status that dropped out the 
trial, random draws of data of patients with a similar health status who did not drop out, 
were imputed. The logistic regression to calculate the probability to have missing data 
(i.e. the propensity score) included the following independent variables: age, sex, smok-
ing status, forced expiratory volume in one second (FEV1) as percentage of predicted 
normal, number of co-morbidities, body mass index (BMI), 6MWD, SGRQ total score and 
EQ-5D utility index scores, at baseline and, 4, 12 and 24 months, monthly exacerbation 
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rates and monthly costs. Multiple imputation was carried out separately for both treat-
ment groups and health outcomes and costs were imputed simultaneously. 
Each of the ten complete datasets was further analyzed by non-parametric bootstrap-
ping using 10,000 bootstraps per dataset [26]. The 95% confidence interval around 
the difference in mean costs and health outcomes was determined by taking the 2.5th 
percentile and the 97.5th percentile of these bootstrap replications. The bootstrap repli-
cates were plotted in cost-effectiveness planes (CE-planes). A CE-plane is an x-y-diagram 
with the x-axis representing the difference in health outcome between the treatment 
and usual care group and the y-axis representing the difference in costs. By plotting 
all bootstrap replicates in this diagram the uncertainty around the point estimates of 
the ICERs was displayed. In addition, the information in the CE-planes was summarized 
in cost-effectiveness acceptability curves, which shows the probability that the ICER of 
the INTERCOM program falls below various ceiling ratios. These ceiling ratios reflect the 
maximum that a decision maker would be willing to pay to have one additional patient 
with a relevant improvement in SGRQ, one exacerbation avoided or one additional QALY 
[27, 28]. All analyses were performed with either SPSS version 13.0 or SAS V8.
Sensitivity analyses
In addition to the probabilistic sensitivity analyses presented in the CE-planes and the 
acceptability curve, univariate sensitivity analyses were conducted to assess the impact 
of assumptions made or analytic methods used on the results. In the first sensitivity 
analysis (SA1) only data from patients who fully completed the trial were analyzed. In 
addition two sensitivity analyses on time horizon were conducted, showing the results 
at four months (SA2) and at twelve months (SA3). Finally, a sensitivity analysis was per-
formed in which patients referred to inpatient pulmonary rehabilitation during the trial 
were excluded from the analyses (SA4). 
Results
Patients
Baseline characteristics of the 199 randomized patients did not differ between the two 
groups (Table 2). Of the total of 199 patients 13 dropped out after randomization and 
before start of the treatment. From the 186 patients that actually started treatment, 175 
patients completed the first four months, while 158 completed the 2-yr study period 
(79%), 75% in the INTERCOM group and 84% in the usual care group. Length of stay in 
the trial was significantly shorter for drop-outs in the INTERCOM group than in the usual 
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care group, with mean (SD) of 262 (192) and 505 (225) days, respectively. In the INTER-
COM group drop-outs were older, tended to have more co-morbidities and worse scores 
on functional and quality of life parameters at baseline than completers, which was not 
the case in the usual care group. 175 patients had at least one outcome measurement 
after the start of treatment and completed at least one cost booklet and were therefore 
included in the cost-effectiveness analysis (figure 1). A more detailed patient enrolment 
and disposition scheme is given elsewhere [13]. 
Resource use 
Table 3 shows the mean resource use per patient as observed during the 2-yr trial. 
Overall, the percentages of item level missing data plus the missing data due to 
drop-out for the different data sources was about 5 to 7% except for prescribed medica-
tion for which this percentage was 9.2%. Missing data was primarily due to drop-out 
before completing the trial. To prevent bias related to differences in the length of the 
observation time, multiple imputation was applied to costs and health outcomes before 
statistically testing differences between the treatment groups. 
Table 2: Baseline characteristics 
INTERCOM (n=102)* Usual care (n=97)*
Women 30 (29%) 28 (29%)
Age (years) 66 (9) 67 (9)
Number of co-morbidities 1.6 (1.6) 1.5 (1.4)
Number of exacerbations in 12 months before trial 1.2 (1.4) 1.0 (1.5)
Number of COPD hospital admissions in 12 months before trial 0.2 (0.5) 0.2 (0.5)
Current smokers 32 (33%) 22 (24%)
Post-bronchodilator FEV1% predicted 58% (17) 60% (15)
FEV1/FVC, % 49% (11) 51% (12)
Wmax % predicted 60% (19) 61% (17)
Fat Free Mass (kg/m2) 17 (2) 18 (2)
SGRQ Total score (0-100 scale)# 39 (15) 38 (15)
SGRQ-symptom score (0-100 scale)# 45 (19) 41 (21)
SGRQ-Activity score (0-100 scale)# 55 (18) 56 (19)
SGRQ-Impact score (0-100 scale)# 27 (16) 25 (15)
EQ-5D utility index score 0.79 (0.21) 0.79 (0.15)
MRC dyspnea score (0-4 scale)$ 1.7 (1.0) 1.5 (0.9)
*Data are n (%) or mean (SD) 
# St. George’s respiratory questionnaire: a higher score indicates a worse quality of life
$ modified Medical Research Council (MRC)
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Costs
Table 4 shows the mean 2-yr costs per patient after multiple imputation. Mean total 
costs, irrespective of whether they were related to COPD or not, were €13,565 for the 
INTERCOM group and €10,814 for the usual care group, a difference of €2,751 (95% CI: 
-631; 6,372). Total direct healthcare costs were €2,147 (95% CI: -1,091; 5,649) higher 
in the INTERCOM group. Because the INTERCOM program is tailored to the individual 
patient, resulting in a variable number of contacts with the INTERCOM care givers, the 
intervention costs were best estimated as the difference in costs for the physiotherapist, 
dietician, respiratory nurse and diet nutrition between the two groups, €1,520 per pa-
tient. Based on the study protocol the 2-yr intervention costs were €1,650 per patient, 
ranging from €1,350 for patients visiting the physiotherapists and the respiratory nurse 
to €2,500 for nutritional depleted patients receiving additional dietary counseling and 
Respifor. 
Table 3: Mean total healthcare utilization and days of absenteeism per patient as observed during the 
trial
INTERCOM (n=87)* Usual care (n=88)*
General practitioner, visits 7.2 (7.0) 7.9 (8.1)
Chest physician, visits 4.4 (3.1) 3.5 (3.6)
Cardiologist, visits 1.6 (2.9) 1.4 (2.0)
Internist, visits 0.4 (1.6) 1.1 (2.2)
Other specialist, visits 2.6 (4.7) 3.8 (5.7)
Physiotherapist, visits 51 (18) 11 (21)
Dietician, visits 2.1 (3.4) 0.6 (2.1)
Respiratory nurse, visits 5.2 (3.1) 0.8 (1.6)
Respifor®, units of 125ml 111 (314) 3.6 (23)
Other healthcare providers, visits# 1.3 (5.7) 2.1 (9.1)
Home care, hours 37 (115) 38 (118)
Paid household help, hours 36 (103) 26 (73)
Unpaid household help, hours 10 (44) 25 (150)
Ambulance rides 0.19 (0.65) 0.23 (0.54)
Hospital admissions 0.75 (1.29) 0.96 (1.35)
Hospital admissions for COPD 0.36 (1.00) 0.40 (0.78)
Total hospital days 7.8 (16) 9.3 (15)
Total hospital days for COPD 4.9 (14) 4.3 (10)
Pulmonary rehabilitation (inpatient days) 3.3 (16) 0.7 (6.8)
Hours unable to work 22 (89) 6.8 (40)
*Data are mean (SD) 
#Other healthcare providers included other and alternative therapists, social workers and psychologists
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Health outcomes
In the INTERCOM group 43% of the patients had an improvement of four or more units in 
SGRQ total score, while 29% had a deterioration of four or more units, resulting in a net 
improvement of 13%. In the usual care group 29% improved and 46% deteriorated more 
than four units, resulting in a net improvement of -17%. The difference in net proportion 
of patients with an improvement in SGRQ total score was significantly different between 
the two groups, 30% (95% CI: 3; 56). Over the entire 2-yr period the INTERCOM group 
had 3.02 exacerbations per patient compared to 2.18 in the usual care group, a not 
significant two-year difference of 0.84 (95% CI: -0.07; 1.78). The mean number of QALYs 
per patient was 1.62 and 1.54 in the INTERCOM and the usual care group respectively, i.e. 
a difference of 0.08, which was not significantly different (95% CI: -0.01; 0.18). 
Cost-effectiveness
From a societal perspective, the ICERs of the INTERCOM program compared to usual care 
were €9,078 per additional patient with a relevant improvement in SGRQ total score and 
€32,425 per QALY. Because the INTERCOM group had a higher number of mean exacerba-
tions, the costs per exacerbation avoided were negative. The CE-planes with SGRQ and 
Table 4: Mean total 2-year costs per patient for different categories of resource use after multiple 
imputation (2007, €)
INTERCOM
(n=87)
Usual care
(n=88)
Difference 95% CI
General practitioner 163 175 -12 (-59; 36)
Specialist 570 610 -40 (-178; 101)
Physiotherapist 1,290 265 1025 (882; 1,167)
Dietician 70 20 50 (24; 77)
Respiratory nurse 147 22 125 (106; 145)
Hospital admissions 2,944 3,353 -408 (-2,084; 1,365)
Diet nutrition 320 31 290 (118; 486)
Prescribed medication 3,532 3,318 214 (-239; 667)
Oxygen use 196 57 139 (-13; 304)
Other direct medical costs* 2,911 2,148 763 (-1,207; 2,909)
Subtotal direct healthcare costs 12,145 9,998 2,147 (-1,091; 5,649)
Costs paid by the patient# 423 486 -63 (-472; 269)
Subtotal direct costs 12,568 10,484 2,084 (-1,198; 5,614)
Productivity costs 997 330 667 (-124; 1,566)
Total costs 13,565 10,814 2,751 (-631; 6,372)
*Other direct medical costs included costs of visits to other therapists, alternative therapists, social 
workers and psychologists, home care, ambulance transportation, pulmonary rehabilitation, psychiatric 
hospital admissions and medical devices.
#Costs paid by the patient included costs of over the counter medication, paid and unpaid household help 
and travel expenses
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QALYs as outcomes showed that the majority of bootstrap replications (>90%) fell within 
the upper-right quadrant indicating that the INTERCOM program resulted in higher costs 
but more patients had a relevant improvement in SGRQ and a higher gain in QALYs, respec-
tively (Figure 2). For total exacerbations most bootstrap replications fell in the upper-left 
quadrant indicating higher costs and more exacerbations. The accompanying acceptability 
curves are shown in Figure 3. The probability that the INTERCOM program is cost-effective 
at a willingness-to-pay of €20,000 and €50,000 per QALY gained was 33% and 67%, respec-
tively. From a third party payer’s perspective the ICERS were slightly lower, i.e. €7,086 per 
additional patient with a relevant improvement in SGRQ total score and €25,309 per QALY, 
resulting in slightly higher probabilities that the INTERCOM program was cost-effective.  
Sensitivity analyses
Results for the sensitivity analyses (Table 5) showed that when only patients that com-
pleted the trial were included in the analysis (SA1), the costs per QALY were comparable 
to the base case analysis.  The results for the sensitivity analyses on time horizon showed 
that the difference in mean number of QALYs between the two groups increased over 
time (SA2 and SA3). It is important to note that part of the cost increase in the INTERCOM 
group was due to four patients who were referred to inpatient pulmonary rehabilitation 
compared to one patient in the usual care group. When these five patients were excluded 
from the analyses (SA4), the difference in cost between the two groups reduced to €909 
and the incremental costs per QALY reduced to €8,421. For all sensitivity analyses the 
ICERs for total exacerbations avoided were negative as a result of a higher number of 
exacerbations in the INTERCOM group (data not shown).
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Discussion
This comprehensive cost-effectiveness analysis of an interdisciplinary community-based 
COPD management program (INTERCOM) compared to usual care has shown that such 
a program can significantly improve disease-specific quality of life in patient with less 
advanced COPD and impaired exercise performance, but the price that has to be paid is 
a cost increase of €2,751 per patient over 2 yrs. All other outcomes showed a consistent 
pattern toward better effects in the INTERCOM group compared to usual care group 
and statistical significance was reached for 6 MWD, cycle endurance time, dyspnoea 
and patient and caregiver global assessment of effectiveness [13]. These positive effects 
could not be explained by differences in medication use between the two groups, as 
this was similar. The only exception to the pattern of better effects in the INTERCOM 
group was the number of exacerbations that was slightly, but not significantly higher 
in the INTERCOM group. Given the consistency of the outcome pattern and considering 
that the 2-yr costs for medication alone were €3,300 and the total 2-yr costs for usual 
care were €10,800, the cost increase of €2,751 per patient seems reasonable for such an 
intensive and comprehensive COPD management program.
The incremental costs per QALY gained of the INTERCOM program were estimated 
to be €32,425. This is the ratio of the additional costs of INTERCOM over usual care 
divided by the gain in QALYs due to INTERCOM. In the Netherlands treatments with a 
cost-effectiveness ratio below €20,000 per QALY gained are generally regarded by policy 
makers as very cost-effective. The maximum acceptable cost per QALY ratio is subject of 
ongoing debate. An advisory board of the Dutch government has recently proposed to 
adopt a maximum willingness-to-pay for a QALY that depends on the burden of disease 
for which the treatment is developed [29]. The maximum acceptable ratio in their pro-
posal would be €80,000 per QALY gained for diseases with the highest burden of disease. 
With a ratio of €32,425 per QALY gained the INTERCOM program would be considered 
as moderately cost-effective, although the uncertainty around this ICER was substantial. 
Currently, for COPD patients, the costs of the separate components of the INTERCOM 
program (i.e. physiotherapy, dietary counseling, counseling by a respiratory nurse and 
diet nutrition) are covered by the nationwide obligatory basic healthcare insurance in 
the Netherlands.  However, this situation may change in the nearby future as the Dutch 
minister of health considers introducing one reimbursement package for ‘chained and 
integrated COPD care’, in which pre-defined types of healthcare are included. Whether a 
program such as INTERCOM would be included in this package is unclear. Other health-
care interventions with comparable, but also much higher cost-effectiveness ratios 
[30-33] are currently reimbursed, providing an indication that a ratio of around €30,000 
as found in the current study was previously considered acceptable for reimbursement. 
It is obvious however, that other criteria, such as budget impact, necessity of care, own 
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responsibility and affordability by the patient also play a role in the decision whether a 
healthcare service should be covered by social healthcare insurance. Interpreting the 
costs per additional patient with a relevant improvement in SGRQ total score is more 
difficult, because no reference data are available and up to now only one study used this 
outcome in a cost-effectiveness analysis [34]. 
The estimated average intervention costs of the entire INTERCOM program were ap-
proximately €1,500 per patient. As expected, these intervention costs were much lower 
than the intervention costs for inpatient rehabilitation [11]. Given the duration and 
intensity of the program, the costs of our community-based intervention seemed also 
low compared to several outpatient programs [7,8,12,35,36].
The increase in costs in the INTERCOM group was higher than the intervention costs. 
Although not significant, patients in the INTERCOM group had higher productivity costs 
and other direct medical costs (see table 4). The latter was mainly caused the fact that 
four patients in the INTERCOM group were referred to inpatient pulmonary rehabilita-
tion during their participation in the trial compared to only one patient in the usual care 
group. This difference may be coincidence, but could also be related to the frequent con-
tact between patient and caregivers resulting in earlier signalling of insufficient improve-
ments or significant worsening. In retrospect, it was also speculated that these patients 
should never have been included because their condition was so severely impaired that 
this community-based program was not sufficiently intensive. However, according to the 
intention to treat principle, these patients were kept in the trial and the costs of these 
inpatient rehabilitation programs were included. If the difference in referrals to inpatient 
pulmonary rehabilitation between the two groups indeed is an unexpected side effect of 
implementing a community-based program, including these costs in the analyses might 
have improved the generalizability of the results to common daily practice. 
In both the base case analysis and sensitivity analysis, the ICERs for exacerbations 
avoided were negative, because the number of COPD exacerbations was slightly higher 
in the INTERCOM group. The definition of an exacerbation in this study was based on 
resource use reported by the patient (moderate exacerbations) and obtained from 
hospital records (severe exacerbations). The frequently scheduled caregiver contacts 
might have increased the opportunity to detect an exacerbation. In addition, improved 
self-management skills in the INTERCOM group might have enhanced the ability to rec-
ognize and report exacerbations sooner as has also been seen in other studies [37,38]. 
Only two comprehensive economic evaluations on pulmonary rehabilitation have 
been published previously [11,12]. The study of Goldstein et al reported the cost-
effectiveness of a 2-month inpatient rehabilitation program followed by 4 months of 
outpatient training in patients with severe stable COPD. The cost required for a single 
patient to achieve a clinically important improvement in different components of the 
health related quality of life questionnaire ranged from $28,993 for mastery to $51,027 
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for fatigue (Canadian dollars). The second study is a 1-yr study by Griffiths et al that re-
ported the cost-utility of a 6-week multidisciplinary outpatient rehabilitation program. 
Compared to standard care the incremental costs of the program were £-152 (95% CI: 
-881; 577) per patient, while the incremental utility per patient was 0.030 (95% CI: 0.002; 
0.058), suggesting that the health improvements were accompanied by net savings. 
Comparison of the studies of Goldstein and Griffiths with our study is complicated by 
differences in the type of intervention, outcome measures and patient population. Both 
the study of Goldstein and Griffiths included patients with severe COPD/ lung disease 
reflected by a mean FEV1% predicted of 35% and 40% respectively, whereas in our study 
this was 60%. We have not found a full economic evaluation on outpatient or home-
based pulmonary rehabilitation in less severe patients.  
Whether an in interdisciplinary program such as the INTERCOM program can be 
implemented in other countries than the Netherlands depends, among other things, on 
the organizational structure of the healthcare system, the reimbursement system, the 
costs of health services for COPD and the geographical circumstances. Furthermore, it 
is important that COPD is acknowledged as a systemic disease, requiring regular assess-
ments other than lung function, and a collaborative network of the different healthcare 
providers in the local community is needed.  
From the combined results of the clinical analyses published elsewhere [13-15] and 
the cost-effectiveness analyses presented here, we conclude that compared to usual 
care, the INTERCOM program resulted in significant improvements in SGRQ total score 
and several exercise performance and dyspnoea measures at a cost increase of €2,751 
per patient. In terms of costs per QALY the program is moderately cost-effective.  
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Abstract 
The aim of this study was to compare the impact of two different sources of resource 
use, self-report versus care provider registrations, on cost and cost utility. Data were 
gathered for a cost-effectiveness study performed alongside a 2-yr randomized con-
trolled trial evaluating the effect of an INTERdisciplinary COMmunity-based manage-
ment program (INTERCOM) for patients with chronic obstructive pulmonary disease 
(COPD). The program was offered by physiotherapists, dieticians and respiratory nurses. 
During the 2-yr period patients reported all resource use in a cost booklet. In addition, 
data on hospital admissions and outpatient visits, visits to the physiotherapist, dieti-
cian or respiratory nurse, diet nutrition and outpatient medication were obtained from 
administrative records. The cost per quality-adjusted life year (QALY) was calculated in 
two ways, using data from the cost booklet or registrations. In total 175 patients were 
included in the study. Agreement between self-report and registrations was almost per-
fect for hospitalizations (rho=0.93) and physiotherapist visits (rho=0.86), but above 0.55, 
moderate, for all other types of care. The total cost difference between the registrations 
and the cost booklet was €464 with the highest difference for hospitalizations €386. 
Based on the cost booklet the cost difference between the treatment group and usual 
care was €2,444 (95% CI: -819: 5,950), which resulted in a cost-utility of €29,100 per QALY. 
For the registrations, the results were €2,498 (95% CI: -88; 6,084) and €29,390 per QALY, 
respectively. This study showed that the use of self-reported data or data from registra-
tions effected within-group costs, but not between-group costs or the cost utility.  
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Introduction
In cost-effectiveness studies performed alongside clinical trials, healthcare utilization 
can be measured using questionnaires or diaries completed by the patients in the trial 
or obtained from medical, billing or other administrative records. The latter is often 
regarded as more accurate than the first. However, retrieving data from medical or ad-
ministrative records can be time consuming and costly, especially when patients contact 
many different care providers. Furthermore, data on services for which the patient pays 
out-of-pocket, such as over-the counter medication or alternative therapists, are missed 
using medical or administrative records only. Self-reported surveys, such as question-
naires or diaries, can provide data on all types of healthcare utilization, but can be less 
valid due to recall-bias. Several studies compared self-reported healthcare utilization 
with data from medical records, but results are inconclusive. Some studies found good 
agreement between both sources [1-4], but others reported substantial differences [5-
7]. In general, agreement seems fairly good on major events such as hospitalizations 
or visits to the emergency department, but self-report of outpatient visits, visits to 
the general practitioner and diagnostic, laboratory or imaging procedures seems less 
valid compared to medical records [8-12]. Although several studies reported about 
the extent of agreement between self-reported healthcare utilization and data from 
medical records [4,7,9-11], the impact of the different types of data collection on cost(-
effectiveness) has not been studied. This is an important issue, because almost perfect 
agreement in hospitalizations between two data sources can still result in a substantial 
difference in costs as a result of the high costs of an inpatient day. On the other hand, 
a substantial difference in visits to the general practitioner may have little impact on 
costs, because of its low unit costs. The aim of this study was to compare the impact of 
using either self-reported resource use or resource use as obtained from administrative 
data of healthcare providers on costs and cost-effectiveness in a sample of patients with 
chronic obstructive pulmonary disease (COPD). Furthermore, we explored whether dif-
ferences in costs estimates between the two different types of data sources were related 
to patient characteristics. 
Methods
Design of the trial, the intervention and the cost-effectiveness study
Data were obtained as part of a cost-effectiveness study performed alongside a 2-yr ran-
domized controlled trial evaluating the effect of an INTERdisciplinary COMmunity-based 
COPD management program (INTERCOM) [13]. The trial included patients with COPD 
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and impaired exercise performance who were recruited from two general hospitals in 
the Netherlands. One-hundred ninety-nine patients were randomized to the INTERCOM 
program (n=102) or usual care (n=97). 
The INTERCOM program consisted of exercise training, education and smoking cessa-
tion support offered by local physiotherapists in the proximity of the patient’s home and 
by respiratory nurses in the hospital. Nutritionally depleted patients in the INTERCOM 
group were referred to a local dietician for counseling and nutritional supplements 
(Respifor®). The program was divided in a 4-month intensive intervention phase followed 
by a 20-month maintenance phase. During the intensive intervention phase all patients 
visited the physiotherapist twice a week, the respiratory nurse on average two times and 
the dietician four times if they were nutritionally depleted. In the maintenance phase, 
these frequencies were lower: once a month for the physiotherapist and at 6, 9, 12 and 
24 months for the dietician. Visits to the respiratory nurse during the maintenance phase 
were upon request and varied widely between patients from 0 to 16 visits. Patients 
assigned to usual care received pharmacotherapy according to accepted guidelines, 
a short smoking cessation advice by their respiratory physician and short nutritional 
advice to eat more and better in case they were nutritionally depleted. Quality of life 
and several functional parameters were assessed at baseline, 4, 12 and 24 months. All 
patients gave written informed consent. 
The cost-effectiveness study was conducted from a societal perspective including all 
COPD and non-COPD related healthcare costs, travel expenses and costs of productivity 
losses. All costs related to conducting the trial have been excluded. Health outcomes 
were expressed in terms of quality-adjusted life years gained (QALYs), using EQ-5D utility 
values. 
Self-report versus care provider registrations of resource use  
During the whole 2-yr study period healthcare utilization was recorded weekly in a cost 
booklet. In this booklet patients recorded visits to general practitioners, medical spe-
cialists, physiotherapists, dieticians, respiratory nurses, alternative therapists, psycholo-
gists, social workers, use of over-the counter medication and medical devices, hospital 
admissions, ambulance rides, time lost from paid work, hours of (un)paid household 
help, number of units of Respifor® used and use of other nutritional supplements. For 
all visits to care providers the travel distance was recorded to be able to calculate travel 
expenses. Each booklet covered a period of 4 weeks and was collected every 2 months. 
In case the recorded information was unclear, patients were contacted by the investiga-
tors by telephone for further clarification. 
Next to the self-reported data from the cost booklet resource use was obtained from 
administrative data of different care providers. Information on the delivery and costs 
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
Impact of the data source on cost-utility 167
of outpatient medication was obtained from the patients’ local pharmacies. For twelve 
patients using oxygen the start en stop date of oxygen supply were obtained from their 
oxygen supplier. The number of hospitalizations, inpatient hospital days and outpatient 
visits to medical specialists were obtained from the administrative systems of the two 
hospitals in the study. All seventeen local physiotherapists who treated patients in the 
INTERCOM group provided information about the number of contacts, the date, duration 
of the visits and whether treatment was for the INTERCOM study or not. The six respira-
tory nurses involved in the study provided the same information for outpatient visits to 
the respiratory nurses for all patients in the INTERCOM group. The five local dieticians 
who treated nutritionally depleted patients in the INTERCOM group provided detailed 
information about the visits to the dietician. Finally, the number of units of Respifor® 
supplied to all nutritionally depleted patients in the treatment group was obtained from 
the supplier (Nutricia Netherlands).
Resource utilization was valued using Dutch guideline prices updated to the year 
2007 [14]. More details about the cost calculation and the cost per unit used can be 
found elsewhere [13], but the most important unit costs are summarized in the Appen-
dix (Table A1). 
Two-different estimates of cost-utility
Cost-utility was calculated in two different ways. In the first analysis, data on healthcare 
utilization were based entirely on self-reported data from the cost booklet. Only data 
on outpatient medication and oxygen use were obtained from registrations as no 
self-reported data were available. In the second analysis, data on healthcare utiliza-
tion were based on registrations. This implied that outpatient medication, oxygen use, 
hospitalizations and visits to the medical specialist in the two hospitals in the study, 
visits to local physiotherapists and respiratory nurses in the hospital and visits to local 
dieticians and units of Respifor® used were based on registrations. The travel expenses 
for visits obtained from the registrations were calculated based on the average distance 
to the healthcare provider (hospital: 7.0, local physiotherapist: 1.8 and local dietician: 
3.9 kilometres) [14]. Data on visits to other care providers, use of over the counter medi-
cation and medical devices, ambulance rides, time lost from paid work, hours of (un)
paid household help, travel expenses for visits to other care providers and use of other 
nutritional supplements besides Respifor® were based on the cost booklet, because data 
from registrations were not available for these data sources. 
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Statistical analyses
All randomized patients who had at least one outcome measurement after start of treat-
ment and completed at least one cost booklet were included in this study. Missing data 
could be the result of drop-out or unavailability of registrations or cost booklets while 
patients were (still) in the trial. The percentage of missing data for the different data 
sources was calculated as the total number of weeks with missing data summed over 
all patients divided by the maximum number of observable weeks if all patients had 
complete data for the entire 2-yr study period (=18200). 
Correlation between resource use data from the registration and self-reported 
resource use from the cost booklet was calculated using Spearman’s rank correlation 
coefficient (rho). Furthermore, the proportion of perfect agreement between the two 
data sources was determined, where perfect agreement was defined as no difference 
between the two data sources. The correlation between the registrations and the cost 
booklet was calculated for the whole 2-yr period, but also for 0 to 4 months, 4 to12 
months and 12 to 24 months to see whether correlation changes over time. 
After valuation of resource use the absolute difference in total costs was calculated for 
each patient as the total costs based on the registrations minus the total costs based on 
the cost booklet. Multivariate linear regression analysis with the absolute difference in 
costs as depend variable  was performed to investigate whether treatment group, drop-
out, sex, age, number of co-morbidities at baseline, disease severity, health status and 
total costs were associated with either under- or over reporting. Underreporting was 
defined as higher costs based on the registrations compared to the cost booklet, while 
over reporting was defined as higher costs as obtained from the cost booklet compared 
to the registrations. In this analysis data from patients who did not complete the full two 
years of the trial were included in the analyses up until the moment patients dropped 
out and no imputation of missing data was done.
To account for costs and health outcomes that were missing due to drop-out and the 
additional uncertainty that these missing values introduce, ‘multiple imputation’ was 
applied before calculating the cost-utility [15]. This was done separately for missing 
costs based on self-reported resource use from the cost booklet and missing costs based 
on resource use from registrations. Each missing value was replaced by ten simulated 
values using the propensity score method in SAS V8 [16,17]. Missing EQ-5D scores were 
imputed simultaneously with costs. More details about the multiple imputation are 
described elsewhere [13]. 
Each of the ten complete datasets was further analyzed by nonparametric bootstrap-
ping using 10,000 replications per dataset [18]. The 2.5th percentile and the 97.5th percen-
tile of these bootstrap replications form the 95% confidence interval of the difference 
in costs and QALYs. The uncertainty around the point estimates of the incremental cost 
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effectiveness ratios (ICERs) was displayed by plotting the bootstrap replications in cost-
effectiveness planes (CE-planes). In addition, cost-effectiveness acceptability curves 
were drawn, which show the probability that the INTERCOM program is cost-effective 
at several values of the willingness-to-pay for one additional QALY [19,20]. All analyses 
were performed with either SPSS version 13.0 or SAS V8.
Results
Subjects
In total 175 of the 199 randomized patients were included in this cost-effectiveness 
study, because they had at least one outcome measurement after start of treatment and 
completed at least one cost booklet. Mean age was 67 years (SD 7), 26% was female, 
FEV1% predicted was 60% (SD 16), EQ-5D utility index score at baseline was 0.80 (SD 
0.18) and patients had on average 1.5 (SD 1.5) co-morbidities at baseline. Baseline char-
acteristics of patients in the INTERCOM and the usual care group were comparable. Of 
the 87 patients in the INTERCOM group that were included, all visited the physiotherapist 
and the respiratory nurses and 21 received additional nutritional advice and Respifor®. 
One hundred fifty-eight patients completed the 2-yr study period; 75% in the INTERCOM 
group and 84% in the usual care group, which was not a statistically significant differ-
ence. Drop-outs in the INTERCOM group had a significantly shorter length of stay in the 
trial than drop-outs in the usual care group. Besides that, drop-out in the INTERCOM 
group was related to a more impaired health status compared to completers, which was 
not the case in the usual care group. 
Availability of data
Information about hospitalizations and outpatient visits to medical specialists obtained 
from hospital records was available for 171 patients (97.7%). All other registrations were 
100% complete. Eighty-three percent of the 158 patients who completed the study filled 
in the cost booklet for the exact 2-yr period, while the remaining seventeen percent 
missed on average 2.6 weeks. The missing number of cost booklets in drop-outs was 
higher. Seventy-one percent of the seventeen drop-outs did not complete the cost 
booklets until their formal date of drop-out with an average of 8.3 weeks missing. After 
the formal date of drop-out the number of weeks with missing data was on average 37.8 
per patient. For all data sources the total percentage of missing data was below 10% 
(Table 1).
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Agreement
For all types of resource use, the mean unimputed resource use as obtained from the 
registrations was higher, except for visits to the physiotherapist, for which the mean 
number of visits obtained from the cost booklet was slightly higher (Table 1). Agreement 
was almost perfect for number of COPD-related and total hospital admissions, number 
of COPD-related and total hospital days and number of visits to the physiotherapists 
(all rho>0.8). Agreement was substantial for visits to the medical specialists, the respira-
tory nurse and the dietician and the number of units Respifor® used (rho>0.6), while 
agreement for COPD-related and total daycare treatment was moderate (rho>0.4). The 
percentage of perfect agreement decreased as the mean resource use increased. Agree-
ment did not worsen or improve over time (Appendix, Table A2). 
Variables related to differences in costs based on self-report or care provider 
registrations
Comparison of the total unimputed costs between the two data sources showed that 
106 of 175 patients (61%) were underreporting, i.e. they had higher costs based on 
the registrations compared to the cost booklet. Sixty-five patients (37%) were over 
Table 1: Mean resource use per patient and correlations between self-report and care provider 
registrations for the complete 2-year study period before multiple imputation of missing data (n=175) 
Number of 
patients
Care provider 
registrations
Self-reported 
cost booklet
Absolute 
difference
Spearman 
rank 
correlation 
coefficient
Percentage 
of  perfect 
agreement
Hospital Mean Missinga Mean Missinga
Daycare treatment 175 0.25 6.0% 0.08 4.5% 0.17 0.55 87%
Daycare treatment for COPD 175 0.035 6.0% 0.006 4.5% 0.03 0.49 98%
Hospital admissions 175 0.79 6.0% 0.69 4.5% 0.10 0.93 88%
Hospital admissions for COPD 175 0.36 6.0% 0.33 4.5% 0.03 0.94 95%
Total hospital days 175 8.0 6.0% 6.6 4.5% 1.4 0.91 79%
Total hospital days for COPD 175 4.3 6.0% 3.6 4.5% 0.7 0.93 93%
Visits to medical specialists 175 10.5 6.0% 9.2 4.5% 1.3 0.70 8%
Visits to the physiotherapist* 87 48.4 5.7% 49.9 6.4% -1.4 0.86 7%
Visits to the respiratory nurse* 87 7.5 5.7% 5.1 6.4% 2.4 0.65 11%
Visits to the dietician# 21 8.1 2.7% 6.6 2.7% 1.5 0.64 29%
Units Respifor® used# 21 491 2.7% 461 2.7% 30 0.68 10%
aThe percentage of missingness was calculated as the total number of weeks with missing data summed 
over all patients divided by the maximum number of observable weeks if all patients had complete data 
for the entire two year study period (=18200).
* Only applicable to patients in the INTERCOM group, # Only applicable to nutritionally depleted patients 
in the INTERCOM group 
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reporting, because they had higher costs based on the cost booklets compared to the 
registrations. For the remaining four patients, the absolute difference between the two 
data sources could not be calculated, because data for visits to the medical specialist 
and hospitalizations were not available from the registrations. In the multivariate linear 
regression, the degree of underreporting was significantly independently associated 
with drop-out and total costs. Patients who dropped out during the trial and patients 
with higher total costs had larger differences in costs between the registrations and the 
cost booklet compared to patient who completed the study and patients with lower to-
tal costs, respectively. The degree of over reporting was only associated with total costs 
with higher total costs resulting in more over reporting. The association of drop-out with 
underreporting was confirmed using the logarithm of costs as the dependent variable. 
No association was found with treatment group, sex, age, number of co-morbidities at 
baseline, health status or indicators of disease severity. 
Costs and costs-utility
The figure in the appendix shows the difference in costs between registrations and the 
cost booklet after multiple imputation. These are the final cost estimates used in the 
cost-utility calculations. The cost difference was highest for hospitalizations, approxi-
mately €390 and lowest for visits to the dietician, approximately €50.
Table 2 shows the mean costs by treatment group after applying multiple imputation 
separately for costs based on the registrations or the cost booklet. Costs for visits to the 
physiotherapist, respiratory nurse, dietician and the use of diet nutrition, all elements 
of the INTERCOM program, were, as expected, significantly higher for the INTERCOM 
group, irrespective of the data source used. Costs for visits to the medical specialist were 
significantly higher in the usual care group based on the registrations, while this was 
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not the case when costs were based on the cost booklet. However, differences between 
the two data sources were small across all types of resource use (Table 2). The difference 
in total costs between the two treatment groups was comparable for both data sources 
€2,498 (95% CI: -88; 6,084) based on the registrations and €2,444 (95% CI: -819; 5,950) 
based on the cost booklet. The gain in QALYs due to the INTERCOM program was 0.08 
(95% CI: -0.01; 0.18). This resulted in ICERs of €29,390 per QALY based on the registra-
tions and €29,100 per QALY based on the cost booklet. CE-planes for both data sources 
were similar (Figure 1). For both the registrations and the cost booklet about 88% of the 
bootstrap replications fell in the upper-right quadrant indicating that the INTERCOM 
program has a higher gain in QALYs, but also higher costs. The acceptability curves 
were also comparable. The probability that the INTERCOM program is cost-effective at 
a willingness-to-pay of €20,000 and €50,000 per QALY gained was in both data sources 
37% and 69%, respectively.
Table 2: Mean costs per patient for different categories of care based on care provider registrations or the 
self-reported cost booklet after multiple imputation of missing data* (2007, €) 
INTERCOM (n=87)* Usual Care (n=88)* Difference in costs INTERCOM and Usual Care
(95% confidence interval)*
Care 
provider 
registrations
Self-
reported 
cost 
booklet
Care 
provider 
registrations
Self-
reported 
cost 
booklet
Care provider 
registrations
Self-reported 
cost booklet
General practitioner 162 162 175 175 -12 (-60; 35) -13 (-61; 34)
Medical specialist 582 571 738 609 -156 (-276; -33) -38 (-175; 102)
Physiotherapist 1,236 1,290 265 264 971 (834; 1,104) 1,026 (882; 1,168)
Dietician 81 70 20 20 62 (32; 92) 50 (23; 76)
Respiratory nurse 215 148 22 22 193 (171; 215) 125 (106; 145)
Hospital admissions 2,793 2,341 3,342 3,021 -549 (-2,204; 1,204) -679 (-2,116; 866)
Diet nutrition 340 318 31 31 309 (145; 500) 287 (115; 483)
Prescribed medication 3,525 3,528 3,313 3,321 212 (-243; 665) 208 (-248; 659)
Oxygen use 198 197 56 57 141 (-10; 306) 141 (-11; 305)
Other direct medical 
costs#
2,908 2,901 2,147 2,148 760 (-1,204; 2,893) 754 (-1,231; 2,889)
Costs paid by the 
patient$
386 424 486 491 -100 (-509; 233) -67 (-475; 266)
Productivity costs 996 983 330 330 667 (-123; 1,563) 653 (-136; 1,552)
Total costs 13,423 12,932 10,925 10,488 2,498 (-855; 6,084) 2,444 (-819; 5,950)
* Grey cells contain data obtained from the two different data sources. Data in white cells are based on the 
same data source either the self-reported cost booklet or care provider registrations. Small differences in 
the white cells are the result of the multiple imputation procedure. 
# Other direct medical costs included costs of visits to other therapists, alternative therapists, social 
workers and psychologists, home care, ambulance transportation, pulmonary rehabilitation (daycare 
treatment and inpatient), psychiatric hospital admissions and medical devices.
$ Costs paid by the patient included costs of over the counter medication, paid and unpaid household 
help and travel expense
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Discussion
This study showed the impact of self-report or registration based resource use on costs 
and cost-utility. Agreement between self-reported resource use and resource use based 
on registrations was good or substantial for most types of care. Because inaccuracy 
increases with longer recall periods [11], the relatively short recall period in our study 
may have contributed to this high agreement. The cost booklets were designed to 
record resource use per week and each booklet covered four weeks. The booklets were 
collected every two months. This is a relatively short recall period compared to other 
studies using recall periods of six or even twelve months [8-10,12]. The high agreement 
between the two data sources for hospital admissions/days were in accordance with 
other studies showing a high agreement for major events [10-12]. The agreement for 
visits to the physiotherapist was higher than in other studies [3,5], probably because the 
visits took place on a regular basis, two times a week in the first four months and once a 
month thereafter. Agreement for daycare treatment in hospital was poor. This may have 
been related to the fact that the cost booklet did not explicitly specify daycare treat-
ment in hospital separately from inpatient hospitalizations including an overnight stay. 
It identified daycare treatment when the date of admission and discharge was the same. 
Our study confirmed that self-report results in underestimation. For all categories 
of care, except one, mean resource use was lower for the cost booklet than for the 
registrations. Analyses of the difference in total costs based on either the cost booklet 
or the registrations showed that both under- and over reporting were associated with 
total costs. The association between increased visit frequency and underreporting was 
reported by several studies before [2,6,11]. As total resource use increases patients are 
more likely to forget visits or unwilling to write everything down. The relation between 
increased visit frequency and over reporting has also been found in other studies [6,9]. 
With an increase of resource use, it is more difficult to remember the exact date of a 
certain visit. As a result visits that occurred outside the actual recall period may have 
been included.
The absolute difference in costs between the registrations and the cost booklet was 
about €460. Despite the almost perfect agreement for hospitalizations and hospital 
days, the cost difference between the registrations and self-reported resource use was 
highest for this type of care, about €390. For visits to the dietician the cost difference 
was lowest, about €50, although agreement for this type of care between the two data 
sources was only substantial. Hence, good agreement between self-reported resource 
use and resource use from registrations does not automatically result in good agree-
ment in costs, when unit costs are high. Van den Brink et al also investigated the effect 
of different data sources on costs for a limited number of types of care [4]. They found 
that cost estimates for medication and stoma care products based on self-report were 
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substantially lower compared to providers’ records .The cost estimates for hospital ad-
missions however did not differ much between the two data sources in contrast to what 
we found in our study. 
The observed difference in total costs of about €500 between the registrations and 
the cost booklet within treatment groups did not have an influence on the difference 
in costs between treatment groups. The cost difference between treatment groups was 
only slightly different, €2,498 based on registrations versus €2,444 based on the cost 
booklet. As a result the CE-ratio, CE-planes and acceptability curves were comparable. 
A limitation of our study was that we did not have both data sources for all types of 
resource use. Although it is common in economic evaluations to combine resource use 
data obtained from different sources, it is unusual to have multiple sources for a single 
type of resource use. It is not common practice to validate resource use data obtained 
from one source with a second source. We collected data from several care provider 
registrations in addition to the data from the cost booklet for the specific purpose to 
validate the booklet. Of the two items with the highest costs in our study, i.e. medication 
and hospitalizations, only the latter was available from both self-report and registra-
tions. Information on outpatient medication was only available from the administrative 
systems of patients’ local pharmacies. Given the length of the study, two years, and the 
large number of different medications used by COPD patients, the choice for registra-
tions was made in order to limit the burden of data registration. For other high costs cat-
egories, such as “other direct medical costs” and “productivity costs”, getting data from 
registrations would have been very difficult if not impossible. However, if only items 
with two data sources would have been included in the cost-effectiveness analysis, the 
cost difference between treatment groups would have been €730 based on registrations 
versus €704 based on the cost booklet, resulting in ICERs of €8,590 and €8,379 per QALY, 
which would not have changed the conclusions.
The final estimate of costs used in the original cost-effectiveness study was based on 
a combination of both sources. Most resource use information was obtained from the 
cost booklet except for outpatient medication and oxygen, which were obtained from 
registrations. For hospitalizations we combined both sources and counted all hospital-
izations irrespective of whether they were recorded by patients only, in the registrations 
only or in both sources. This resulted in higher costs for hospitalizations compared to the 
data presented in this paper and therefore in somewhat different estimates for the cost 
difference between treatment groups and the cost-effectiveness, €2,751 (95%CI:-632; 
6,372) and €32,425 per QALY, respectively [13].
In conclusion, we showed that self-reported resource use led to different cost estimates than 
care provider registrations, but it did so in both treatment groups. As a result, estimates of the 
difference in costs between two treatment groups and estimates of the cost-utility of the IN-
TERCOM program were comparable between the two methods of resource use measurement. 
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Appendix
Table A1: Unit costs for the most important types of resource utilization (2007, €)
Type of healthcare
Unit Unit costs 
Contacts with care providers:
Medical specialist, general hospital Contact 59
Physiotherapist Contact 24
Dietician Contact 31
Respiratory nurse Contact 27
Hospital care
General hospital Day 356
Daycare treatment Day 242
Respifor® Unit 2.76
Travel expenses, public transport/ car Km 0.17
Table A2: Mean resource use per patient and correlation between self-report and care provider 
registration over time before multiple imputation of missing data
Time period Care provider 
registrations
Self-reported cost 
booklet
Absolute 
difference
Spearman rank 
correlation coefficient
N Mean N Mean
Hospital admissions 0-4 months 170 0.07 175 0.07 0.00 1.0
4-12 months 170 0.20 174 0.18 0.02 0.93
12-24 months 165 0.53 167 0.46 0.08 0.94
Hospital days 0-4 months 170 0.74 175 0.71 0.02 1.0
4-12 months 170 1.87 174 1.65 0.22 0.93
12-24 months 165 5.55 167 4.46 1.08 0.93
Visits to medical specialists 0-4 months 170 1.45 175 1.65 -0.20 0.63
4-12 months 170 3.44 174 3.24 0.19 0.60
12-24 months 165 5.82 167 4.54 1.27 0.64
Visits to the physiotherapist 0-4 months 87 21.4 87 22.6 -1.2 0.74
4-12 months 87 13.1 86 14.0 -0.8 0.82
12-24 months 81 14.9 80 14.7 0.2 0.77
Visits to the respiratory nurse 0-4 months 87 2.03 87 1.49 0.54 0.55
4-12 months 87 2.33 86 1.76 0.58 0.68
12-24 months 81 3.41 80 2.03 1.38 0.61
Visits to the dietician 0-4 months 21 2.43 21 2.62 -0.19 0.65
4-12 months 21 2.67 21 2.00 0.67 0.58
12-24 months 20 3.15 20 2.01 1.1 0.55
Units of Respifor® used 0-4 months 21 272 21 180 91 0.54
4-12 months 21 91 21 128 -38 0.52
12-24 months 20 135 20 160 -25 0.57
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Discussion
The main goal of this thesis was to develop tools that enable the assessment of the cost-
effectiveness of treatment options for COPD and to provide such information. Two dif-
ferent approaches were used to obtain this information. First, a population-based COPD 
progression model was developed which can be used to evaluate the cost-effectiveness 
of a wide range of COPD interventions over a long time horizon and can provide policy 
makers with comparable information on a nationwide level. Secondly, an empirical eco-
nomic evaluation was performed alongside a clinical trial evaluating the effectiveness 
of a COPD management program. In this chapter, results of both approaches will be 
discussed separately. Furthermore, the advantages, disadvantages and complementary 
nature of both methods will be presented. It will also be discussed how the outcomes of 
the studies in this thesis can be used in policy making with respect to COPD care. Finally, 
recommendations for further research will be given.
Part one: studies related to the development of a COPD 
progression model
The first part of this thesis presented papers describing the estimation of the input 
parameters and the structure of the COPD model. Furthermore, examples of the pos-
sible use of the model were included as well as a paper describing the cost-effectiveness 
of smoking cessation interventions in COPD patients using the COPD model. Models 
synthesize data from various sources in a systematic way and combine these data into 
a consistent framework. In the COPD model described in this thesis data on COPD 
prevalence, incidence, mortality, decline in lung function, smoking prevalence and 
smoking transition rates, exacerbation-related parameters, quality of life and costs were 
combined into a population-based COPD disease progression model describing the 
course of the disease from diagnosis till death. The model aims to be representative 
for all patients with a physician-diagnosis of COPD. Patients with undiagnosed COPD 
are not included, because data on prevalence and incidence are based on a physician-
diagnosis of COPD obtained from registrations of general practices. A model including 
undiagnosed patients is hard to fill with evidence-based estimates of input parameters, 
because the number of undiagnosed patients and their COPD-related resource use 
is completely unknown because it is not registered as such. The model is a dynamic 
population model which means that dynamics influencing the incidence of COPD in 
the Dutch general population, such as prognosis of birth, migration and mortality and 
changes in smoking prevalence are taken into account [1]. An advantage of the model 
being dynamic is that the model projects the changes in the total Dutch COPD popula-
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tion over time. The model can also be used to follow a pre-specified fixed cohort of 
patients over time by selecting patients within a certain age range, adjusting the COPD 
severity distribution at the start of the simulation and setting the number of newborns 
and the COPD incidence to zero. 
Summary of findings
Chapter two to seven described the structure and input parameters of the first and 
the second version of the COPD model. The most interesting input parameters of the 
models and the most important outcomes will be discussed in this paragraph. The total 
number of COPD patients in 2000 was estimated to be 305,000 (chapter three). The ma-
jority of these patients had mild or moderate airflow obstruction (82%) according to the 
GOLD classification (chapter two). For the period 2000-2025 the prevalence of COPD was 
projected to increase by about 40% in males and 90% in females. Total COPD-related 
healthcare costs were projected to increase from €280 to €495 million (chapter three). 
Several GP registries combined resulted in a prevalence estimate for 2007 of 321,000 
patients (uncertainty interval: 225,100; 395,500), which was used as input data for the 
second version of the model.  For this version of the model all exacerbation-related in-
put parameters except for costs were estimated by means of a meta-analysis. The annual 
total exacerbation frequency by COPD severity stage was found to range from 0.82 (95% 
uncertainty interval (UI): 0.46;1.49) for mild to 2.1 (1.51; 2.94) for very severe COPD. The 
frequency of severe exacerbations increased from 0.11 (0.02; 0.56) in mild to 0.28 (0.14; 
0.63) in very severe COPD (chapter five). The FEV1 decline due to an exacerbation was 
estimated to be 0.19 % predicted (95% CI: 0.092; 0.29) per exacerbation (chapter seven). 
The case-fatality of a severe exacerbation was found to be 15.6% (95% CI: 10.9; 20.3) 
(chapter six). The association between exacerbations and quality of life was derived from 
studies from Goossens and O’Reilly that reported utility values during a moderate and 
severe exacerbation, respectively. Based on these values the annual utility loss due to an 
exacerbation was estimated to be 1.66% (95% CI: 1.23; 2.09) of the baseline utility value 
for a moderate exacerbation and 4.82% (3.11; 6.53) of the baseline value for a severe 
exacerbation ([2,3].
Chapter three, four and seven included examples of the potential of the model for 
cost-effectiveness analyses. Chapter three presented two examples of cost-effectiveness 
calculations assuming increased implementation of smoking cessation interventions 
for COPD patients. Compared with usual care, one-year implementation of minimal 
counseling (10 minutes) by the general practitioner was estimated to be cost saving 
and the cost per QALY for intensive counseling plus bupropion was estimated to be 
€7,300, both using a time horizon of 25 years. Due to a lack of data at that time, the 
12-month continuous abstinence rates that were used in this study had to be based on 
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studies among smokers in the general population. However, abstinence rates for the 
same intervention are currently assumed to be higher in the general population than in 
COPD patients [4,5]. It took some years before the number of studies evaluating smok-
ing cessation interventions in COPD patients was sufficient to be able to calculate better 
estimates of the cost-effectiveness of smoking cessation interventions using abstinence 
rates specific for COPD patients (chapter four). Compared with usual care the costs per 
QALY gained of one year implementation of minimal counseling (less than 90 minutes), 
intensive counseling (≥ 90 minutes) and intensive counseling plus pharmacotherapy 
(NRT, bupropion or nortriptyline) were estimated to be €16,900, €8,200 and €2,400, 
respectively, using a time horizon of twenty-five years. The calculations of the cost-
effectiveness of smoking cessation in chapter three and four were done with the first 
version of the COPD model. Using the second version of the model (chapter 7), the cost-
effectiveness ratio for intensive counseling plus pharmacotherapy was estimated to be 
€10,800 per QALY gained (chapter seven). However, this estimate was based on calcula-
tions assuming a longer implementation period than in chapter four, i.e. three years 
instead of one year(s). Moreover, effects were evaluated over a shorter time horizon, 
ten years instead of twenty-five years. Using the same implementation period and time 
horizon as in the study in chapter four would have resulted in a ratio of €5,700 per QALY 
gained, which was not significantly different from the result in chapter four taking into 
account the uncertainty around the outcomes. Chapter seven also presented the cost 
per QALY gained for three-year implementation of the combination of ICS/LABA (€8,300) 
and three year implementation of a pulmonary rehabilitation program, the INTERCOM 
program (€17,200) both using a time horizon of ten years. The latter estimate included 
the additional intervention costs directly related to the program, e.g. physiotherapist, 
dietician, respiratory nurse and diet nutrition above the costs for maintenance therapy 
and exacerbations already included in the model. Because the INTERCOM trial did not 
provide evidence that the intervention significantly affected other types of costs, such 
as for example a reduction in costs for hospitalizations, we did not model any changes 
in the costs for maintenance treatment and exacerbations as a result of the interven-
tion. This is the main explanation for the difference in cost per QALY of the model-based 
estimate compared with the trial-based estimate, €32,400 (chapter eight).
Input parameters
As described above the model is filled with several input parameters. According to the 
principles of good practice for modelling [6], all key input parameters should be based 
on systematic reviews. This increases the validity and generalizability of the model out-
comes substantially, because in this way input data are based on the evidence available 
in the current literature and are not biased towards one single study population. All 
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exacerbation-related parameters, except for costs, were based on systematic reviews 
and meta-analyses (chapter five, six and seven). However, due to data limitations it is 
sometimes unavoidable to base input parameters on only a few or even one data source. 
A disadvantage of systematic reviews and meta-analyses based on just a few studies 
is that this often results in one mean estimate, which can not be further specified by 
subgroup. An example of this is the case-fatality of a COPD exacerbation, which should 
preferably be further specified by sex and age (chapter six). Another example is the 
smoking abstinence rates presented in chapter four. Preferably, rates would have been 
specified by COPD severity and the group intensive counseling plus pharmacotherapy 
to support smoking cessation would have been further specified by type of pharma-
cotherapy. For the epidemiological input parameters of the model a meta-analysis of 
all available evidence in the literature would not be appropriate, because the model 
was intended to be representative for the Dutch COPD population. Therefore the model 
was filled with Dutch data on prevalence, incidence, smoking data and costs, mostly 
obtained from one or a couple of data sources. Mortality data were obtained from the 
DYNAMO-HIA project and originally based on the General Practice Research Database 
(GPRD) from the UK [7]. The model could be transferred to different settings by replacing 
the epidemiological input data by setting-specific data. 
Severity of COPD
One of the major difficulties in developing a COPD model is the concept of COPD disease 
severity. In the current version of the model disease severity and disease progression 
was based on the degree of airflow obstruction defined in terms of the FEV1% predicted, 
as has been done in all other available COPD models [8-15]. Chapter two showed the 
results of the estimation of the severity distribution of COPD in the Netherlands based 
on lung function. The complexity of COPD severity can however not be described by 
the degree of airflow obstruction alone, because patients within each GOLD severity 
stage can vary substantially in terms of symptoms, exacerbations and prevalence of co-
morbidities [16]. The same is true for disease progression, which was defined as annual 
decline in lung function based on data from the Lung Health Study, a large study in 
patients with mild and moderate airflow obstruction [17]. Although the decline in lung 
function was specified by sex, age, smoking status and baseline FEV1% and influenced by 
exacerbations, other acknowledged prognostic factors, such as BMI, health status, and 
dyspnoea [18] were not taken into account due to data limitations. Several composite 
measures based on multiple parameters have been proposed as better ways to define 
disease severity in COPD [19-21]. The recently published Dutch “Zorgstandaard COPD” 
also chose not to use a severity distribution based on lung function alone, but proposed 
a new classification based on burden of disease (=”ziektelast”) specified as mild, moder-
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ate or severe burden of disease [22]. This new classification includes parameters such as 
diagnostic problems, achievement of treatment goals, lung function, dyspnoea, coping, 
nutritional status, exacerbations and co-morbidity and would better reflect the true 
disease severity of COPD and the health problems patients experience. A clear exact 
definition of this concept of burden of disease is still missing, which makes the compari-
son between groups and interventions difficult. The exact distinction between the three 
proposed severity stages is also difficult because scientific evidence for cut-off points for 
the different parameters is still insufficient. Another difficulty is that the burden of dis-
ease of a patient is dynamic and can vary within a patient over time [22]. Using a severity 
distribution based on multiple parameters in the model would be challenging, because 
it requires continuous monitoring of changes in all of these parameters. Therefore the 
COPD severity in the model was only based on lung function.
Model validation 
Validation is an important step in the development of a model [23]. Different types of 
model validation can be distinguished: internal validation, between-model validation, 
predictive or prospective validation and external validation [23,24]. The internal validity of 
the developed COPD model was secured by performing fifteen different model checks to 
prevent internal inconsistencies. This was done by setting several major input parameters 
at zero or at extreme values to see whether the model outcomes responded as expected 
[25]. Furthermore, model results for certain subgroups were compared, such as smokers 
versus former smokers and mild versus severe COPD to see whether the model outcomes 
were plausible. Finally, the mean life expectancy of a COPD patient above 45 years of age 
was calculated and compared with published data. The mean age of the COPD patients 
in the model was 69 years. The mean life expectancy of these patients calculated by the 
model was 10.5 years, which was comparable with the mean life expectancy of 10 to 12 
years for a patient with a mean age of 65-70 years estimated by Van Baal et al (adapted 
from [7,26]. Given that the life expectancy of a 65-70 year old person in the general 
population is about 14 to 17 years for males and 17 to 21 years for females our estimate 
of the life expectancy of a COPD patient seemed reliable [27]. Internal validation refers to 
the situation that if the model is filled with input parameters that are obtained from one 
particular trial it should be able to reproduce the outcomes of that trial. Although internal 
validation was not completely possible in our case, because input data were obtained 
from multiple resources, we tried to check the internal validity of the COPD model using 
data from the TORCH trial [28,29]. We used the model to simulate the cohort of patients 
included in the TORCH trial by selecting patients between 40 and 80 years of age and 
adjusting the severity distribution at baseline. Furthermore we replaced the exacerbation 
rates and all-cause mortality rates in the model at baseline by the rates observed in the 
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trial. Table 1 shows that the model outcomes after three years resembled the trial data 
fairly well, except for the all-cause mortality rate in very severe COPD which was about 
1.4% lower in the COPD model. This is probably the result of the higher percentage of 
males in the very severe COPD group in the trial (83%) compared with our model (54%) 
in combination with the higher all-cause mortality rates in males compared with females 
(chapter seven). Based on the outcomes of the internal checks and simulation of the 
TORCH trial we concluded that the COPD model was internally valid.
The prospective validity of the first version of the model (chapter three) was checked 
by comparing the prevalence projections of this model for the year 2007 with preva-
lence data for this year obtained from GP registrations [26]. Based on this comparison 
the prospective validity of the first version of the model seemed good for female 
COPD patients, but less so for male COPD patients. For males, the model projected an 
increase from 188,000 patients in 2000 to 216,000 in 2007, while the actual prevalence 
in 2007 was 172,000. Figure 1 shows that this was mainly the result of an overestima-
tion of the prevalence in the highest age groups. The latter was probably caused by 
a change in the number of smokers at older ages. The updated smoking prevalence 
figures for the year 2007 showed that especially in older males the smoking prevalence 
decreased substantially in the past years and faster than expected in 2000 [30,31]. The 
smoking prevalence in the cohort of 65-70 year old males for example was projected 
by the model to decrease from 31% in 2000 to 24% in 2007, while the new input data 
for the year 2007 reported a smoking prevalence rate of 14% for this group of patients. 
For female patients the model performed quite well by projecting an increase in total 
number of patients from 117,000 in 2000 to 147,000 in 2007, which was comparable to 
the prevalence observed in 2007, 149,000. However, figure 1 shows that also for females 
the prevalence was slightly overestimated in the older ages. 
Two comments should be made regarding the assessment of the prospective validity 
of the model. First, it should be noted that the data sources for the prevalence for the 
year 2000 and 2007 were not completely the same. For the year 2000 data on prevalence 
Table 1: Internal validation of the COPD model using input data of the TORCH trial
Outcomes of the TORCH trial after three years [28,29] Outcomes of the COPD model after three years
Annual exacerbation rate All-cause mortality at 
three years
Annual exacerbation rate All-cause mortality at 
three years
Moderate COPD 0.82 11.4% 0.84 11.7%
Severe COPD 1.24 15.2% 1.27 15.3%
Very severe COPD 1.79 24.3% 1.82 22.9%
Overall 1.17* 15.2% 1.20 15.2%
* Weighted mean based on the severity distribution of the population. The overall annual exacerbation 
rate published by Calverley et al was based on negative bionomial regression.
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were based on three general practice registrations (CMR, RNH and Transition-project) 
[26]. The new prevalence estimates for 2007 were also based on three general practice 
registrations, but the data from the Transition-project were replaced by data from the 
RNHUH-LEO, because the Transition-project seems to overestimate current prevalence 
[32]. This may imply that the prevalence estimates for 2000, the start of the simulation, 
were already too high. To check the real prospective validity of the model prevalence 
estimates for the years 2000 and 2007 should be based on the same data registrations 
to ensure that differences in prevalence could not be the result of methodological dif-
ferences. Secondly, the differences in prevalence estimates between the different GP 
registrations were substantial and therefore uncertainty around the prevalence rates for 
2007 was high [32]. This was probably also the case for the prevalence rates for 2000, but 
in the first version of the model we did not take into account uncertainty. For 2007, all 
age-specific prevalence rates could vary from 25% lower to 35% higher rates. The preva-
lence projections for females for 2007 using the first version of the model fell within this 
uncertainty interval. For males this was not the case indicating that prevalence projec-
tions for 2007 of the first version of the model were probably too high.   
To assess the between-model validity of the model the outcomes of the newest ver-
sion of the model were compared with other published models. A model-based study of 
Earnshaw et al used input data from the TORCH trial to estimate the cost-effectiveness 
of treatment with ICS/LABA [15]. Compared with placebo the cost-effectiveness of life-
time treatment with ICS/LABA was estimated to be $33,900 per QALY (about €29,800 
per QALY in 2007€). Using the same treatment effects for ICS/LABA on exacerbation 
frequency and all-cause mortality, the same study population and equal intervention 
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Figure 1: Comparison of observed and projected age-specific prevalence rates
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costs, our COPD model found a cost-effectiveness ratio of €36,600, slightly higher than 
the results of Earnshaw. 
External validation of the model by comparing the model outcomes with other 
sources not used as input for the model was difficult, because such data sources were 
not available for the Dutch setting. The only parameter of the model we were able to 
validate with independent data was the COPD severity distribution, which was assumed 
to be 27% in mild, 55% in moderate, 15% in severe and 3% in very COPD. This finding was 
confirmed by a study from Steuten et al, which also reported that almost 80% of Dutch 
primary care COPD patients were classified as having mild or moderate COPD [33].
Recommendations for future research with respect to COPD modelling
Several aspects in the field of COPD modelling require more research. One of the 
items for future research is the concept of COPD disease severity. To better reflect the 
complexity of the disease, future COPD models should incorporate other ways to de-
fine disease severity than based on lung function alone. This involves including other 
parameters such as BMI, fat-free mass, dyspnoea, exercise capacity, exacerbation history 
and co-morbidities. The severity distribution based on burden of disease proposed by 
the Zorgstandaard COPD is no realistic alternative yet, because the concept of burden of 
disease needs to be further elaborated and a uniform definition should be made before 
it can be used in daily practice [22]. Currently, all published COPD models are Markov 
models. Because one of the aspects of a Markov model is that patients can only be in one 
state, including more parameters to define COPD severity would increase the number 
of states exponentially. Therefore a Markov model may not be the most appropriate ap-
proach to use when developing a COPD model including several parameters to define 
COPD severity. Patient-level simulation may then be a better way to model the natural 
history and complexity of a disease such as COPD. However, data to fill models are often 
lacking [34]. A Markov model may also be less suitable for modelling COPD because of 
its property that transitions or probabilities do not depend on past values. In this way 
the probability to get an exacerbation can not depend on the number of exacerbations 
in the past, although it has clearly been shown that the most important predictor for a 
COPD exacerbation is a history of exacerbations [35]. 
With respect to the input parameters of the COPD model more research should be 
done on the utility decrement during exacerbations, the COPD-related costs specified 
by GOLD or other severity stage and data on COPD-related productivity losses. With 
respect to the first point, most COPD models made assumptions because data on the 
utility decrement during exacerbations were completely lacking. Only recently, two 
studies published results about the utility decrement in either a moderate or a severe 
hospitalization [2,3]. However, the information on this type of parameter is still very 
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limited. With respect to costs, no Dutch study published COPD-related costs by disease 
severity. If data on both costs and lung function are available the sample is often too 
small to give reliable estimates. With respect to the third point representative data 
about the mean annual number of days absent from work or data on early retirement 
due to COPD are still limited which is the main reason that up to now our model only 
included direct medical costs. A large population-based study or patient registry should 
be done to investigate COPD-related healthcare costs by disease severity and to yield 
data on days absent from work and early retirement. A good example of such a type 
of study is the ECLIPSE study in which unfortunately no data on healthcare utilization 
were collected [36]. If representative data on days of work loss would become available, 
we would be able to include COPD-related costs of productivity losses and perform the 
cost-effectiveness analyses from a societal perspective.  
The introduction of this thesis showed that information on the cost-effectiveness 
of especially non-pharmacological treatment options is still limited. Despite the lack 
of data on cost-effectiveness of COPD interventions, many of these interventions are 
included in national and international guidelines, such as the Zorgstandaard COPD 
and the GOLD guidelines [22,37]. Given the increasing healthcare expenditures and 
the limited healthcare budgets taking into account cost-effectiveness data in guideline 
development seems appropriate. Therefore, more studies should be done investigating 
the cost-effectiveness of COPD care, especially in real life. 
Part two: studies related to the economic evaluation of an 
interdisciplinary community-based COPD management program
Aim of the second part of this thesis was to estimate the (cost-)effectiveness of an in-
terdisciplinary, community-based COPD management program (INTERCOM) in patients 
with less advanced airflow obstruction and impaired exercise capacity (peak exercise 
capacity during an incremental cycle ergometer test <70%). Effectiveness of this pro-
gram was evaluated in a large, two-year randomized controlled trial comparing the 
INTERCOM program, consisting of exercise training, education, nutritional therapy and 
smoking cessation support with care as usual [38]. Furthermore, an economic evalua-
tion was performed alongside the clinical trial. This thesis presented a paper describing 
the cost-effectiveness of the program, as well as a paper describing a methodological 
issue in performing economic evaluations based on patient data.
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Summary of findings
The clinical evaluation showed that at four months patients in the INTERCOM group had 
significantly improvements in disease-specific quality of life, dyspnoea, exercise capac-
ity, muscle function and body composition compared with patients receiving usual care. 
Over the total two-year period significant differences were found in disease-specific 
quality of life, dyspnoea, exercise capacity, but not in the number of exacerbations. The 
INTERCOM study furthermore showed that implementation of a COPD program in a 
community-based hospital-guided setting seemed feasible, but adequate coordination 
of the program and repeated education of participating local care providers seems very 
important for the success or failure of the program [38]. The economic evaluation of the 
program (chapter eight) found that the total two-year costs in the INTERCOM group 
were €2,751 (95% CI: -632; 6,372) higher than in the usual care group. The gain in QALYs 
in the INTERCOM group was 0.08 (95% CI: -0.01; 0.18) resulting in an incremental cost-
effectiveness ratio of €32,400 per QALY gained. 
Because the INTERCOM program was compared with usual care only, results for effec-
tiveness and cost-effectiveness only apply to the INTERCOM program as an integrated 
package of care, i.e. the combination of exercise, education and for some patients nu-
tritional therapy and smoking cessation support. The study design did not allow us to 
draw firm conclusions about the cost-effectiveness of the separate components of the 
program. In a post-hoc analysis the INTERCOM group was split in the group of muscle 
wasted patients (fat free mass index ≤15 (female)/ ≤16 (male) kg/m2) receiving exercise, 
education and nutritional therapy and the group of non-muscle-wasted patients receiv-
ing exercise and education only. This analysis showed that over two years the group 
receiving nutritional therapy had significant improvements in fat free mass index and 
BMI, which were not found in the group receiving exercise and education only. Part 
of the higher costs for nutritional counseling and supplements in the muscle-wasted 
group were compensated by significantly lower hospitalization costs [39]. However, 
these findings were based on a low number of patients and the study was not designed 
to test the additional effect of nutritional therapy properly. 
The increase in total costs in the INTERCOM group was higher than the costs of the 
program (about €1,500 per patient), which was mainly the result of higher costs for 
inpatient pulmonary rehabilitation. During the trial five patients were referred to an 
inpatient pulmonary rehabilitation program, four in the INTERCOM group and one in 
the usual care group. Because these inpatient rehabilitation programs lasted on average 
about 70 days, the costs involved with these programs were substantial. The difference 
in referral to inpatient pulmonary rehabilitation between the INTERCOM group and the 
usual care group could have been coincidence, but it could also have been an unex-
pected side effect of the program. The high frequency of visits to care providers in the 
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INTERCOM group could have resulted in earlier signalling of significant worsening of 
the disease and a need for more intensive therapy. In retrospect, these patients should 
probably not have been included in the trial, because a community-based program was 
not intensive enough given their severe condition. To hold on to the intention-to-treat 
principle and to improve the generalizability to daily practice, the costs for inpatient pul-
monary rehabilitation were included in the analyses. Exclusion of the patients referred 
to inpatient pulmonary rehabilitation from the analysis would have reduced the cost per 
QALY for the INTERCOM program from €32,400 to €8,400.
Collection of resource use data
The cost-effectiveness study of the INTERCOM program was performed from a societal 
perspective including all COPD as well as non-COPD related costs. An advantage of this 
approach was that the potential effect of the intervention on the costs of treatments for 
co-morbidities can be taken into account. However, we did not explicitly ask patients 
to specify whether the reported healthcare use was COPD-related or not, except for 
hospitalizations. Therefore it was not possible to make a distinction between COPD- and 
non-COPD related healthcare costs afterwards. During the total two-year study period, 
data on total healthcare utilization was recorded weekly in cost booklets filled in by the 
patients themselves. Each booklet covered a period of four weeks and was collected 
every two months, which made the recall period relatively short in comparison to other 
studies [40]. Chapter ten showed that using self-reported data resulted in general in an 
underestimation of healthcare use when compared to caregiver registrations. Although 
the agreement in number of hospitalization days between the cost booklet and registra-
tions was almost perfect, the underestimation of costs was highest for this type of care 
due to the high unit costs per inpatient day. This problem was already accounted for 
in the original economic evaluation presented in chapter nine, where hospitalizations 
were based on the combined data of the cost booklet and electronic hospital records. 
Although the use of self-reported data was shown to have an effect on the within-group 
costs, it did not affect the difference in costs between the INTERCOM group and the cost 
utility (chapter nine). 
Generalizability of the results
The INTERCOM trial included patients with impaired exercise performance recruited 
by chest physicians in general hospitals. Therefore the results and outcomes of the 
INTERCOM trial can not be generalized directly to all patients with less severe airflow 
obstruction. This was also not the intention as the main aim of the study was to see 
whether patients with an impaired exercise performance regardless of their degree of 
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airflow obstruction could benefit from pulmonary rehabilitation. By including patients 
with impaired exercise capacity the patient population in the trial probably had a more 
impaired health status compared to the total COPD patient population. The patients 
with an impaired exercise capacity included in the trial showed for example a decreased 
hand grip force, quadriceps force and maximal inspiratory and expiratory pressure, 
expressed as percentage of predicted normal [41].  The clinical analyses of the trial fur-
thermore showed that the patients randomized to usual care had an impressive decline 
in exercise capacity, especially the muscle-wasted patient indicating the severity of the 
condition of the patient population included in the trial [39]. Another indication that the 
patients included in the trial had a more impaired health status than the average COPD 
patient was provided by comparing the mean annual number of inpatient hospital days 
for COPD for patients in the usual care group of the INTERCOM trial and the total COPD 
population. The mean number of hospital days for COPD was around two in the usual 
care group compared with 0.9 for the average COPD patient based on national registra-
tions [42].
Recommendations for further research with respect to integrated COPD care
With respect to pulmonary rehabilitation additional studies should be done investigat-
ing the effect of these types of programs in patients with less advanced airflow obstruc-
tion and impaired exercise capacity. The latter criterion was in the current study based 
on the results of a cycle ergometer test. Because it is not feasible to perform this test in 
a community-based setting other methods to easily measure exercise capacity should 
be explored. Whether a program such as the INTERCOM is also effective in patients with 
an impaired exercise capacity based on other parameters need to be investigated. Fur-
thermore, additional research should be done investigating the effectiveness and cost-
effectiveness of the major components of pulmonary rehabilitation programs, such as 
nutritional supplements in combination with exercise versus exercise alone. Up to now, 
most studies evaluated the effectiveness of a total program including multiple com-
ponents (exercise, education and self-management) compared with patients receiving 
care as usual. The INTERCOM program was provided by community-based healthcare 
providers (local physiotherapists and dieticians) and hospital-based respiratory nurses 
and supervised by a hospital-based physiotherapist. Whether is would be feasible to 
transfer a program such as the INTERCOM program completely to a community-based 
setting needs to be investigated. 
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Trial-based versus modelling-based cost-effectiveness studies 
The two methods used to obtain cost-effectiveness information, trial-based and model-
based studies are complementary. Modelling studies can not be done without trials and 
observational studies providing model input data, while trials usually do not have a suf-
ficient follow-up time to find estimates of long-term effects. Modelling is then needed 
to assess these effects. Therefore trial-based and model-based studies are a valuable 
supplement to each other. Different aspects of both methods will be discussed in this 
paragraph. Trial-based cost-effectiveness studies have the advantage that effects and 
costs are obtained from the same patient population. This means that effects and costs 
are directly related, where in model-based studies data from various sources are com-
bined. One of the consequences of the latter is that variables in probabilistic sensitivity 
analysis are often treated as independent, because data on the correlation between 
variables are lacking, while in bootstrapping patient-level data the association between 
effects and costs of a patient is taken into account. Another advantage of trials is that 
they have a high internal validity. However, the external validity may be limited, because 
patients included in trials are often not representative for the whole patient population 
as a lot of trials use multiple inclusion and exclusion criteria [43]. One of the most often 
used inclusion criterion in COPD trials is that patients need to be in a stable state of the 
disease at study entry, while presence of an acute life-threatening condition is the most 
important reason to exclude patients. Because a lot of COPD patients suffer from (severe) 
co-morbidities [44], part of the probably more severe COPD population is excluded from 
trials. The generalizability of model-based studies is dependent on the external validity 
of the input data. Using systematic reviews and meta-analysis to estimate input data 
using data from trials as well as observational studies improves the validity and external 
validity of the results [6]. 
The main advantage of modelling is that results can be extrapolated beyond the study 
duration. With regard to this aspect modelling is only useful if the beneficial effects of 
the intervention are expected to continue after the trial duration. A perfect example of 
such an intervention is a stop-smoking therapy as presented in chapter four and chapter 
seven for which the maximum annual number of QALYs gained due to the intervention 
is reached ten to fifteen years after its implementation (chapter four). For these studies 
the short-term effectiveness in terms of percentage of additional quitters was obtained 
from clinical trials, while the long-term effects on disease progression and mortality 
needed to be based on modelling. However, extrapolation of effects beyond the study 
duration may require making assumptions about the continuation of the effect. In the 
pharmacological scenario presented in chapter seven the effect of treatment with a 
combination of ICS/LABA was obtained from a three-year clinical trial, while effects were 
assumed to remain constant in the years four to ten thereafter. These kinds of assump-
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tions should be accompanied with proper sensitivity analyses. If interventions only have 
an effect on quality of life, which is not expected to continue after the trial, modelling 
does not have an additional value with regard to the extrapolation effect. This was for 
example shown by the scenario on pulmonary rehabilitation in chapter seven, which 
was assumed to have an effect on quality of life only. This positive effect on quality of 
life was applied the first three years and not to the years thereafter. Because all costs 
and health benefits related to the intervention occurred in the first three years, the 
cost-effectiveness of three-year implementation of this intervention was the same using 
a five, ten and twenty year time horizon. Modelling can also be relevant to translate 
intermediate endpoints into final endpoints relevant for policy makes, such as mortality 
or QALYs. This was shown in the scenario analysis in chapter three, four, and seven in 
which a difference in smoking abstinence after one year or a difference in lung function 
decline, exacerbation frequency and all-cause mortality was translated into a difference 
in QALYs. 
Role of the study outcomes in policy making
Cost-effectiveness information can play a role in several phases of the development 
and use of medical technology [45], such as the decision about reimbursement. Cur-
rently costs of all interventions investigated in this thesis are already covered by the 
nationwide obligatory basic healthcare insurance in the Netherlands. For the INTERCOM 
program applies that all separate components of the program, physiotherapy, dietary 
counseling, counseling by a respiratory nurse and diet nutrition are currently reim-
bursed for COPD patients. In the recent past a new financing system of COPD care was 
proposed next to the currently available reimbursement system. Since July 2010, an 
integrated payment system or bundled payment approach for “chained and integrated 
COPD care” has been introduced [46,47]. This new reimbursement system primarily 
aims to improve the quality of care for patients with chronic diseases by increasing the 
cooperation between healthcare providers in the primary care setting (such as GP’s, 
practice nurses, physiotherapists and dieticians) and by better targeting the patient’s 
needs [47]. In the new situation health insurers contract groups of care providers called 
“care-groups” by paying them prospectively a fixed price per patient. This fee covers 
the full range of COPD care services for a fixed period, mostly one year. The care groups 
either provide all necessary care themselves or contract other individual care providers 
if a certain type of care can not provided by the care group. Insurers only contract care 
groups that provide care according to the “COPD care standard”. Up-to-now only costs 
of services are included in the new system; drugs, diagnostics and medical devices are 
not (yet) included. Cost-effectiveness information of COPD interventions as presented in 
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this thesis can contribute to the development of the “COPD care standard” and therefore 
indirectly influence the type of COPD care provided by the care groups and the type of 
COPD care potentially reimbursed by the healthcare insurers. 
In addition to informing reimbursement decisions cost-effectiveness information can 
also play a role in the planning phase of a new technology or intervention or for its use in 
daily practice [45] The information presented in this thesis can contribute to evidence-
based policy making and guideline development for COPD, such as the Zorgstandaard 
COPD, CBO guideline for diagnosis and treatment of COPD, “NHG-standaard COPD” or 
the international GOLD guidelines [22,37,48,49]. The first part of the thesis described 
the COPD model that can be used to estimate the cost-effectiveness of a wide range of 
interventions from prevention to care for very severe COPD patients and allows compar-
ing interventions of different intensity and target group. A major advantage of using a 
model is that the results for the different interventions are comparable because there 
are no methodological differences [50].  The model can also be used to calculate the 
cost-effectiveness of a combination of interventions, i.e. integrated approaches, since 
single interventions or treatments will probably not reduce the burden of COPD suf-
ficiently (chapter seven). Results from the second part of this thesis, the results from the 
INTERCOM trial, increased the information on cost-effectiveness of non-pharmacological 
interventions for patients with less severe COPD and informed policy makers develop-
ing treatment guidelines for pulmonary rehabilitation. Up to the publication of the 
INTERCOM trial there was hardly any information about the effectiveness of pulmonary 
rehabilitation programs in patients with less severe airflow obstruction and data on 
cost-effectiveness of these programs in this patient group were completely lacking. The 
significant (faster) deterioration in quality of life, dyspnoea, exercise capacity and muscle 
function observed in the usual care group and the positive effects of the INTERCOM 
program stress the need not to wait with pulmonary rehabilitation till patients have 
severe airflow obstruction, but to start at earlier stages of the disease [38].
Several chapters in this thesis provided new and additional data on cost-effectiveness 
of treatment options for COPD. The costs per QALY ratios for the different COPD interven-
tions reported ranged between €2,400 for smoking cessation and €32,400 for pulmonary 
rehabilitation, both compared with usual care. Whether all these interventions could be 
considered cost-effective depends on the threshold value used. In the past, interven-
tions with a cost per QALY below the often quoted threshold value of €20,000 were 
considered very cost-effective in the Netherlands. More recently, an advisory board of 
the Dutch government (RVZ) proposed a variable willingness to pay for a QALY depend-
ing on the burden of the disease under study [51]. They proposed a maximum accept-
able ratio ranging from €8,000 for diseases with a disease burden of 0.1 to €80,000 for 
diseases with the maximum burden of 1.0. According to the same report the burden of 
disease for COPD is 0.61, which would correspond with a maximum willingness-to-pay 
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for a QALY of about €48,000. The burden of disease based on the utility values included 
in the model would however be lower, resulting in a maximum acceptable cost per QALY 
ranging from €8,000 for mild COPD to €35,000 for very severe COPD. Based on all these 
possible maximum willingness-to-pay values for COPD care increased implementa-
tion of smoking cessation interventions for smoking COPD patients can be regarded 
as cost-effective. The probability that the cost per QALY of intensive counseling plus 
pharmacotherapy for smoking cessation falls below a maximum willingness-to-pay of 
€20,000 was 97%, respectively. The findings for smoking cessation support the advice 
given in guidelines that COPD patients should be offered the most intensive smoking 
cessation intervention feasible not only from a clinical but also from an economic 
perspective. Treatment with ICS/LABA for all patients with moderate and severe COPD 
can also be considered cost-effective based on the calculation performed for this thesis. 
The probability of ICS/LABA to be cost-effective using a maximum willingness- to-pay 
of €20,000, the maximum willingness-to-pay for a moderate COPD patient, was 100%. 
However, it should be noted that effectiveness of this intervention was based on one 
trial assuming an effect on lung function decline, exacerbation frequency and mortality. 
The mean burden of disease for the patients included in the INTERCOM trial was 0.21, 
which would correspond with a threshold value of about €16,000 per QALY. Therefore 
the INTERCOM program could not be labelled as very cost-effective, but the ratio was 
below the mentioned threshold values of €35,000 and €48,000 per QALY gained. 
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Summary
Introduction: Chronic obstructive pulmonary disease (COPD) is a disease character-
ized by progressive airflow limitation that is not fully reversible and its progression is 
often accompanied by periods of increasing symptoms (cough, sputum production and 
dyspnoea) named exacerbations. The main risk factor for COPD is long-term smoking. 
Treatment of COPD mainly consists of support for smoking cessation, pharmacotherapy 
such as short- and long-acting bronchodilators and inhaled corticosteroids, and non-
pharmacological treatment, such as pulmonary rehabilitation and self-management 
programs. The burden of COPD in terms of prevalence, disability and healthcare costs is 
high and is projected to increase in the nearby future. Therefore the need for informa-
tion on efficient treatment options in terms of both effects and costs is high. The aim 
of this thesis was to develop tools that enable the assessment of the cost-effectiveness 
of treatment options for COPD and to provide such information. This information was 
obtained in two ways:
- by developing a population-based COPD model, which can be used to estimate the 
cost-effectiveness of a wide range of COPD interventions.
- by performing an empirical economic evaluation linked to a clinical trial that evalu-
ated the effectiveness of a COPD management program
Part one: studies related to the development of a COPD progression model
In chapter two the severity distribution of COPD in the Dutch COPD population in terms 
of the degree of airflow obstruction was estimated. This distribution was used as starting 
distribution of the COPD prevalence in the COPD model. For this study all patients with 
a physician-diagnosis of COPD from two different sources of general practitioners data 
were selected. Patients were classified into four COPD severity stages based on their 
FEV1% predicted using the GOLD classification. The distribution among Dutch COPD 
patients was estimated to be 27% mild, 55% moderate, 15% severe and 3% very severe 
airflow obstruction. 
Chapter three described the structure and input parameters of the first version of the 
COPD model developed in 2002/2003. The COPD model is a dynamic population model 
that projects the Dutch incidence, prevalence, mortality, disease progression and health-
care costs of COPD over time, taking into account population dynamics such as progno-
sis of birth and mortality and changes in smoking prevalence. The model is a Markov 
model with six main states, no COPD, four COPD severity stages based on lung function, 
and death. All states are specified by sex, age and smoking status. Transition between 
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COPD severity stages was based on the annual decline in lung function depending on 
sex, age, smoking and lung function at start. Furthermore, each COPD severity stage was 
associated with a probability to die, a utility value and COPD-related healthcare costs. 
The model was used to make projections of current practice for the period 2000-2025 
to estimate the future burden of COPD. These projections showed that the prevalence 
of COPD was estimated to increase from 24 to 33 per 1000 for males and from 15 to 27 
per 1000 for females. The associated healthcare costs were expected to increase from 
€280 to €495 million. The model was also used to estimate the cost-effectiveness of two 
smoking cessation interventions for COPD patients, minimal counseling by the GP and 
intensive counseling plus bupropion. 
An application of the first version of the model is shown in chapter four. This chapter 
presented the cost-effectiveness of smoking cessation interventions for COPD patients. 
First, a systematic review was performed of randomized controlled trials evaluating 
smoking cessation interventions in COPD patients. A meta-analysis was done to cal-
culate the 12-month continuous abstinence rates for four categories of interventions: 
usual care, minimal counseling (<90 minutes), intensive counseling (≥90 minutes) and 
intensive counseling plus pharmacotherapy (NRT, bupropion or nortriptyline). The esti-
mated abstinence rates were used in the COPD model to estimate the cost-effectiveness 
of one-year implementation of the three interventions for 50% of the smoking COPD 
patients compared with usual care, using a time horizon of 25 years. Compared with 
usual care, the cost per QALY gained were €16,900 for minimal counseling, €8,200 for 
intensive counseling and €2,400 or intensive counseling plus pharmacotherapy. The 
latter two categories of interventions resulted in low cost per QALY gained comparable 
to results for smoking cessation support in the general population. Compared with 
intensive counseling, intensive counseling plus pharmacotherapy was cost saving and 
should therefore be the option of first choice. 
The first version of the model did not include COPD exacerbations. To improve this 
model several exacerbation-related parameters needed to be estimated. One, of these 
parameters, the exacerbation frequency specified by GOLD severity stage, was described 
in chapter five. A systematic review was performed to identify randomized controlled 
trials and cohort studies reporting the exacerbation frequency in COPD patients receiv-
ing usual care or placebo. The association between the mean FEV1% predicted of study 
populations and the exacerbation frequencies was estimated using weighted log linear 
regression with random effects. The association was estimated separately for the total 
number of exacerbations defined as an increased use of healthcare (event-based defini-
tion) and severe exacerbations defined by a hospitalization. The estimated regression 
equations were used to estimate the exacerbation frequencies by GOLD stage using 
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the mean FEV1% predicted for each stage. Based on the 37 relevant studies found, 
the annual event-based frequencies per GOLD stage were estimated to be 0.82 (95% 
uncertainty interval (UI): 0.46; 1.49) for mild COPD, 1.17 (0.93; 1.50) for moderate COPD, 
1.61 (1.51; 1.74) for severe COPD and 2.10 (1.51; 2.94) for very severe COPD. For severe 
exacerbations, the annual frequencies were estimated to be 0.11 (0.02; 0.56), 0.16 (0.07; 
0.33), 0.22 (0.20; 0.23) and 0.28 (0.14; 0.63), respectively. 
Another exacerbation-related parameter, the case-fatality of a severe exacerbation, 
was addressed in chapter six. A literature search was performed for studies reporting 
mortality or survival during and after a hospitalization for an exacerbation of COPD. 
Studies needed to have a follow-up of at least 1.5 years and they needed to present a 
survival curve or mortality rates on at least three time-points after hospital admission. 
For each study the reported or estimated survival curve was divided into a critical and 
a stable period. Mortality during the stable period was then estimated by extrapolat-
ing the survival curve during the stable period back to the time of exacerbation onset. 
The case-fatality of the exacerbation was defined as the excess mortality related to the 
exacerbation and was calculated as 1 minus the backwardly extrapolated survival dur-
ing the stable period at the time of exacerbation onset. For the six selected studies the 
case-fatality was found to range between 11.4% and 19.0%. The weighted average case 
-fatality rate was estimated to be 15.6% (95 CI: 10.9; 20.3). 
In chapter seven the second updated and extended version of the COPD model 
(2008-2010) was presented. Compared with the first version all input parameters on 
demography, prevalence, incidence, and mortality of COPD, smoking prevalence and 
costs were updated to the year 2007. Furthermore, exacerbations were built into the 
model by including an annual probability to experience a moderate or severe exacerba-
tion for each COPD severity stage. Exacerbations were modeled to affect lung function 
decline, mortality, quality of life and costs. The average decline in lung function per 
exacerbation was estimated to be 0.19% predicted (95% CI: 0.092; 0.29). The annual util-
ity loss due a moderate and a severe exacerbation were estimated to be 1.66% (95% CI: 
1.23; 2.09) and 4.82% (3.11; 6.53) from the baseline utility value, respectively. The costs 
were estimated to be €94 (95% CI: 80; 108) for a moderate and €4100 (2348; 5852) for 
a severe exacerbation. In contrast to the first version of the model, the second version 
of the model included probabilistic sensitivity analysis because the important model 
parameters were entered into the model as probability distributions. The potential use 
of the model was shown by calculating the ten-year cost-effectiveness for four scenarios 
of three year implementation of three different COPD interventions. Compared with 
minimal treatment the cost per QALY was €8,300 for the pharmacological intervention, 
€10,800 for the smoking cessation therapy, €8,700 for the combination of the pharmaco-
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logical intervention and the smoking cessation therapy and €17,200 for the pulmonary 
rehabilitation program. The probability of the interventions to be cost-effective at a 
ceiling ratio of €20,000 varied from 58% for the pulmonary rehabilitation program to 
100% for the pharmacological intervention. 
Part two: studies related to the economic evaluation of an interdisciplinary 
community-based COPD management program 
The second part of this thesis started with an economic evaluation performed alongside 
the INTERCOM trial, a trial evaluating the effectiveness of an interdisciplinary communi-
ty-based COPD management program for patients with less severe airflow obstruction 
than usually included in pulmonary rehabilitation programs (chapter eight). In this 
two-year trial 199 patients with less advanced airflow obstruction and impaired exercise 
performance were randomized to the INTERCOM program or usual care. The INTERCOM 
program consisted of exercise training and an educational intervention for all patients 
and smoking cessation counseling, nutritional therapy and nutritional supplements 
upon indication. These interventions were offered by local physiotherapists and dieti-
cians and hospital-based respiratory nurses. The total two-year costs, COPD- plus non-
COPD related costs, were related to three health outcomes: the St. George’s Respiratory 
Questionnaire (SGRQ), the total number of exacerbations and the number of QALYs. 
Mean total 2-year costs per patient were €13,565 in the INTERCOM group and €10,814 
in the usual care group, resulting in a difference of €2751 (95% CI: -631; 6372). The cost-
effectiveness ratios were estimated to be €9,078 per additional patient with a relevant 
improvement in SGRQ total score and €32,425 per QALY. The costs per exacerbation 
avoided were negative, because the INTERCOM group had a higher number of exacerba-
tions. Exclusion of five patients that were referred to in-patient pulmonary rehabilita-
tion during the trial (4 in the INTERCOM group, 1 in the usual care group), would have 
reduced the incremental cost-effectiveness ratio to €8412 per QALY gained.
Chapter nine reported a validation study of the cost booklet that was used in the 
INTERCOM trial to collect resource use data. Data on the number of hospital admissions, 
outpatient visits, visits to the physiotherapists, dietician and respiratory nurse and 
nutritional supplements used were obtained from administrative records or caregiver 
registrations and compared with the numbers reported by the patients in the cost book-
let. What was new in this study is that we calculated the impact of using costs based on 
the cost booklet or based on care-giver registrations on the cost-utility. Total costs based 
on the cost booklet were €464 lower compared with the costs based on the care-giver 
registrations (two treatments combined). The cost difference between the INTERCOM 
and the usual care group based on the cost booklet was €2,444 (95% CI: -819; 5950), 
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resulting in a cost-utility of €29,100 per QALY. For the care-giver registrations the results 
were comparable, a cost difference of €2498 (95% CI: -88; 6084) and a cost per QALY of 
€29,390. In this study the use of self-reported data did have an effect on within-group 
costs, but not on the between-group costs or the cost-utility.
Discussion: With respect to part one, the development and application of the dy-
namic COPD population model, this chapter summarized the findings and comparisons 
were made between model outcomes for the cost-effectiveness of smoking cessation 
interventions based on the first and second version of the model. It further discussed 
three different aspect of the model: the input parameters, the definition of severity of 
COPD and the validation of the model. The COPD model was extensively validated and 
was found to have a good internal validity and acceptable between-model validity. The 
predictive validity of the first model in terms of the prediction of future prevalence was 
good for female patients, but it overestimated the prevalence for male patients some-
what. The discussion about the second part of this thesis, the empirical study on multi-
disciplinary, integrated COPD care, also started with a summary of the main findings and 
addressed the aspects of the cost-effectiveness of the total program in comparison with 
its different components. It also discussed the impact of the inclusion of five patients 
referred to inpatient pulmonary rehabilitation during the trial. Other aspects discussed 
were the collection of the resource use data by means of cost booklets and care-giver 
registrations and the generalizability of the results. The comparison between part one, 
the model-based and part two, the trial-based studies in the discussion showed that 
both approaches have their own advantages, but moreover that both methods are 
complementary. Finally, the role of the studies for policy making was discussed. The 
studies in this thesis showed that the COPD model can be regarded as an up-to-date 
COPD progression model that is useful to provide policy makers with information on 
the long-term costs and effects of a wide range of COPD interventions including the 
uncertainty. The results of the COPD interventions evaluated showed that smoking ces-
sation interventions and especially intensive counseling with pharmacotherapy can be 
regarded as cost-effective for COPD patients. Based on the cost per QALY the INTERCOM 
program can be considered moderately cost-effective. These data could be used to sup-
port evidence-based guideline development for COPD. 
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Introductie: Chronisch obstructief longlijden (COPD) is een ziekte die gekenmerkt 
wordt door luchtwegobstructie die progressief en niet volledig omkeerbaar is. De 
belangrijkste symptomen van COPD zijn hoesten, productie van slijm en kortademig-
heid. Patiënten met COPD hebben regelmatig last van periodes waarin de symptomen 
toenemen. Deze plotselinge verergeringen van de klachten worden exacerbaties 
genoemd. De belangrijkste risicofactor voor COPD is langdurig roken. De behandeling 
van COPD bestaat voornamelijk uit medicamenteuze behandeling, zoals het gebruik 
van kort- en langwerkende luchtwegverwijders en inhalatiecorticosteroïden en niet-
medicamenteuze behandeling, zoals het ondersteunen van het stoppen met roken en 
het volgen van longrevalidatie en zelfmanagement programma’s. De prevalentie, het 
gezondheidsverlies en de zorgkosten voor COPD zijn hoog en het is de verwachting 
dat dit in komende jaren toeneemt. Daarom is het voor beleidsmakers relevant om 
informatie te hebben over de kosten en effecten van interventies bij COPD om zo de 
meest efficiënte behandelmogelijkheden te vinden. Het doel van dit proefschrift was 
om instrumenten te ontwikkelen om de kosteneffectiviteit van behandelingen bij COPD 
te kunnen bepalen en deze instrumenten in te zetten om informatie over de kostenef-
fectiviteit te verschaffen. Op twee manieren is geprobeerd dit doel te bereiken:
Door het ontwikkelen van een populatiemodel voor COPD, dat gebruikt kan worden 
om de kosteneffectiviteit van een breed scala aan behandelingen voor COPD door te 
rekenen
Door het uitvoeren van een economische evaluatie parallel aan een gerandomiseerde 
klinische studie die de effectiviteit van een multidisciplinair management programma 
voor COPD onderzocht. 
Deel 1: Studies gerelateerd aan het COPD-model:
In hoofdstuk twee is op basis van de mate van luchtwegobstructie een ernstindeling 
gemaakt van de COPD-populatie in Nederland. Deze verdeling is gebruikt om de COPD-
prevalentie in het COPD-model bij start van de simulatie te verdelen naar ernst. Voor 
dit onderzoek zijn alle patiënten met een diagnose COPD uit twee verschillende bron-
nen met huisartsgegevens geselecteerd. De geselecteerde patiënten werden op basis 
van hun longfunctie, de FEV1 als percentage van voorspeld, ingedeeld in vier COPD-
ernststadia: milde, matige, ernstige of zeer ernstige COPD (GOLD-classificatie). Op deze 
manier werd de ernstverdeling voor de COPD patiënten in Nederland geschat op: 27% 
milde, 55% matige, 15% ernstige en 3% zeer ernstige luchtwegobstructie. 
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Hoofdstuk drie beschrijft de structuur en invoerwaarden van de eerste versie van het 
COPD-model dat ontwikkeld is in 2002/2003. Het COPD-model is een dynamisch popula-
tiemodel wat de incidentie, prevalentie, sterfte, het ziektebeloop en de zorgkosten voor 
COPD simuleert over de tijd. Het model houdt hierbij rekening met de dynamiek in de 
algemene bevolking als gevolg van geboorte, sterfte en veranderingen in rookgedrag. 
Het model is een Markovmodel met zes verschillende gezondheidstoestanden: geen 
COPD, vier COPD ernstklassen en dood, die allemaal gespecificeerd zijn naar geslacht, 
leeftijd en rookstatus. De overgang tussen de verschillende COPD-ernstklassen is geba-
seerd op de jaarlijkse afname in longfunctie, welke afhankelijk is van geslacht, leeftijd, 
rookstatus en de longfunctie bij aanvang. Elke COPD-toestand is geassocieerd met een 
kans op overlijden, een utiliteitswaarde en COPD-gerelateerde zorgkosten. Het model 
is gebruikt om projecties te maken van de toekomstige prevalentie en zorgkosten voor 
COPD voor de periode 2000 tot 2025. Deze projecties lieten een stijging zien van de pre-
valentie van 24 naar 33 per 1000 voor mannen en van 15 naar 27 per 1000 voor vrouwen. 
De zorgkosten voor COPD werden geschat te stijgen van €280 naar €495 miljoen. Het 
model is daarnaast gebruikt om de kosteneffectiviteit van twee stoproken interventies 
voor COPD patiënten te berekenen, de minimale interventiestrategie stoppen met ro-
ken voor de huisartspraktijk en intensieve ondersteuning in combinatie met bupropion. 
Een toepassing van de eerste versie van het model is gegeven in hoofdstuk vier van 
dit proefschrift. In dit hoofdstuk wordt de kosteneffectiviteit van verschillende typen 
stoproken interventies voor COPD-patiënten gepresenteerd. Voor dit onderzoek werd 
eerst een systematisch literatuurstudie gedaan naar gerandomiseerde, klinische studies 
die de effectiviteit van stop-roken interventies bij COPD-patiënten onderzochten. De 
data uit de gevonden studies werden gecombineerd in een meta-analyse om de conti-
nue abstinentie op 12 maanden voor vier verschillende typen interventies te berekenen: 
standaard zorg (geen specifieke stop-roken interventie), minimale ondersteuning (< 90 
minuten), intensieve ondersteuning (≥ 90 minuten) en intensieve ondersteuning in 
combinatie met stop-roken medicatie (nicotinevervangers, bupropion of nortriptyline). 
De geschatte stopkansen werden gebruikt in het COPD-model om de kosteneffectiviteit 
van één jaar implementatie van de drie typen interventies voor 50% van de rokende 
COPD patiënten door te rekenen in vergelijking met standaardzorg over een tijdsho-
rizon van 25 jaar. In vergelijking met standaardzorg waren de kosten per gewonnen 
QALY €16900 voor minimale ondersteuning, €8200 voor intensieve ondersteuning en 
€2400 voor intensieve ondersteuning in combinatie met medicatie. De kosteneffectivi-
teitsratio van intensieve ondersteuning met en zonder medicatie was vergelijkbaar met 
de ratio die gevonden is voor een vergelijkbare interventie voor rokers in de algemene 
bevolking. Intensieve ondersteuning in combinatie met stop-roken medicatie was kos-
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tenbesparend in vergelijking met intensieve ondersteuning zonder medicatie en zou 
daarom de eerste keus bij stop-roken ondersteuning van COPD patiënten moeten zijn.
In de eerste versie van het model werd geen rekening gehouden met de impact 
van COPD-exacerbaties. Om de invloed van exacerbaties op het ziekteverloop mee te 
nemen te kunnen nemen in het model moesten verschillende exacerbatie-gerelateerde 
parameters geschat worden. Eén van deze parameters was de exacerbatiefrequentie 
uitgesplitst naar COPD-ernstklasse (hoofdstuk vijf). Om deze frequentie te bepalen 
werd een systematische review gedaan naar gerandomiseerde klinische studies en 
cohortstudies die de exacerbatiefrequentie bij COPD-patiënten rapporteerden. Vervol-
gens werd het verband tussen de gemiddelde FEV1 als percentage van voorspeld van de 
studiepopulaties en de exacerbatiefrequentie geschat m.b.v. gewogen, random-effect 
loglineaire regressie. Het verband tussen de longfunctie en de exacerbatiefrequentie 
werd apart geschat voor het totaal aantal exacerbaties en het aantal ernstige exacer-
baties. Een exacerbatie werd hierbij gedefinieerd als een toename in symptomen en 
klachten leidend tot een toename van het zorggebruik. Een ernstige exacerbatie werd 
gedefinieerd als een exacerbatie-gerelateerde ziekenhuisopname. De geschatte regres-
sievergelijkingen werden gebruikt om de exacerbatiefrequentie per GOLD-ernstklasse 
te bepalen door de gemiddelde FEV1 als percentage van voorspeld per ernstklasse in te 
vullen in de geschatte vergelijking. In totaal werden 37 relevante studies gevonden. De 
totale exacerbatiefrequentie per jaar werd geschat op 0.82 (95% onzekerheidsinterval 
(UI):0.46-1.49) voor mild COPD, 1.17 (0.93-1.50) voor matig COPD, 1.61 (1.51-1.74) voor 
ernstig COPD en 2.10 (1.51-2.94) voor zeer ernstig COPD. Voor ernstige exacerbaties 
werd de frequentie per jaar per ernstklasse geschat op respectievelijk 0.11 (0.02-0.56), 
0.16 (0.07-0.33), 0.22 (0.20-0.23) and 0.28 (0.14-0.63).
Om het risico op sterfte ten gevolge van een ernstige exacerbatie te schatten (hoofd-
stuk zes) werd een literatuuronderzoek gedaan naar studies die sterfte of overleving 
rapporteerden na een ziekenhuisopname voor een COPD-exacerbatie. De studies 
moesten een duur van tenminste 1,5 jaar hebben. Daarnaast moesten de studies de 
overleving op tenminste drie momenten in de tijd rapporteren of een overlevingscurve 
presenteren. Voor elke studie werd de overlevingscurve opgesplitst in twee stukken, 
de curve tijdens de kritieke fase en de curve tijdens de stabiele fase. De sterftekans 
tijdens de stabiele fase werd vervolgens geschat door de overlevingscurve tijdens de 
stabiele fase terug te extrapoleren naar het begin van de exacerbatie. De extra sterfte, 
gedefinieerd als 1 min de teruggeëxtrapoleerde sterfte tijdens de stabiele fase, werd 
toegeschreven aan de exacerbatie. De literatuurstudie leverde zes relevante studies 
op. De gewogen gemiddelde sterftekans ten gevolg van een ernstige exacerbatie werd 
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geschat op 15.6% (95% betrouwbaarheidsinterval (BI): 10.9-20.3). Binnen deze studies 
varieerde de kans op sterfte tussen de 11.4% en 19%.
In hoofdstuk zeven is de tweede, vernieuwde en uitgebreide versie van het COPD-
model (2008-2010) beschreven. In vergelijking met de eerste versie is het model op een 
aantal punten veranderd. Allereerst zijn de invoerwaarden voor demografie, COPD-
prevalentie, incidentie en sterfte, de prevalentie van roken en de kosten geactualiseerd 
naar het jaar 2007. Verder is de invloed van exacerbaties in het model ingebracht. Voor 
elke COPD-ernstklasse is een jaarlijkse kans gespecificeerd op het krijgen van een niet-
ernstige en ernstige exacerbatie. Exacerbaties hebben in het model invloed op de da-
ling in longfunctie, sterfte, kwaliteit van leven en de kosten. De gemiddelde afname in 
longfunctie ten gevolg van een exacerbatie is geschat op 0.19% van voorspeld (95% BI: 
0.092-0.29). Het effect van exacerbaties op de kwaliteit van leven is geschat als procen-
tuele daling in de utiliteitswaarde op jaarbasis ten opzichte van de utiliteit bij start. Deze 
is geschat op 1.66% (95% BI: 1.23-2.09) voor een niet-ernstige exacerbatie en 4.82% 
(95% BI: 3.11-6.53) voor een ernstige exacerbatie. De kosten van een exacerbatie werden 
geschat op €94 (95% BI: 80-108) voor een niet-ernstige en €4100 (95% BI: 2348-5852) 
voor een ernstige exacerbatie. Ten derde is het met de vernieuwde versie van het model 
mogelijk om probabilistische sensitiviteitsanalyses te doen, omdat rekening gehouden 
is met de onzekerheid rond de belangrijkste invoerwaarden. De mogelijkheden van 
het model zijn geïllustreerd door in een aantal scenario’s de kosteneffectiviteit van drie 
verschillende behandelingen ten opzichte van minimale behandeling door te rekenen. 
Hierbij werd verondersteld dat de interventies drie jaar werden geïmplementeerd en 
werden de kosten en effecten geëvalueerd over een periode van tien jaar. De kostenef-
fectiviteit was €8300 per gewonnen QALY voor de medicamenteuze interventie, €10800 
voor de stoproken interventie, €8,700 voor de combinatie van deze twee interventies en 
€17200 voor het longrevalidatieprogramma. 
De kans dat de kosteneffectiviteitsratio van de verschillende interventies onder de 
€20000 per gewonnen QALY was, varieerde van 58% voor het longrevalidatieprogramma 
tot 100% voor de medicamenteuze interventie. 
Deel 2: Studies gerelateerd aan de economische evaluatie van een transmuraal, 
interdisciplinair COPD managementprogramma
Het tweede deel van dit proefschrift begint met de economische evaluatie die uitge-
voerd is parallel aan de INTERCOM trial (hoofdstuk acht). Deze trial onderzocht de 
effectiviteit van een transmuraal, interdisciplinair COPD-managementprogramma bij 
patiënten met een minder ernstige mate van luchtwegobstructie dan de patiënten 
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die normaal gesproken deelnemen aan longrevalidatieprogramma’s. In de twee jaar 
durende studie zijn 199 patiënten met een matig ernstige luchtwegobstructie en in-
spanningsbeperking random toegewezen aan de groep die het INTERCOM programma 
kreeg of de controlegroep. Het INTERCOM programma bestond uit een trainings- en 
educatieprogramma. Daarnaast participeerden patiënten op indicatie in een stoproken-
programma en/of kregen zij voedingsadvies en supplementen. De verschillende onder-
delen van het programma werden uitgevoerd door fysiotherapeuten en diëtisten in de 
directe woonomgeving van de patiënt en door longverpleegkundigen in het ziekenhuis. 
Het programma omvatte vier maanden revalidatie gevolgd door een actieve onder-
houdsfase van 20 maanden. De gemiddelde totale COPD en niet-COPD gerelateerde 
kosten per patiënt over 24 maanden waren €13565 voor de INTERCOM groep en €10814 
voor de controlegroep. Het kostenverschil tussen beide groepen was €2751 (95% BI: 
-631;6372). De kosteneffectiviteitsratio’s werden geschat op €9078 per extra patiënt met 
een klinische relevante verbetering in de SGRQ totaal score en €32400 per gewonnen 
QALY. Een deel van de kostenstijging in de INTERCOM groep werd veroorzaakt door vier 
patiënten die tijdens de studie verwezen werden naar een longrevalidatiecentrum ten 
opzichte van één patiënt in de controlegroep. Wanneer deze patiënten uit de analyses 
werden gelaten, daalden de kosten per QALY naar €8412.
Hoofdstuk negen beschrijft de validatie van het kostenweekboek wat gebruikt is in 
de INTERCOM studie om het zorggebruik van de patiënten in kaart te brengen. Voor 
deze studie zijn extra gegevens verzameld uit ziekenhuisregistraties en registraties 
van de verschillende zorgverleners. Vervolgens is voor ziekenhuisopnames, bezoeken 
aan de specialist, de fysiotherapeut, de diëtist en de longverpleegkundige en voor 
voedingssupplementen een vergelijking gemaakt tussen het aantal verkregen uit de 
registraties en de gegevens zoals ingevuld door de patiënten in het kostenweekboek. 
Verder is gekeken naar de invloed van de kostenbron, registraties versus kostenweek-
boek, op de kosteneffectiviteit. De totale kosten per patiënt gebaseerd op gegevens 
uit het kostenweekboek waren €464 lager dan de kosten gebaseerd op gegevens uit 
de registraties (beide behandelingen gecombineerd). Het verschil in kosten tussen de 
INTERCOM en de controlegroep op basis van het kostenweekboek was €2444 (95% BI: 
-819;5950), wat resulteerde in een kosteneffectiviteitsratio van €29100. De resultaten 
op basis van de registraties waren vergelijkbaar. Het kostenverschil op basis van de 
registraties was €2498 (95% BI: -88;6084) en de kosteneffectiviteitsratio was €29390. 
Het gebruik van gegevens op basis van zelfrapportage had in deze studie dus wel een 
invloed op de kosten binnen een behandelgroep, maar niet op het verschil in kosten 
tussen de beide behandelgroepen of de kosteneffectiviteit.
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Discussie:  In dit hoofdstuk zijn allereerst de resultaten van deel één van dit proef-
schrift, de studies over de ontwikkeling en toepassing van het dynamische populatie-
model voor COPD, samengevat en besproken. Verder zijn de modeluitkomsten voor de 
kosteneffectiviteit van stop-roken interventies van de eerste en tweede versie van het 
model vergeleken. Daarnaast zijn drie verschillende aspecten van het model belicht: de 
invoerwaarden, de definitie voor ernst van de COPD die gebruikt is in het model en de 
validatie van het model. Vooral het laatste punt wordt uitgebreid besproken. Het model 
bleek een goede interne validiteit te hebben en een redelijke tussen-modelvaliditeit. 
De voorspellende validiteit is getest door te kijken naar hoe goed de eerste versie van 
het model de toekomstige prevalentie van COPD kon simuleren. Deze voorspellende 
validiteit bleek goed te zijn voor het aantal vrouwelijke patiënten. Voor mannen werd 
de toekomstige prevalentie wat overschat door het model. De discussie wat betreft het 
tweede deel van dit proefschrift, de empirische studie naar het transmurale, interdis-
ciplinaire COPD managementprogramma, begint ook met een samenvatting van de 
belangrijkste resultaten. Daarnaast komen de volgende punten aan bod: de kostenef-
fectiviteit van het totale programma versus de verschillende individuele componenten, 
de impact van inclusie van vijf patiënten die tijdens de studie verwezen werden naar een 
intern longrevalidatieprogramma op de resultaten, de manier waarop het zorggebruik 
in de studie gemeten is en de generaliseerbaarheid van de uitkomsten. Een vergelijking 
van deel één, de modelstudies, en deel twee, de empirische studies, laat zien dat beide 
methoden hun eigen voordelen hebben, maar bovenal complementair aan elkaar zijn. 
Tenslotte is de rol van de uitkomsten bij het bepalen van beleid bediscussieerd. De 
studies in dit proefschrift laten zien dat het ontwikkelde COPD-model beleidsmakers 
kan voorzien van nuttige informatie over de kosten en effecten van een breed scala 
aan COPD-behandelingen. De kosteneffectiviteitsberekeningen die voor dit proefschrift 
gedaan zijn, laten zien dat stop-roken interventies en in het bijzonder intensieve onder-
steuning in combinatie met stop-roken medicatie voor COPD-patiënten kosteneffectief 
zijn. Op basis van de gevonden kosten per gewonnen QALY kan het INTEROM pro-
gramma als matig kosteneffectief worden beschouwd. De uitkomsten kunnen gebruikt 
worden voor het wetenschappelijk onderbouwen van de richtlijnontwikkeling voor de 
behandeling van COPD.
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Dankwoord
“Promoveren is niet één van de dingen die ik persé wil in mijn leven, maar als het er zo van 
komt is het oké”. Zoiets moet ik ongeveer geantwoord hebben tijdens mijn sollicitatie-
gesprek op de vraag of ik wilde promoveren. Ondanks mijn niet al te gemotiveerde ant-
woord werd ik aangenomen. Waarschijnlijk omdat de vragenstellers wel wisten dat deze 
wat afwachtende houding meestal wel verandert in de loop van de tijd. En inderdaad, ze 
hebben gelijk gekregen, want mijn proefschrift is af! Het is er dus toch van gekomen. En 
bij het afronden van dit proefschrifttraject hoort uiteraard het bedanken van alle mensen 
die een bijdrage geleverd hebben aan het tot stand komen van dit boekje. 
Allereerst wil ik natuurlijk mijn promotor, Maureen Rutten-van Mölken bedanken. 
Maureen, jij stond voor de uitdagende taak om mij als beginnend onderzoeker wegwijs 
te maken in de wereld van onderzoek doen en publiceren. Dank je voor al je uurtjes van 
overleg, het meedenken over het oplossen van obstakels en voor je uitgebreide com-
mentaar op mijn artikelen en rapporten. Ik heb grote bewondering voor jouw kennis en 
kwaliteiten. Jouw gedegen manier van commentaar leveren maakte mijn stukken zeker 
beter en hebben een grote bijdrage geleverd aan mijn huidige manier van schrijven. Dat 
we allebei perfectionisten zijn, was niet altijd bevorderlijk voor de voortgang van een 
project, maar hopelijk wel voor de kwaliteit. Ook bewaar ik goede herinneringen aan de 
keren dat we samen of met andere collega’s naar de ERS congressen gingen. Kortom, 
bedankt voor de intensieve begeleiding en de fijne samenwerking in de afgelopen 
jaren. En het allerleukste is dat het schrijven van dit proefschrift precies zolang geduurd 
heeft dat jij nu mijn promotor i.p.v. copromotor kunt zijn. 
Met jou, Talitha Feenstra mijn copromotor, verliep de intensiteit van het contact in vla-
gen. In de eerste jaren hadden we veelvuldig contact vanwege de ontwikkeling van het 
COPD model en de kostenstudie naar astma en COPD. Ik werkte zelfs één dag per week 
bij het RIVM. Daarna was het contact een paar jaar wat minder. De afgelopen jaren was 
onze samenwerking weer intensiever door de tweede fase van het COPD model. Talitha, 
jouw bijdrage aan dit proefschrift was substantieel. Jouw kennis was onmisbaar voor 
de ontwikkeling van het COPD model. Ik heb veel van je geleerd. Je vormde een goede 
schakel tussen de modelleergroep van het Chronische Ziektemodel enerzijds en wij als 
“buitenstaande” gezondheidseconomen anderzijds. Hartelijk dank voor je begeleiding 
en je grote bijdrage aan de artikelen over het COPD model. 
Rudolf Hoogenveen, jouw naam moet zeker genoemd worden in dit dankwoord. Zon-
der jou was er geen COPD model in deze vorm geweest en was een groot deel van de 
publicaties in dit proefschrift niet tot stand gekomen. Dank je wel voor al het program-
meerwerk dat je hebt gedaan voor het COPD model en voor je eindeloze geduld om 
mij weer eens te helpen met een vraag over de code van Mathematica. Bedankt ook dat 
je steeds weer probeerde om mij in simpele taal de complexe structuur van het model 
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uit te leggen. Gelukkig hebben we nu ook iemand hier in huis die mij uitleg kan geven, 
waardoor het hopelijk voor jou wat rustiger zal worden. 
Maiwenn Al, ook jou wil ik expliciet noemen. Jij was het vijfde lid van het COPD model-
leerteam. Bedankt voor je bijdrage aan het COPD model en al je hulp op het gebied van 
statistiek. Regelmatig stak ik mijn hoofd om de deur voor even een kort vraagje. Fijn dat 
je altijd bereid was te helpen. 
Naast de personen die betrokken waren bij het COPD model project wil ik natuurlijk 
de personen waar ik samen mee gewerkt heb aan de INTERCOM studie bedanken. Op 
wetenschappelijk gebied waren dat Carel van Wetering en Annemie Schols. Carel, jij was 
de drijvende kracht achter de INTERCOM studie. Ik bewonder je voor je jarenlange inzet 
voor het project voor een groot deel ook nog in je eigen tijd. Daarnaast heb ik respect 
voor je vasthoudendheid om je de wetenschappelijke beginselen en statistische analy-
ses eigen te maken. Eindeloos was jouw geduld. Dank je voor de fijne samenwerking en 
de gezelligheid. Ondanks de afstand was het nooit een straf om een dag in Veldhoven 
data in te voeren. Hoewel ik me af en toe wel wat opgelaten voelde onder jouw stroom 
van bedankjes, was je echt een fijne collega-onderzoeker. Ik heb er nooit spijt van gehad 
dat ik het stokje van Floortje heb overgenomen. Annemie, als promotor van Carel was 
ons directe contact niet zo frequent, maar ik vond het leuk en leerzaam om samen met 
jou deel uit te maken van het INTERCOM onderzoeksteam. 
Floortje van Nooten, dank je wel voor jouw grote bijdrage aan de dataverzameling. 
Toen jij wegging bij het iMTA en ik het INTERCOM project van je overnam, kwam ik in 
een gespreid bedje terecht. Alles was keurig bijgehouden en een groot deel van de 
kostendata was al verzameld. Wat kun je nog meer wensen?!
Esther Phoelich en de andere onderzoeksverpleegkundigen wil ik graag bedanken 
voor het coördineren van de dataverzameling. Er zijn heel wat kostenweekboekjes door 
jullie handen gegaan en jullie keken er scherp op toe dat alle boekjes op tijd terugkwa-
men. Dankzij jullie inzet was het percentage missende boekjes heel klein. Hulde! Gonnie 
Geraerts, Miranda Coolen, de regionale apothekers en alle deelnemende fysiotherapeu-
ten en diëtisten uit de eerste lijn, hartelijk dank voor de hulp bij het verzamelen van de 
kostendata en van de extra gegevens voor de validatie van het kostenweekboek. 
Naast alle personen die een directe bijdrage hebben geleverd aan mijn projecten wil 
ik natuurlijk alle iBMG/iMTA collega’s bedanken voor hun hulp bij kleine en grote vragen. 
Ook al is het aantal directe collega’s in de afgelopen jaren flink toegenomen de gezellige 
werksfeer is er niet minder op geworden. Eén collega wil ik in het bijzonder noemen en dat 
is Kim mijn kamergenote. We delen nu al heel wat jaren samen een kamer en niet alleen 
dat. Dat we in dezelfde periode zwanger waren en bijna tegelijk een kleine kregen was 
wel de grootste gemeenschappelijke deler. Bedankt voor al je hulp en alle gezelligheid. 
Lieve vrienden en familie, hartelijk dank voor jullie belangstelling in mijn werk en voor 
dit proefschrift, ook al was het soms best moeilijk te volgen waar ik me nu zoal mee 
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bezig hield. Schoonzussen, geweldig dat jullie aanboden om wekelijks op de kids te 
passen. Trudy, met jou als oppas hebben we het geweldig getroffen. Pa en ma Hoog-
endoorn, ook jullie staan altijd voor ons klaar. Dank jullie wel voor alle belangstelling 
en praktische steun! Lieve mam, dank voor alles wat je voor mij hebt gedaan en nu nog 
voor ons en de kinderen doet. Je stond helemaal achter mijn keuze om te gaan studeren, 
op mezelf te gaan wonen en op stage naar Canada te gaan, ook al zal dat niet altijd 
gemakkelijk geweest zijn gegeven de omstandigheden. Ik heb veel bewondering voor 
je. Het is verdrietig dat pap het afronden van dit proefschrift niet meer mee kan maken, 
maar ik weet dat hij trots op mij geweest zou zijn. 
Pieter en Frederik, mijn kleine, grote broers, leuk dat jullie spontaan ‘ja’ zeiden op mijn 
vraag of jullie mijn paranimf wilden zijn, ook al hadden jullie geen idee wat het inhield. 
Hopelijk bestaan er rokkostuums in jullie lengtemaat. Aanstaande schoonzusjes, jullie 
ook bedankt voor alle interesse.
Lieve Steven en Nienke, promoveren zinkt in het niet in vergelijking met jullie komst 
in mijn leven. Het is prachtig om jullie te zien opgroeien en ontwikkelen, allebei zo uniek 
en bijzonder. Ik geniet enorm van jullie. Lieve Wim, het schrijven van dit proefschrift 
mocht van mij niet ten koste gaan van de tijd met de kinderen. Het is dus wel duidelijk 
wie er tijd tekort gekomen is het laatste jaar. Dank je wel voor de vele koppen thee die je 
’s avonds naar zolder bent komen brengen als ik daar nog aan het werken was. Je hebt 
me in de afgelopen jaren altijd gemotiveerd om dit proefschrift af te maken. Ik weet dat 
ik altijd bij je terecht kan. Dank je voor alles!  
Groot is Uw trouw, o Heer, 
iedere morgen aan mij weer betoond. 
Al wat ik nodig had, hebt U gegeven. 
Groot is Uw trouw, o Heer,
aan mij betoond. 
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Curriculum vitae
Martine Hoogendoorn-Lips was born in Gouda on March 14, 1979. She graduated from 
secondary school (Gymnasium) at the Driestar College in Gouda. From 1997 to 2002 she 
studied Human Nutrition at Wageningen University, where she graduated (cum laude) 
with specializations in Epidemiology and Public Health. As part of her study she did a 
four month internship at the University of British Columbia in Vancouver, Canada. Since 
2002 she has been working as a researcher at the institute for Medical Technology As-
sessment (iMTA) of the Erasmus University in Rotterdam. Her first project focused on the 
development of the COPD progression model described in this thesis. Between 2006 and 
2010 she worked on the two other projects included in this thesis, the cost-effectiveness 
study of the INTERCOM trial and the extension and update of the COPD model. During 
her time at iMTA she also performed cost of illness studies on asthma, COPD and meta-
bolic syndrome, a study on the measurement of utilities for COPD and cost-effectiveness 
studies of a new drug for smoking cessation and pharmacological agents for COPD. In 
2011 she participated in one of the organizing boards of the fifth European Conference 
on Tobacco or Health. Currently she continues her research at iBMG/iMTA on modelling 
and economic evaluations in COPD care. Martine is married with Wim and they have two 
children, Steven (2007) en Nienke (2009).
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